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CHAPTER 1 
 
INTRODUCTION 
 
Dopaminergic circuits 
The catecholamine neurotransmitter dopamine (3,4-Dihydroxyphenethylamine; DA) plays 
a key role in regulating the functions of the central nervous system (CNS) and the brain.  
Dopaminergic neurotransmission is known to play an important role in mediating locomotion, 
cognition, mood, motivation, salience, and reward.  Dopaminergic innervation of the brain can 
be classified into four major pathways: the mesocortical pathway, the nigrostriatal pathway, the 
tuberoinfundibular pathway, and the mesolimbic pathway (Fig. 1).  The tuberoinfundibular (TI) 
pathway plays a role in regulating neuroendocrine function and is a collection of hypothalamic DA 
neurons that project from the hypothalamic arcuate nucleus to the pituitary gland.  Signaling from 
tuberoinfundibular DA (TIDA) neurons is known to have an inhibitory effect on the pituitary gland’s 
release of prolactin, a hormone that regulates lactation, libido, fertility, and body weight (Fitzgerald 
and Dinan, 2008, Lyons et al., 2012).  The nigrostriatal pathway is essential for movement and 
locomotion and consists of DA neurons whose cell bodies originate in the substantia nigra and 
project to the dorsal striatum.  Degeneration of DA neurons in the nigrostriatal pathway is a 
hallmark of Parkinson’s Disease (PD), and results in impaired motor function, including resting 
tremor and loss of coordinated movement. The mesocortical dopaminergic pathway consists of 
projections from the midbrain (specifically the Ventral Tegmental Area; VTA) to the prefrontal cortex 
(PFC).  The mesocortical pathway is involved in regulating emotion and cognition, as well as 
learning and working memory (Brozoski et al., 1979, Surmeier, 2007).  The DA neurons of the 
mesolimbic pathway also originate in the VTA, but project to the Nucleus Accumbens (NAc) in 
the ventral striatum.  DA release in the NAc has been implicated in reward and pleasure.  Direct 
electrical or chemical stimulation of the NAc results in DA release and elicits behaviors similar to 
2 
  
Figure 1. Schematic of dopaminergic projections in the brain. Dopaminergic neurons 
originating in the ventral tegmental area (VTA) and substantia nigra (Snr) project to other 
regions of the brain to form four major pathways: mesocortical (VTA neurons project to 
prefrontal cortex), mesolimbic (VTA neurons project to nucleus accumbens), nigrostriatal 
(Snr neurons project to striatum).  Tuberoinfundibular pathway is not depicted.  Image 
adapted from Bear et al. (2006). 
 
Frontal lobe Striatum
Substantia nigra
Ventral tegmental area
Nucleus accumbens
Prefrontal cortex
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those that occur in response to natural rewards (Wise, 1998).  In particular, the reward-
potentiating effects of drugs of abuse, including the psychostimulants amphetamine (AMPH) 
and cocaine (COC), result from elevation of DA levels in the NAc (Carboni et al., 1989, Wise, 
1998).   
 
Dopaminergic signaling is thought to play an important role in regulating the response of 
neurons to other neurotransmitters.  This gives DA a complex role in integrating several different 
inputs (Surmeier et al., 2007), so it is unsurprising that perturbations of the signaling process can 
have drastic effects on brain function.  In addition to being altered in Parkinson’s Disease and 
drug abuse, DA homeostasis abnormalities are associated with several other neuropsychiatric 
disorders, including Major Depressive Disorder, schizophrenia, Bipolar Affective Disorder (BAD), 
Attention Deficit Hyperactivity Disorder (ADHD), and Autism Spectrum Disorder (ASD).  
Furthermore, drugs whose mechanisms of action are known to alter dopaminergic 
neurotransmission are the standard course of treatment for several of these disorders, such as 
methylphenidate (MPH) and AMPH (ADHD; targets DA transporter (DAT)), risperidone (ASD; 
targets DA receptor D2R), L-DOPA (Parkinson’s Disease; DA precursor), and haloperidol 
(schizophrenia; targets DA receptor D1R).  
 
The dopaminergic synapse 
DA homeostasis is controlled at the synaptic level at four main stages: DA synthesis, 
vesicular release of DA, the sensitivity and expression levels of the pre- and post-synaptic DA 
receptors, and the degradation and clearance of extracellular DA from the synaptic space.  DA is 
synthesized in the cytosol of presynaptic terminals of DA neurons, where tyrosine hydroxylase 
(TH) hydrates the amino acid tyrosine (Tyr) to dihydroxyphenylalanine (DOPA), which is then 
decarboxlyated by the enzyme aromatic amino acid decarboxylase (AADC) into DA (Fig. 2). TH 
hydration of Tyr is the rate limiting step of the DA synthetic pathway, so the amount of DA that is 
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Figure 2. Dopamine Synthesis.  Dopamine (DA) is synthesized from the amino acid 
tyrosine, which is taken up into the presynaptic neuron and hydroxylated by Tyrosine 
Hydroxylase (TH) to dihydroxyphenylalanine (DOPA).  DOPA is then decarboxylated by 
aromatic amino acid decarbolxylase (AADC) into DA. 
 
!
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synthesized can be regulated by the level of expression of TH.  After synthesis, DA is then 
loaded into synaptic vesicles by the vesicular monoamine transporter (VMAT, encoded by gene 
SCL18).  VMAT is an amine/proton antiporter, which uses the proton gradient generated inside 
the vesicle by V-ATPase to load DA against its concentration gradient into the synaptic vesicles.  
Given enough L-DOPA precursor, dopaminergic neurons can load DA inside vesicles at 
concentrations approaching 1 M (Staal et al., 2004, Sulzer et al., 2005).  DA-containing vesicles 
fuse with the plasma membrane in response to increased levels of Ca2+, which occurs when 
voltage-gated Ca2+ channels are activated by the arrival of an action potential.  DA is then 
released into the synaptic cleft, and activates DA receptors (DRs) in the synapse.   
 
DRs are G-protein coupled receptors (GPCR) that couple to either Gαs or Gαi/o.  There 
are five types of DRs: D1, D2, D3, D4, and D5, which are further divided into two subgroups, 
D1-like receptors, which consist of D1 and D5, and the D2-like receptors, which consist of D2, 
D3, and D4.  The D1-like receptors couple to Gαs, and upon activation, stimulate the production 
of cAMP by adenylyl cyclase, which activates protein kinase A and has a stimulatory effect on 
the cell.  In contrast, the D2-like receptors couple to Gαi/o, which dampens cell activity by 
suppressing adenylyl activity, resulting in a decrease in cAMP.  D2 receptors can be expressed 
on post-synaptic as well as pre-synaptic neurons, where they function as autoreceptors, 
dampening pre-synaptic activity when activated (Fig. 3).  DA transmission can be regulated by 
the expression of DRs, the activity of autoreceptors on the presynaptic neuron, and by the 
internalization of DRs from the plasma membrane. 
 
Termination of the DA signal is achieved by removing DA from the synaptic space. This 
occurs by diffusion of DA away from the synaptic cleft, enzymatic degradation of DA by 
monoamine oxidases (MAO’s) and catechol-O-methyltransferase (COMT) to the major 
metabolite, homovanillic acid (HVA) (Fig. 4), or by the active reuptake of DA into the  
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Figure 3. Overview of the dopaminergic synapse. DA is synthesized in the 
presynaptic neuron (top), and is packaged into secretory vesicles by the vesicular 
monoamine transporter (VMAT).  Upon arrival of an action potential, the vesicles fuse 
with the plasma membrane and release DA into the synaptic cleft.  DA activates 
dopamine receptors (D1R: D1-like receptors; D2R: D2-like receptors) on both the post-
synaptic and pre-synaptic densities, controlling intracellular signaling.  DA is then cleared 
from the synapse by active reuptake into the presynaptic neuron via the dopamine 
transporter (DAT), enzymatic degradation, or diffusion. Tyr: tyrosine; L-DOPA: L-3,4-
dihydroxyphenylalanine; TH: tyrosine hydroxylase; AADC: aromatic amino acid 
decarboxylase; MAOA: monoamine oxidase A. 
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Figure 4. Enzymatic degradation of DA.  The enzymes Catechol-O-methyl transferase 
(COMT) and Monoamine oxidase (MAO)/aldehyde dehydrogenase remove DA from the 
synapse by converting it into the metabolite homovanillic acid (HVA). 
 
!Monoamine oxidase (MAO), 
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presynaptic terminal by the DAT (Fig. 3).  Once inside the presynaptic terminal, DA can then be 
reloaded into vesicles by VMAT for re-release.   
 
Dopamine transporter structure 
The DAT is a solute-dependent carrier (SLC) transporter, and in particular, is part of the 
SLC6 family, which includes other neurotransmitter and amino acid transporters such as the 5-
HT transporter (SERT), the norepinephrine transporter (NET), the glycine transporter (GLYT), 
and the GABA transporter (GAT), among others.  The SLC6 transporters are secondary active 
transporters, as they use the electrochemical gradients generated by Na+/K+ ATPase pumps in 
the plasma membrane to symport substrate against the substrate’s concentration gradient into 
the cytosol (Torres et al., 2003).  The DAT requires both Na+ and Cl- ions to cotransport DA, 
with a predicted stoichiometry of two Na+ ions and one Cl- ion per molecule of substrate (Giros 
and Caron, 1993, Sonders and Amara, 1996).   
 
Topology and overall structure  
In humans, the DAT (hDAT) is encoded by the gene SLC6A3. The hDAT cDNA was 
cloned in the early 90’s, and consists of 620 amino acids (Giros et al., 1992).  The number of 
transmembrane (TM) domains, intracellular loops (ILs), extracellular loops (ELs), and locations 
of the N- and C-termini were predicted using hydrophobicity analysis (Giros et al., 1992), 
allowing for generation of topology maps similar to that shown in Figure 5.  From this model, it 
was predicted that the DAT would have 12 transmembrane (TM) domains.  Furthermore, it was 
predicted to have 6 ILs and 6 ELs, with glycosylation sites located on EL2 between TM3 and 
TM4, and both N- and C-termini located in the cytosol.  High-resolution crystal structures of the 
bacterial homolog for SLC6 transporters, the LeuT, have been used to confirm this general 
topology (Yamashita et al., 2005).  Finally, the recent crystallization of the Drosophila 
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Figure 5. hDAT topology map.  Sequence analysis of the hDAT predicts the DAT is a 
membrane protein consisting of 12 transmembrane domains.  The DAT is predicted to 
have both N- and C-termini located on the intracellular face, with the extracellular loop 
between the third and fourth transmembrane domains containing a disulfide bond and N-
linked glycosylation sites. Image adapted from Loland et al., 2002. 
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melanogaster DAT (DATcryst) (Fig. 6) further confirmed structural predictions based on the 
topology maps and LeuT structure (Penmatsa et al., 2013).   
 
Substrate and ion binding sites  
Both the LeuT and the DATcryst confirm that the substrate and the two sodium binding 
sites are composed of the unwound regions of TM1 and TM6 (oriented antiparallel to each 
other), in addition to TM3 and TM8 (Yamashita et al., 2005, Penmatsa et al., 2013).  While the 
two Na+ binding sites translated exactly between the LeuT and the DATcryst, the LeuT (as a Cl- 
independent transporter) lacks a Cl- binding site.  However, the location of a Cl- binding site was 
predicted from studies with a Cl- dependent variant of the LeuT (LeuT E290S) to consist of a 
coordination between TM2, TM6, and TM7, near the Na1 site (Kantcheva, et al., 2013).  This 
was confirmed  in the DATcryst (Penmatsa et al., 2013). 
 
N- and C-termini  
Limited structural data is available regarding the N- and C-termini of the LeuT and the 
neurotransmitter:sodium symporters (NSSs), with the exception of the DATcryst structure 
resolved in 2013 (Penmatsa et al., 2013).  The DATcryst structure showed that the C-terminus 
contains an alpha helix itself, and appears to act as a “latch” covering the cytoplasmic gate 
(Penmatsa et al., 2013).  However, to date, only computational and physiological data exist to 
model the hDAT N-terminus.  Both the N- and C-termini contain several phosphorylation sites, 
including consensus sequences for calcium/calmodulin-dependent kinase II (CaMKII), protein 
kinase A (PKA), and protein kinase C (PKC) (Giros and Caron, 1993).  In fact, interaction 
between the C-terminus and CaMKII has been suggested to be necessary for CaMKII-mediated 
phosphorylation of the N-terminus (Fog et al., 2006).  Phosphorylation of the N-terminus is vital 
for regulating certain functions of the hDAT, namely reverse transport of DA (Khoshbouei et al., 
2004).  In particular, the putative phosphorylation sites at Ser residues, 2, 4, 7, 12, and 13, are 
11 
 
  
!
Figure 6.  Drosophila dopamine transporter (DATcryst) structure.  DATcryst was co-
crystalized with the tricyclic antidepressant nortriptyline, two sodium ions, a chloride ion, 
and one molecule of cholesterol (represented by magenta, purple, green, and yellow 
spheres, respectively).  DATcryst structure viewed parallel to plasma membrane.  Image 
adapted from Penmatsa et al., 2013. 
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thought to be especially important for reverse transport of DA (Khoshbouei et al., 2004, Bowton 
et al., 2010).   
 
Oligomerization  
The LeuT has been crystallized as a dimer (Yamashita et al., 2005), with TM12 and TM9 
important for this dimer interface.  However, the DATcryst structure suggests that TM12 is kinked 
in the dDAT due to the presence of a proline residue at position 572 and unlikely to form dimers 
like the LeuT does (Penmatsa et al., 2013).  Furthermore, the DATcryst did not form dimers or 
oligomers in the micelles used to crystallize it (Penmatsa et al., 2013).  Contrary to the crystal 
structure of DATcryst, there is physiological data that suggests the hDAT does in fact form 
oligomers (Hastrup et al., 2001, Torres et al., 2003, Hastrup et al., 2003, Sorkina et al., 2003, 
Chen and Reith, 2008) and that this oligomerization influences transporter function (Torres et 
al., 2003, Chen and Reith, 2008).  However, it has been suggested that instead of TM9 and 
TM12 being the interface of dimerization, as occurs in the LeuT, DAT dimerization interface 
actually occurs with TM4 and TM6, and possibly TM2 (Hastrup et al., 2001, Hastrup et al., 2003, 
Torres et al., 2003).    
 
Dopamine transporter function 
One of the most celebrated models of substrate transport is the alternating-access 
model, as proposed by Patlak in 1957 and later popularized by Jardetzky in 1966 (Patlak, 1957, 
Jardetzky, 1966).  This model proposes that the transporter, which spans the cell membrane, is 
open to either the extracellular environment (“outward-facing” conformation) or the intracellular 
environment (“inward-facing” conformation), and alternates between the two conformations to 
transport substrate.  When the transporter substrate interacts with its binding site, the 
transporter changes its conformation and opens to the other side of the membrane, releasing 
the substrate.  There are mechanistic variations of the alternating access model, including the 
13 
rocker-switch model (Fig. 7a), of which the prokaryotic proton-coupled lactose transporter LacY 
is an example (Abramson et al., 2003), and the gated-pore mechanism, or the occluded model 
of alternating access (Fig. 7b), which is used to model SLC6 transporters and the SLC6 
bacterial homolog, the LeuT (Forrest and Rudnick, 2009).   
 
The rocker-switch model can be characterized by an equilibrium between two 
conformational states: inward-facing and outward-facing.  Transport occurs by binding of the 
substrate and ion(s) to their respective sites while the transporter is in an outward-facing 
conformation.  The transporter then “rocks” around the substrate binding region and opens to 
the cytosol in an inward-facing conformation, releasing substrate and ions.  Unlike the rocker-
switch model, the occluded access model is characterized by an equilibrium between three 
conformational states: outward-facing, occluded, and inward-facing.  The occluded state occurs 
because of the presence of two gates, an extracellular gate and an intracellular gate.  When the 
transporter is in the outward-facing conformation, the substrate and ions can bind to their 
respective sites; then, the extracellular gate closes and the transporter adopts the occluded 
state, with both intracellular and extracellular gates closed, trapping the substrate within.  The 
transporter must then adopt the inward-facing conformation and the intracellular gate must open 
for the substrate and ions to be released into the cytosol. 
 
Altering the conformational equilibrium in which the DAT exists can influence transporter 
function.  An example of this principle in practice is the functional regulation of the DAT by zinc 
(Zn2+).  In ELs 2 and 4, there are three amino acid residues that have been demonstrated to 
coordinate Zn2+ binding: His193 (EL2), His375 (EL4), and Gln396 (EL4) (Fig. 8) (Norregaard et 
al., 1998, Loland et al., 2002).  When Zn2+ interacts with this binding site, the DAT shows 
impaired DA uptake, but retains normal substrate binding (Norregaard et al., 1998).  This 
suggests that by “pinning” together EL2 and EL4, Zn2+ impairs the ability of the transporter to  
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Figure 7. Models of alternating access. (a) Rocker-switch mechanism. Substrate 
(black sphere) and ion(s) (blue/green spheres) enter when the transporter is in outward 
facing conformation (left).  After substrate binds, the transporter changes conformation 
by rotating around the substrate/ions, adopting an inward facing conformation (right) 
and releases substrate/ions into the cytosol. (b) Occluded State Mechanism. Substrate 
and ion(s) enter when the transporter is in outward facing conformation with the 
extracellular gate open (left).  Upon substrate binding, the extracellular gate closes and 
the transporter adopts an intermediate occluded state (middle).  The transporter 
changes conformation to the inward facing state and the intracellular gate opens (right), 
releasing substrate/ions into the cytoplasm. 
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Figure 8. Endogenous zinc binding sites in the hDAT and hDAT Y335A.  Residues in 
extracellular loops 2 (His193) and 4 (His375, E396) coordinate the binding of zinc with 
the hDAT.  Mutation of Y335A (highlighted) results in uptake-deficient transporter, 
partially rescued by addition of zinc.  Image from Loland et al., 2002. 
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change conformation and disallows the translocation of substrate.  Further investigations into 
the relationship between the outward and inward face were conducted by mutating a residue 
located in IL3 (a region known to be part of the intracellular gating mechanism), Tyr335 to Ala 
(hDAT Y335A) (Loland et al., 2002).  The hDAT Y335A displays an impaired ability to uptake 
DA, as well as decreased surface expression, though substrate affinity is normal (Loland et al., 
2002).  Addition of Zn2+ partially rescues this phenotype, restoring some uptake function of the 
hDAT Y335A (Loland et al., 2002).  This suggests that hDAT Y335A is unable to shift towards 
an inward-facing conformation without EL2 and EL4 being brought into close proximity (in this 
case, by Zn2+).  
 
While the alternating access model of transport provides a useful construct for thinking 
about DAT uptake dynamics, the actual DAT transport process appears to be more nuanced, as 
there is evidence that the DAT does not uptake substrate and ions in a stoichiometric manner.  
The process of transporting substrate across the plasma membrane is electrogenic, and 
induces a measurable current: since DA carries a positive charge at physiological pH, based on 
the 2Na+/1Cl-/1 substrate+ stoichiometry, the inward current should reflect a transference of two 
positive charges per transport cycle.  Indeed, as seen when DAT is expressed in mammalian 
cells or in Xenopus oocytes, the transport of substrate, including DA, AMPH, and (1-methyl-4-
phenylpryidium) MPP+ into the cytosol generates an inward current (Sonders et al., 1997, Sitte 
et al., 1998, Khoshbouei et al., 2003).  However, it has been observed that the inward current 
passed is greater than that predicted by stoichiometry (Sonders and Amara, 1996, Kahlig et al., 
2004).  This suggests that the DAT does not always abide by the alternating access model, and 
instead may exhibit channel-like activity in passing currents (Fig. 9).  Another complication in 
assessing DAT-mediated transport is that the DAT exhibits a second, constitutive leak current 
that can be blocked by uptake inhibitors like COC and by substrates (Sonders et al., 1997,  
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Figure 9.  Model of DAT uptake activity.  The DAT exhibits behavior consistent with the 
alternating access model (a, b), but also shows channel-like activity, behaving as a pore 
for substrates (black spheres) and ions (blue/green spheres; c). 
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Kahlig et al., 2004).  Interestingly, this “leak” activity can vary based upon intracellular conditions 
and dynamics (Ingram et al., 2002, Carvelli et al., 2004).   
 
Reverse transport: amphetamine-induced dopamine efflux 
The DAT also is capable of reversing the direction of substrate transport, resulting in the 
translocation of substrate from the intracellular to the extracellular side.  The most dramatic 
example of this function involves the mechanism of action of the psychostimulant AMPH.  The 
historical study of reverse transport of substrate function has been well summarized by 
Roberston and colleagues in 2009 (Roberston et al., 2009), though the physiological role of this 
mechanism remains an enigma (Leviel, 2011).   
 
Amphetamine 
AMPH and its derivatives are structurally similar to DA (Fig. 10), and are able to act as 
substrates for the DAT.  AMPH can affect DAT function by acting as a competitive inhibitor of the 
DAT, preventing the DAT from transporting DA into the cell, thereby increasing extracellular DA 
levels, having a similar effect as cocaine, a DAT inhibitor that blocks DA transport.  However, AMPH 
also induces the DAT to reverse the transport of DA into the extracellular space (a DA efflux event), 
further enhancing the levels of extracellular DA and contributing to the rewarding effects and abuse 
potential of AMPH.  A summary of the differences between the mechanism of DAT blockers (like 
COC) and the mechanism of AMPH is seen in Figure 11.  The behavioral effects of AMPH are 
thought to be mediated by the DAT, since mice and Drosophila melanogaster lacking the DAT do 
not show any locomotor response to AMPH, although they do exhibit constitutively elevated DA 
levels as well as hyperlocomotion (Giros et al., 1996, Pizzo et al., 2013). 
 
The mechanism by which AMPH induces the reverse transport of DA has been studied for 
several decades, and the understanding of the mechanism has seen much evolution.  The first  
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Figure 10.  Chemical structures of DAT substrates.  The psychostimulants 
amphetamine and methamphetamine share structural similarities with the endogenous 
substrate dopamine, and are recognized as substrates by the DAT. 
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Figure 11.  Mechanism of action of psychostimulants. (a) Cocaine (COC) is an 
inhibitor of the DAT, contributing to the elevation of extracellular dopamine by preventing 
the reuptake of dopamine released through vesicular fusion. (b) Amphetamine (AMPH) is 
a substrate for the DAT, and is transported into the presynaptic neuron. AMPH prevents 
the loading of dopamine into synaptic vesicles, increasing the intracellular dopamine 
concentration.  AMPH then induces the DAT to adopt an efflux-willing conformation, 
which releases DA into the extracellular space through the DAT itself. Image from 
Katzung et al., (2009). 
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mechanism introduced, the facilitated exchange diffusion model, was suggested in 1979 by Fischer 
and Cho (Fischer and Cho, 1979) (Fig. 12). Consistent with the alternating access model of 
transport, the facilitated exchange diffusion model suggests the exchange of extracellular AMPH for 
intracellular DA: as AMPH interacts with the outward-facing conformation of the DAT, it is 
transported into the neuron and the DAT changes its conformation to an inward-facing state to 
release the substrate.  Once AMPH is released into the cell, the DAT is left in an inward-facing 
conformation, available to bind to intracellular DA.  As the transporter returns to its outward-facing 
conformation, it then releases DA into the extracellular environment (Fischer and Cho, 1979).   
 
Once AMPH has been transported into the presynaptic bouton, it interferes with the loading 
of DA into vesicles, raising the intracellular concentration of unsequestered DA.  AMPH is a 
substrate for the VMAT as well and is transported into secretory vesicles.  The weak-base 
hypothesis, (discussed in more detail in a review by Sulzer et al.,  2005), suggests that, as a weak 
base, AMPH sequesters protons inside the secretory vesicle, destroying the proton gradient 
necessary for VMAT to load DA into the vesicle.  Another hypothesis proposes that AMPH 
competes with DA for transport by VMAT, and would cause depletion of DA from the vesicles via the 
facilitated exchange diffusion model (Sulzer et al., 2005).  Regardless, AMPH causes the elevation 
of DA inside the cell, which can trigger the reverse transport of DA (Fischer and Cho, 1979). 
 
However, in 2005, the DAT was also discovered to adopt a channel-like state in response to 
AMPH, resulting in the rapid release of DA (DA efflux) (Kahlig et al., 2005) (Fig. 13).  This 
mechanism is radically different from the facilitated exchange diffusion model in that there is no 
known stoichiometry between ions and substrate, and occurs on the order of milliseconds rather 
than slower diffusion.  Additionally, such an efflux event can be considered within the range of a DA 
quantum from vesicular release, a release of approximately 2,000-14,000 molecules of DA, which 
can influence high-affinity DA receptors in 20-100 nearby dopaminergic synapses (Sulzer and  
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Figure 12.  Alternating access model of AMPH-induced DA efflux. AMPH (red 
sphere) and ions (blue/green spheres) bind to outward facing DAT (a), and DAT changes 
conformation to inward facing, releasing AMPH into cytosol (b).  Intracellular DA (black 
sphere) binds to inward facing DAT (c), and DAT changes conformation to outward 
facing to release DA into the extracellular space (d). 
 
Extracellular*
Intracellular*
a" b" c" d"
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Figure 13.  Model of AMPH-induced DA efflux mechanism: channel-like activity.  
AMPH (red sphere) and ions (blue/green spheres) bind to outward facing DAT (a), and 
DAT changes conformation to inward facing, releasing AMPH into cytosol (b).  AMPH 
induces transporter to adopt channel-like state (c), allowing DA (black sphere) to pass 
through transporter, resulting in DA efflux event. 
 
Extracellular*
Intracellular*
a" b" c"
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Pothos, 2000, Cragg and Rice, 2004, Kahlig et al., 2005).  This DA quantum release also suggests 
that this coordinated burst of DA release may have a discernable impact on dopaminergic signaling, 
and may contribute to AMPH’s effects (Kahlig et al., 2005).   
 
Interacting proteins and reverse transport of DA 
The ability of AMPH to cause the DAT to undergo the conformational changes required for 
DA efflux is likely to depend, at least in part, upon alterations to the DAT via phosphorylation and/or 
changes in interactions with other intracellular proteins/entities.  The N-terminus of the DAT in 
particular possesses several consensus sequences for phosphorylation sites by kinases such as 
CaMKII and PKC.  When phosphorylation of the DAT N-terminus is prevented either by 
truncation or targeted mutation of Ser residues to Ala, the ability of AMPH to induce DA efflux is 
dramatically inhibited (Khoshbouei et al., 2004).  Furthermore, phosphomimetic mutations (Ser 
to Asp) of the N-terminus promote AMPH-induced DA efflux (Khoshbouei et al., 2004).  
Although the phosphorylation state of the N-terminus of the DAT is important for AMPH-induced 
DA efflux, it appears to have no effect on the ability of the DAT to uptake substrate  
(Khoshbouei et al., 2004), indicating that this mechanism regulates DAT functions in an 
asymmetric manner.  
 
AMPH has been observed to cause the activation of CaMKII, in synaptosomal preparations 
(Iwata et al., 1997, Choe and Wang, 2002, Wei et al., 2007).  Consistent with the idea that AMPH 
acts as a substrate for the DAT and enters the neuron via DAT uptake, when DAT expressing 
synaptosomes were exposed to a DAT inhibitor, AMPH failed to activate CaMKII (Iwata et al., 
1997).  AMPH has also been shown to increase the intracellular concentration of Ca2+ in DAT 
expressing cells (Gnegy et al., 2004), an increase dependent upon the activation of L-type and N-
type Ca2+ channels, both of which are voltage-gated channels (Kantor et al., 2004).  Furthermore, in 
the absence of extracellular Ca2+, the ability of AMPH to activate CaMKII in synaptosomal  
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preparations is also diminished (Iwata et al., 1997).  As elevated Ca2+ levels activate CaMKII, AMPH 
likely activates CaMKII and other Ca2+ dependent intracellular signaling pathways by increasing the 
concentrations of Ca2+ inside DAT-expressing cells.  Once activated, CaMKII associates with and 
phosphorylates the distal DAT N-terminus serine residues, promoting DA efflux (Fog et al., 
2006, Bowton et al., 2010).  Inhibition of CaMKII impairs the ability of AMPH to induce DA efflux 
both in vitro and in vivo, as does the prevention of CaMKII/DAT interactions (Fog et al., 2006). 
 
PKC has also been shown to be activated in vivo by the addition of AMPH to brain 
slices, which then also phosphorylates serine residues of the DAT N-terminus (Giambalvo, 1992, 
Foster et al., 2002, Giambalvo, 2004, Johnson et al., 2005).  Inhibition of PKC in rat striatal slices 
prevents AMPH-induced DA efflux (Kantor and Gnegy, 1998, Johnson et al., 2005). While PKC 
does phosphorylate the N-terminus, AMPH-induced PKC activation also results in the internalization 
of the DAT (Zhu et al., 1997), which requires the C-terminus of the DAT (Holton et al., 2005).  PKC 
can also be activated by the addition of phorbol esters such as PMA, which causes internalization 
and ubiquitination/degradation of the DAT (Hong and Amara, 2013).  However, transporters 
internalized in response to AMPH-activation of PKC usually undergo recycling and eventually are 
trafficked back to the surface in neurons (Hong and Amara, 2013).  
 
Interaction partners for the DAT are not limited to kinases, as evidenced by the growing 
body of evidence supporting the role of Syntaxin 1 (STX1), a member of the soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein complex, in the 
AMPH-induced DA efflux mechanism.  STX1 is required for the docking and fusion of synaptic 
vesicles with the plasma membrane, and therefore plays an essential role in the exocytotic 
release of neurotransmitters (Sudhof, 2004).  There is evidence suggesting that STX1 directly 
interacts with the N-terminus of several different SLC6 neurotransmitter transporters (Deken et 
al., 2000, Quick, 2003, Lee et al., 2004), and alters their electrophysiological properties (Quick, 
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2003, Carvelli et al., 2008).  For STX1 interactions with the DAT, glutathione-S-transferase 
(GST) pulldowns show that the first 33 residues of the DAT N-terminus are important for this 
interaction (Binda et al., 2008), the same region of the DAT N-terminus necessary for AMPH-
induced DA efflux.  Furthermore, this DAT/STX1 interaction is mediated by AMPH-activated 
CaMKII and supports AMPH-induced DA efflux (Binda et al., 2008). 
 
Dopamine transporter variants and neuropsychiatric disease 
While the mechanism by which the reverse transport of DA affects physiology remains 
mysterious (Leviel, 2011), the information available about the role of dysregulated reverse transport 
in psychiatric disease is growing as more neuropsychiatric disease-associated hDAT variants are 
being identified and characterized.  These neuropsychiatric disorders include ADHD, ASD, BAD, 
and early-onset PD.  While dopaminergic signaling has been implicated in each of these disorders 
individually, several cases of comorbidity occur between these conditions.  ADHD and BAD are 
documented to share symptoms and can occur simultaneously with pediatric onset of BAD (Geller 
et al., 2002, Faraone and Tsuang, 2003), while patients with ASD often display symptoms of ADHD 
as well.  Since hyperactivity is a shared trait in each of these disorders, it can be suggested that 
these individual neuropsychiatric disorders share at least some common pathological dysregulation 
of neuropathways.  
 
Due to the prevalence of functionally altered DAT variants found in these disorders, as 
discussed later in this chapter, DAT dysfunction appears to be a promising mechanism or paradigm 
in the underlying dysregulation of the putative common neuropathway(s) in these disorders.  In fact, 
the most well-known mouse model of a hyperactive state, like that observed in human ADHD, is the 
DAT knockout mouse (KO) (Giros et al., 1996), although in humans lacking function DAT, infantile 
dystonia and juvenile Parkinson’s Disease occur (Kurian et al., 2009, Kurian et al., 2011).  
Furthermore, a specific hDAT variant (hDAT A559V) has been identified in five individuals, each 
27 
presenting with either BAD, ADHD, or ASD (Grunhage et al., 2000, Mazei-Robison et al., 2005, 
Bowton et al., 2014).  Intriguingly, the individuals who share a common disorder are siblings (i.e., 
ADHD siblings, ASD siblings). This raises the question of whether the interplay between different 
environments and the same genetic variants can result in the manifestation of different disorders.  
On the other hand, perhaps particular disorders can arise from interactions between the hDAT 
variant and other distinct, though as yet unidentified, variants in the probands’ genetic backgrounds.  
 
The hDAT variants discussed both in this section and in the original work of this thesis 
possess a functional commonality: an impaired or altered ability to reverse transport DA.  To date, 
there are two (often overlapping) kinds of disease-associated impairments in reverse transport: (1) 
anomalous DA efflux (ADE), characterized by a mutant DAT constitutively leaking DA into the 
extracellular space and (2) impaired or altered ability of the hDAT to respond to AMPH in a 
coordinated manner.  While the effects of these dysfunctions are still not immediately translatable to 
physiology, the growing body of evidence suggests that this mechanism is physiologically relevant 
to the etiology of neuropsychiatric disorders.  Table 1 summarizes the functional phenotypes of the 
hDAT variants characterized to date, as well as their associated disease and the number of 
individuals with the variant.   
 
hDAT A559V 
The hDAT A559V variant is the most well-studied functional variant of the hDAT and was 
first identified in a patient with bipolar disorder (Grunhage et al., 2000), then in two patients 
(siblings) with attention deficit hyperactivity disorder (ADHD) (Mazei-Robison et al., 2005), and in 
two unrelated patients with autism spectrum disorder (Bowton et al., 2014).  The hDAT A559V 
variant was first functionally characterized in vitro in 2008, and was shown to have unchanged DA 
uptake from type (WT) hDAT, but exhibited anomalous DA efflux, as revealed by blocking DA leak 
with the DAT inhibitor COC, and abnormal response to AMPH (Mazei-Robison et al., 2008).  The  
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Variant # Affected Individuals 
Disease(s) 
associated 
Surface 
Expression Uptake 
Anomalous 
DA efflux 
AMPH 
response 
A559V1 5 
Bipolar, 
ADHD, 
ASD 
Normal Normal Yes Impaired 
T356M2 1 ASD Normal Impaired Yes Impaired 
D421N2 1 ADHD, PD3 Normal Impaired Yes Impaired 
R615C 1 ADHD Impaired Impaired N/A4 Normal4 
R51W 1 ASD Normal Normal N/A Impaired 
STX1 
R26Q5 1 ASD Normal Increased N/A Impaired 
R445C 1 Infantile Dystonia Impaired
6 Impaired No7 Impaired8 
Table 1. Disease-associated variants and their respective functional phenotypes.  
11 Individual with bipolar disorder, 2 individuals (siblings) with ADHD, and 2 individuals 
(siblings) with ASD.  2De novo mutation.  3Individual had both ADHD and PD, as well as 
heritable I312F variant (impaired uptake only, present in non-symptomatic sibling 
(Hansen et al., 2014).  4R615C has increased basal phosphorylation levels and 
interaction with CaMKII, may affect ADE/AMPH response, but not tested.  5Syntaxin1 
(STX1) is an interacting protein with the hDAT, involved in the AMPH-induced DA efflux 
mechanism (Binda et al., 2008). Functional phenotypes are for WT hDAT when 
coexpressed with STX1 R26Q.  6hDAT variant displays decreased glycosylation.  7hDAT 
variant was tested for ADE.  8Cells heterologously expressing hDAT R445C were patch 
pipette loaded with DA, bypassing impairments in uptake. 
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hDAT A559V is unable to uptake AMPH, and therefore does not respond to AMPH treatment with 
the DA efflux phenotype typical of WT hDAT (Mazei-Robison et al., 2008, Bowton et al., 2014).  
Instead, ADE by hDAT A559V is blocked by application of AMPH (Mazei-Robison et al., 2008).  
The mechanism behind this ADE was further explored in 2010, and was discovered to be supported 
by D2-autoreceptor activation of CaMKII, which mediates phosphorylation of the hDAT N-terminus 
(Bowton et al., 2010).  It did not go unnoticed that this mechanism is similar to that which occurs 
during the AMPH-induced mechanism of DA efflux, and in fact, pseudophosphorylation of the N-
terminus of hDAT A559V (mimicking AMPH-mediated phosphorylation) supports channel-like 
activity of the DAT, possibly leading to DA efflux or ADE (Bowton et al., 2010).  It is intriguing that 
despite the hDAT A559V’s inability to respond to AMPH, a phosphorylation pathway normally 
stimulated by AMPH is dysregulated in the hDAT A559V. 
 
The relationship between the intracellular machinery susceptible to subversion by AMPH 
and the hDAT A559V’s functional phenotype was also investigated in the context of AMPH-induced 
trafficking of the hDAT (Bowton et al., 2014).  AMPH is known to induce redistribution of the 
transporter at and away from the plasma membrane (Saunders et al., 2000, Kahlig et al., 2004, 
Johnson et al., 2005, Kahlig et al., 2006, Boudanova et al., 2008).  However, in the case of hDAT 
A559V, AMPH does not induce internalization in vitro unless it is perfused into the intracellular 
environment via whole-cell patch clamp or PKCßII is inhibited (Bowton et al., 2014).  PKCßII is an 
isoform of PKCß that is required for D2R-mediated regulation of DAT surface expression and has 
also been shown to interact with the hDAT to promote DA efflux (Johnson et al., 2005).  hDAT 
A559V cells show increased basal levels of activated PKCßII at the plasma membrane compared to 
cells expressing WT hDAT, perhaps due to the increased activity of D2Rs (Bowton et al., 2010, 
Bowton et al., 2014).  Additionally, inhibition of PKCßII rescues the impaired ability of AMPH to 
induce DA efflux in hDAT A559V cells (Bowton et al., 2014).  It is possible that elevated activity of 
PKCßII contributes to the constitutively elevated phosphorylation of the hDAT A559V N-terminus, 
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which has been suggested to not only support constitutive ADE, but also promote an inward-facing 
conformation (Bowton et al., 2010, Bowton et al., 2014).  Since DA uptake is unaffected, but AMPH 
uptake is, it is tempting to suggest that perhaps the A559V mutation results in an increased affinity 
for AMPH, preventing AMPH from being released into the cytosol in high enough amounts to evoke 
cellular responses. 
 
Finally, hDAT A559V has been developed as a behavioral model (Mergy et al., 2014).  Mice 
expressing the hDAT A559V show elevated extracellular DA levels in the brain, as well as an 
increase in basal locomotion (Mergy et al., 2014).  However, as predicted by in vitro 
characterizations, hDAT A559V shows normal uptake.  Additionally, as expected, mice with the 
hDAT A559V variant show a decreased locomotor response to AMPH, as well as an impaired ability 
to depolarize DA neurons (Mergy et al., 2014).  It is tempting to speculate that ADE, and/or the 
underlying AMPH-susceptible machinery, plays a role in depolarization of DA neurons.  The hDAT 
A559V mouse model is now being used as a model for studying the impact of DAT dysfunction in 
neuropsychiatric disease.   
 
hDAT R615C  
Another ADHD-associated hDAT variant, the hDAT R615C, was characterized in 2012 
(Sakrikar et al., 2012). Although this variant was not tested for ADE, it displays altered functional 
characteristics that may impact ADE.  Unlike the hDAT A559V or hDAT D421N variants, hDAT 
R615C shows no impairment in AMPH-induced DA efflux as measured by amperometric current 
in vitro, although it does have impaired DA uptake.  Furthermore, the R615C hDAT was shown 
to have increased levels of endocytosis and turnover, with decreased overall total and surface 
expression compared to WT hDAT.  Impaired surface expression of the DAT results in elevated 
DA levels and hyperlocomotion (Giros et al., 1996), so it is possible that the hDAT R615C might 
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contribute to ADHD pathology via a concomitant impairment in DA uptake and surface 
expression. 
 
However, Sakrikar et al also found that hDAT R615C showed a 2-fold increase in 
association with CaMKII, as well as an increase in phosphorylation of the hDAT R615C 
(Sakrikar et al., 2014).  Importantly, CaMKII phosphorylates the N-terminus of the hDAT during 
the AMPH-induced DA efflux mechanism, so these data led researchers to believe that the 
hDAT R615C was able to compensate for lack of surface expression, and still show similar 
AMPH-induced DA efflux. This would suggest that neurons expressing hDAT R615C would 
have abnormal regulation of phosphorylation of the N-terminus, which has been shown to result 
in spontaneous DA efflux in the hDAT A559V variant (Bowton et al., 2010).  Although to date the 
hDAT R615C has not yet been tested for ADE, it bears the hallmarks of an ADE hDAT variant 
and merits further investigation.  It is also tempting to speculate that, due to its elevated basal 
phosphorylation, the hDAT R615C may have altered sensitivity to AMPH under differing cellular 
conditions. 
 
hDAT D421N 
Recently, an adult individual with both early-onset Parkinson’s Disease and ADHD was 
identified out of a cohort of patients with Parkinson’s-like movement disorders (Hansen et al., 2014).  
This individual is the first documented case of being compound heterozygous for variants in the 
hDAT, possessing a heritable variant, hDAT I312F and a de novo variant, hDAT D421N.  The hDAT 
I312F showed an impairment in DA uptake in vitro, but was also present in an unaffected sibling.  
However, the de novo hDAT D421N demonstrated a functional phenotype similar to the ASD de 
novo variant, hDAT T356M (Hamilton and Campbell et al., 2013; discussed in detail in the body of 
this thesis), impaired DA uptake, impaired DA efflux response to AMPH, and ADE (Hansen et al., 
2014).  Another similarity with the hDAT T356M is that the D421N mutation also perturbs affinity for 
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Na+ by interfering with the second Na+ binding site (Hansen et al., 2014).  As is the case for hDAT 
T356M, there have not yet been any published investigations on the intracellular mechanisms 
surrounding the observed ADE of hDAT D421N, nor whether the AMPH-susceptible 
phosphorylation pathways are dysregulated in these variants, as is the case with the hDAT A559V.  
 
hDAT R445C 
Another hDAT variant found in an individual with Parkinson’s-like symptoms (Infantile 
Dystonia) is the hDAT R445C (Ng et al., 2014).  While this variant showed decreased formation of 
the mature hDAT when expressed in a heterologous cell line and decreased surface expression, 
enough was expressed to allow functional assessment.  This transporter was shown to have 
ablated AMPH-induced DA efflux, did not present any evidence of ADE, nor did this transporter 
variant possess the ability to uptake substrate (Ng et al., 2014).  The absence of virtually all function 
of the hDAT R445C variant is an intriguing puzzle, but unfortunately does not allow for any 
conclusive remarks regarding the role of reverse transport of DA in infantile dystonia, except to note 
that this is an additional case of impaired/absent reverse DA transport capability. 
 
While the hDAT R445C is, thus far, the only infantile dystonia-associated hDAT variant to be 
tested for AMPH response or ADE, it is only one of 13 different hDAT variants discovered to be 
present in this disorder (Kurian et al., 2009, Kurian et al., 2011, Ng et al., 2014).  A striking 
commonality is that, when expressed heterologously, all 13 of these variant hDAT constructs show 
decreased maturation and glycosylation, as well as decreased trafficking and surface expression 
(Table 2).  However, since the heterologous expression systems differ between the studies and 
manifest differing levels of surface expression, it is uncertain whether this impaired glycosylation is a 
disease-relevant characteristic of these variants or merely an artifact.  The relationship between 
impaired hDAT glycosylation and Infantile Dystonia is unclear, although all 7 of the hDAT variants 
tested for uptake function in vitro (predictably) showed decreased ability to transport substrate.  
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Variant # Affected Individuals 
Surface 
Expression Uptake 
Mature 
Glycosylation 
R85L** 1 Impaired Impaired Impaired 
V158F* 1* Impaired N/A Impaired 
L224P 1 Impaired N/A Impaired 
G327R# 1# Impaired N/A Impaired 
A314V 3 Impaired Impaired Impaired 
L368Q 2 Impaired Impaired Impaired 
G386R*** 1*** Impaired Impaired Impaired 
P395L 1 Impaired Impaired Impaired 
R445C** 1 Impaired Impaired Impaired 
Y470S*** 1*** Impaired Impaired Impaired 
R521W 1 Impaired N/A Impaired 
P529L# 1# Impaired N/A Impaired 
P554L* 1* Impaired N/A Impaired 
 
  
Table 2. Infantile Dystonia-associated hDAT mutations and respective in vitro 
functional phenotypes.  *Same individual, **Same individual, ***Same individual, 
#Same individual. Total unique individuals: 12 
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Impaired DA uptake has been identified in other disorders (ADHD, ASD) that lack the 
devastating neurodegeneration of infantile dystonia, so the possibility that impaired trafficking is a 
disease-relevant characteristic of these variants cannot simply be dismissed.  More data will need to 
be collected on this subject, which may be illuminated if another hDAT variant could be found and 
shown to have the same phenotypical profile as hDAT R445C (functionally “dead”) but with normal 
surface expression and glycosylation.   
 
Angelman syndrome 
Although the body of work is very limited, Angelman syndrome (AS) has also been 
investigated in the context of AMPH-induced reverse transport of DA.  AS is a neurogenetic disorder 
caused by a defective ubiquitin ligase Ube3A allele inherited maternally (Mabb et al., 2011), and its 
symptomology includes ASD and movement disorders.  Mice lacking the maternally inherited 
Ube3A allele have been used to model AS, and were shown to have autoinihibted αCaMKII in the 
brain (Weeber et al., 2003).  The important role played by αCaMKII in AMPH-induced DA efflux led 
Steinkellner and colleagues to explore whether this mechanism was impaired in the mouse model of 
AS (Steinkellner et al., 2012).  When AMPH was applied to brain slices from AS mice, it was found 
that DA efflux was reduced compared to WT mice, while DA uptake was unchanged.  This shows 
an example of AMPH-induced DAT reverse transport being impaired in a disorder in which ASD 
symptoms present.   
 
Fragile X mental retardation syndrome 
Fragile X mental retardation protein (FMRP) is an RNA-binding protein, and the gene that, 
when missing, contributes to Fragile X mental retardation syndrome (FXRS).  Knockout models of 
the gene encoding FMRP (Fmr1), are a well-validated model of FXRS.  FMRP was found to interact 
with 78 ASD candidate genes (Darnell et al., 2014), including PKC-ß.  Although no evidence was 
found to suggest a direct interaction between FMRP and the hDAT, behavioral studies performed 
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on the Fmr1 KO mouse model have shown attenuated AMPH-induced DA release in the dorsal 
striatum, corresponding to a decreased stereotypic behavioral response to high doses (10 uM) of 
AMPH (Fulks et al., 2010).  However, there is limited information available about the mechanism by 
which this impaired AMPH response occurs, and could be due to the observed decrease in the 
number of presynaptic afferents in the Nac in Fmr1 KO mice compared to WT mice (Smith et al., 
2014).  However, AMPH administration in the prefrontal cortex, a brain region largely lacking DAT 
expression, improved cognitive symptoms and enhanced object recognition (Ventura et al., 2004).  
Although there is as yet no solid connection between DA reverse transport and FXRS, a clinical 
study showed that treatment with either MPH or Adderall (AMPH) improved attention deficit and 
motor symptoms of some individuals with FXRS, while other individuals reported worsening 
symptoms in response to treatment with stimulants (Berry-Kravis and Potanos, 2004).  As these 
treatments are commonly recognized as ADHD treatments and are known to target the DAT, it may 
be worth investigating a link between the ADHD/DAT mechanism and FXRS. 
 
Studying hDAT mediated reverse transport of DA 
The central issue that complicates studying the role of the DAT in disease is that any 
inhibitor or previous genetic KO targets both the uptake and efflux functions of the DAT.  For 
example, commonly used inhibitors of the DAT, like COC block the transporter in an un-competitive 
manner.  COC can block both the outward constitutive DA leak, and prevents AMPH-induced DA 
efflux.  KO of the DAT results in a hyperactive state in mice as well as in Drosophila melanogaster 
(Giros et al., 1996, Pizzo et al., 2013), and in compensations in the other monoamine systems, like 
5-HT.  DAT KO animals are of limited use in understanding the role of the DAT in humans, since 
there are several cases of human DAT-deficiency syndrome, which have much more devastating 
results in humans, such as infantile parkinsonism. Therefore, understanding the mechanism 
underlying the reverse transport of DA and creating new genetic models that allow this mechanism 
to be asymmetrically manipulated are vitally important.   
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Chapters 2 and 3 of this thesis address the question of asymmetric manipulation of AMPH-
induced DA efflux, through the direct interaction between the hDAT N-terminus and the membrane 
lipid phosphatidylinositol (4,5)-bisphosphate (PIP2) (Chapter 2), and possibly through the 
intracellular gating regions (Chapter 3).  As a result of the data generated in this part of my 
dissertation, an animal model of impaired AMPH-induced DA efflux has been discovered and 
produced (Drosophila melanogaster), which will help to inform the physiology of AMPH-induced DA 
efflux in future studies.  The study in Chapter 2 is available in its entirety in Nature Chemical Biology 
(Hamilton and Belovich et al., 2014), while the data in Chapter 3 are as yet unpublished.   
 
Chapter 4 establishes the ASD-associated hDAT variant, hDAT T356M, as a functionally 
impaired protein, with the presence of ADE and impaired AMPH-induced efflux.  Furthermore, this 
work marks the first instance of a Drosophila melanogaster behavioral model of ASD 
symptomology, namely hyperlocomotion.  This can be found in full in Molecular Psychiatry 
(Hamilton and Campbell et al., 2013).  Chapter 5 demonstrates how hDAT T356M function can be 
partially restored by the addition of Zn2+ (reduction of ADE, improvement of AMPH-induced DA 
efflux), and the study therein can be found in Molecular Autism (Hamilton and Shekar et al., 2015).  
Taken together, Chapters 4 and 5 establish hDAT T356M as a behaviorally relevant, functionally 
impaired ASD-associated coding variant, as well as contribute to the mechanistic understanding of 
how Zn2+-susceptible conformational states of the hDAT influence the hDAT’s ability to respond to 
AMPH.  
 
Chapter 6 underscores the importance of the AMPH-induced DA efflux mechanism in ASD, 
and reports the identification and characterization of two independently occurring variants, one in the 
hDAT itself (hDAT R51W) and another in an interacting protein, Syntaxin 1 (STX1 R26Q).  hDAT 
R51W is shown to have an asymmetric impairment in function, where only the AMPH-induced DA 
efflux mechanism is affected while substrate uptake and surface expression remain unaffected.  
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STX1 is known to interact with the N-terminus of the hDAT, and is important for AMPH-induced DA 
efflux (Binda et al., 2008).  When co-expressed with WT hDAT, this ASD-associated variant, STX1 
R26Q, impairs the hDAT’s efflux response to AMPH.  Finally, this study shows that the STX1/hDAT 
interaction necessary for AMPH-induced efflux is mediated by Casein Kinase 2 (CK2), for which an 
inhibitor is currently undergoing clinical trials.  These data are published in EBioMedicine (Lancet) 
(Cartier and Hamilton et al., 2015), and emphasize the importance of the DAT reverse transport 
mechanism in ASD. 
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CHAPTER 2 
 
PHOSPHATIDYLINOSITOL (4,5)-BISPHOSPHATE REGULATES 
PSYCHOSTIMULANT BEHAVIORS THROUGH ITS INTERACTION 
WITH THE DOPAMINE TRANSPORTER N-TERMINUS1 
 
Abstract 
Phosphatidylinositol (4,5)-bisphosphate (PIP2) regulates the function of ion channels and 
transporters. Here, we demonstrate that PIP2 directly binds the human dopamine (DA) 
transporter (hDAT), a key regulator of DA homeostasis and a target of the psychostimulant 
amphetamine (AMPH). This binding occurs through electrostatic interactions with positively 
charged hDAT N-terminal residues and is shown to facilitate AMPH-induced, DAT-mediated DA 
efflux and the psychomotor properties of AMPH. Substitution of these residues with uncharged 
amino acids reduces hDAT-PIP2 interactions and AMPH-induced DA efflux without altering the 
hDAT physiological function of DA uptake. We evaluated the significance of this interaction in 
vivo using locomotion as a behavioral assay in Drosophila melanogaster. Expression of mutated 
hDAT with reduced PIP2 interaction in Drosophila DA neurons impairs AMPH-induced 
locomotion without altering basal locomotion. We present what is to our knowledge the first 
demonstration of how PIP2 interactions with a membrane protein can regulate the behaviors of 
complex organisms. 
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!
1"The work presented in this chapter is in press as Hamilton P. J.*, A. N. Belovich*, G. Khelashvili, C. Saunders, K. 
Erreger, J. A. Javitch, H. H. Sitte, H. Weinstein, H. J. G. Matthies** and A. Galli** (2014). “PIP2 regulates 
psychostimulant behaviors through its interaction with a membrane protein.” Nature Chemical Biology 10(7):582-9. * 
and ** denote equal contribution. 
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Introduction 
The functional regulation of plasma membrane proteins by lipid molecules is an integral 
component of cell function and metabolism (McLaughlin and Murray, 2005, Suh and Hille, 
2008). Phosphatidylinositol (4,5)-bisphosphate (PIP2) is the phospholipid precursor of the 
second messengers inositol trisphosphate (IP3), diacylglycerol (DAG), and phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3), and is, itself, capable of acting as a second messenger and 
cofactor for regulating protein function (Czech, 2000, Suh and Hille, 2008, Whorton and 
MacKinnon, 2011, Ben-Aissa et al., 2012, Kadamur and Ross, 2013). Additionally, PIP2 has 
been shown to modulate, through electrostatic interactions, the in vitro function of ion channels 
and transporters, including the serotonin transporter (SERT) (Suh and Hille, 2008, Buchmayer 
et al., 2013). A sizeable research effort has been dedicated to determining the diversity of 
cellular roles for PIP2 and defining the ubiquity of its electrostatic interactions with various 
plasma membrane proteins, but how these interactions might modulate the behaviors of 
complex organisms in vivo has never been studied.  
 
The plasma membrane dopamine (DA) transporter (DAT) is a presynaptic protein that 
plays a pivotal role in regulating DA neurotransmission by mediating the high-affinity reuptake of 
synaptically-released DA. Gene knockout experiments in multiple organisms, including 
Drosophila melanogaster (Hamilton and Campbell et al., 2013, Pizzo et al., 2013), point to the 
DAT as the main target for the locomotor stimulatory effects of amphetamine (AMPH) (Giros et 
al., 1996). AMPH’s addictive properties are mediated, at least in part, through elevation of 
extracellular DA by inducing DA efflux through the DAT (Sulzer et al., 2005, Robertson et al., 
2009). Thus, in order to target and limit AMPH actions pharmacologically, it is essential to 
understand how to precisely manipulate the DAT to prevent DA efflux without altering its 
physiological function of DA uptake.  
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The DAT N-terminus is a structural domain of functional significance. AMPH targets the 
N-terminus to cause posttranslational modifications (e.g. phosphorylation (Cervinski et al., 
2005)), which are essential for AMPH to cause DA efflux (Khoshbouei et al., 2004, Fog et al., 
2006) and behaviors (Pizzo et al., 2013). Notably, DAT localization to plasma membrane lipid 
rafts is also vital for DA efflux (Cremona et al., 2011) and AMPH-induced behaviors (Pizzo et al., 
2013). In this study, we elucidate how plasma membrane PIP2, which is enriched in lipid rafts 
(Hope and Pike, 1996, Wang and Richards, 2012), dictates specific aspects of the transport 
cycle through its interactions with the N-terminus of the DAT. In terms of AMPH-induced DA 
efflux, our experimental and computational data demonstrate that the regulatory effect of PIP2 
stems from its electrostatic association with the N-terminus. Here, we introduce the first animal 
model (Drosophila melanogaster) in which we evaluate the behavioral consequences of altered 
PIP2 interactions with a plasma membrane protein. We reveal that DAT-PIP2 interactions are 
required for AMPH-induced behaviors, thereby presenting PIP2 and its synthetic pathway as 
novel regulators of AMPH abuse. 
 
Results 
DAT associates with PIP2    
In this study, we aimed to determine the modalities of the regulatory function of PIP2 in 
terms of DA homeostasis and AMPH actions. We hypothesized that this regulatory function may 
be mediated through a physical association between DAT and PIP2. Using live confocal 
imaging, we show that in hDAT cells, green fluorescent protein(GFP)-tagged hDAT (GFP-hDAT; 
green) co-localized (yellow) with a red fluorescent protein(RFP)-tagged plasma membrane PIP2 
sensor (red) (Fig. 14a). As a PIP2 sensor, we used the pleckstrin homology (PH) domain from 
phospholipase Cδ (PHPLCδ-mRFP) that binds specifically to PIP2 at the plasma membrane and 
has been used to monitor pools of PIP2 (Varnai and Balla, 1998). In these cells, we further 
probed the association of hDAT with PIP2 by immunoprecipitating (IP) PIP2 with an anti-PIP2 
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Figure 14. Phosphatidylinositol (4,5)-bisphosphate (PIP2) interacts with hDAT. 
(a) hDAT and PIP2 colocalize at the plasma membrane. In hDAT expressing cells, 
GFP-hDAT (green) colocalizes (yellow) at the plasma membrane with the PIP2 sensor 
PHPLCδ-mRFP (red; representative image from three live experiments with 10-15 
cells imaged per experiment) Scale bar, 5 µm. (b) PIP2 associates with endogenous 
mouse DAT in striatal tissue. In striatal lysate, DAT was detected in PIP2 
immunoprecipitates using an anti-DAT antibody (+). DAT immunoreactivity was 
absent in the beads fraction (-) and in PIP2 immunoprecipitates from DAT knock out 
(KO) animals (endogenous mouse IgG is observed) (representative of n = 3).  
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antibody and immunoblotting the immunoprecipitates for DAT (IB) with an anti-DAT antibody 
(see below). These data strongly suggest that PIP2 associates with hDAT in this cell line. To 
reveal the association between PIP2 and DAT in brain tissue, immunoprecipitations were 
performed from the striatal tissue of wild-type mice (WT; in presence (+) or absence (-) of the 
anti-PIP2 antibody) or DAT knock out (KO) mice (Giros et al., 1996) (Fig. 14b). In contrast to WT 
mice, DAT-PIP2 association was lacking in DAT KO mice. Moreover, in the absence (-) of the 
PIP2 antibody, no immunoreactivity was detected. These data demonstrate that PIP2 associates 
with the DAT both in cell culture and ex vivo.  
 
The DAT N-terminus interacts directly with PIP2 
PIP2 is negatively charged at physiological pH (McLaughlin and Murray, 2005). 
Electrostatic interactions between PIP2 and target proteins are thought to lead to changes in 
protein conformation and, subsequently, their activity (Hilgemann and Ball, 1996, McLaughlin et 
al., 2002). It is recognized that PIP2 binds positively charged (basic) residues, such as Arg and 
Lys, possibly in proximity to one or more hydrophobic amino acids (Suh and Hille, 2008). 
Recently, residues K352 and K460 of the SERT (a DAT homolog) have been identified in vitro 
as possible sites that mediate SERT-PIP2 association (Buchmayer et al., 2013). In the DAT, the 
homologous amino acids to K352 and K460 are Lys at position 337 (K337) and Arg at position 
443 (R443). We reasoned that these two DAT residues represent possible PIP2 binding sites of 
functional significance. However, charge-neutralizing substitution of K337 and R443 to Ala 
(hDAT K337A-R443A), to prevent the interaction of these residues with PIP2, caused substantial 
trafficking of the DAT away from the plasma membrane, as assessed by cell surface 
biotinylation. The amount of hDAT K337A-R443A at the cell surface was reduced by 82.6 ± 
5.2% (p ≤ 0.01 by Student’s t-test; n = 7) with respect to hDAT. Therefore, in DAT, in contrast to 
SERT, these two residues support DAT surface expression, preventing us from determining  
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whether their possible interaction with PIP2 regulates any mechanistic aspect of the transport 
cycle. 
 
The N-terminus of the DAT is a structural domain that has been shown to regulate 
specific aspects of DAT transport cycle, without altering DAT surface expression (Khoshbouei et 
al., 2004, Fog et al., 2006, Bowton et al., 2010). It also contains several Lys and Arg residues 
(Fig. 15). We therefore sought to determine whether the N-terminus of the DAT directly interacts 
with PIP2 in vitro. To this end, we generated a purified recombinant GST-fused N-terminal DAT 
fragment comprising the first 64 N-terminal amino acids of hDAT (GST-64 hDAT) (Binda et al., 
2008). The lipid binding analysis of the GST-fusion proteins was conducted using liposomes 
composed of mixed lipids (phosphatidylcholine, either with or without PIP2) as previously 
described (Varnai et al., 2002). The GST fusion proteins bound to liposomes were pelleted 
(liposome-pull down) and the binding was assessed by immunoblotting (anti-GST antibody). 
Figure 16a (top) shows the pull down of GST fusion proteins (GST and GST-64 hDAT) by 
liposomes containing (+) PIP2, as compared to liposomes lacking (-) PIP2. The presence (+) or 
absence (-) of PIP2 did not alter pull down of GST alone (GST control). As an additional control, 
we “sequestered” PIP2 by preincubating the liposomes with a basic peptide consisting of the 
sequence of the putative PIP2 binding domain of the Kv7.2 channel fused to the fatty acid 
moiety, palmitic acid (Robbins et al., 2006) (pal-HRQKHFEKRR; positively charged at 
physiological pH) (Robbins et al., 2006). This peptide is known to interact electrostatically with 
the polar head groups of PIP2 to hinder its interaction with plasma membrane proteins (Robbins 
et al., 2006). Preincubation of PIP2-containing liposomes with 3 µM of the basic peptide (pal- 
HRQKHFEKRR) inhibited pull down of GST-64 hDAT. Figure 16a (bottom) shows quantitation 
of immunoblots obtained from multiple experiments. Comassie stain was utilized to verify equal 
loading. These in vitro data provide the first evidence of a direct interaction between PIP2 and a 
specific region of a neurotransmitter transporter, the DAT N-terminus.  
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Figure 15. Sequences of the N-terminal regions of various transporters. The N-
terminal regions of the human dopamine transporter (hDAT), serotonin transporter 
(hSERT), norepinephrine transporter (hNET), and vesicular monoamine transporter 2 
(hVMAT2) are shown; positively charged residues are represented in red. 
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Figure 16. hDAT-PIP2 electrostatic interactions are mediated by the hDAT N-
terminus. (a) hDAT N-terminus binds directly to PIP2. GST-64 hDAT is enriched in 
liposome-pull downs with liposomes containing PIP2 (+) as compared to liposomes 
lacking PIP2 (-) (** = p ≤ 0.01 by one-way ANOVA followed by Bonferroni post-hoc 
test; n = 3; mean ± s.e.m.). Pull down of GST control was not altered by the presence 
(+) of absence (-) of PIP2 in the liposomes (p ≥ 0.05 by one-way ANOVA followed by 
Bonferroni post-hoc test; n = 3; mean ± s.e.m.). Preincubation of liposome containing 
PIP2 with 3 µM of pal-HRQKHFEKRR (+) inhibited the pull down of GST-64 hDAT 
with liposomes containing PIP2 (** = p ≤ 0.01 by one-way ANOVA followed by 
Bonferroni post-hoc test; n = 3). Full blot is in Supplementary Figure 8. (b) 
Electrostatic potential (EP) isosurfaces (+1kT/e (+ charge)) shown as blue wireframes 
and (-1kT/e (- charge)) as red wireframes calculated for the predicted structure of the 
wild type N-terminus. (c) View from the intracellular side of the N-terminus (model) 
adsorbing on the lipid membrane. For clarity, the orientation of the N-terminus in 
panel (c) was obtained by a 180° rotation of the N-terminus configuration shown in 
panel (b). The level of the PIP2 segregation by the N-terminus is expressed as the 
ratio of local and ambient lipid fraction values, and illustrated in color code (cold 
colors represent an enrichment of PIP2). The positive residues in the N-terminus 
(yellow) that attract PIP2 electrostatically are highlighted.  !
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Computational modeling of hDAT interaction with PIP2 
To obtain molecular level structural insights into hDAT N-terminal interactions with PIP2-
containing membranes, we generated a structural context using a previously described 
homology model of the hDAT (Beuming et al., 2008, Kniazeff et al., 2008, Bisgaard et al., 2011). 
To this we have added a recently constructed model of the DAT N-terminus obtained with a 
combination of structure-prediction methods (Rosetta, Modeller) and atomistic molecular 
dynamics (MD) simulations (see Methods). These in silico modeling steps enabled the 
prediction of 3-dimensional folds of the N-terminal loop segment composed of hDAT residues 1-
59, in the context of the complete transmembrane domain. The resulting hDAT model was used 
in mean-field-level calculations (SCMFM; see Methods) to quantify the electrostatic interaction 
of the N-terminus with PIP2-enriched lipid membranes.  
 
The dominant role of the electrostatic component of the interaction energy between the 
hDAT N-terminus and PIP2-containing membranes was substantiated by the shape and the 
values of the electrostatic potential isosurfaces (EPIs) surrounding the molecular model of the 
hDAT N-terminal segment shown in Figure 16b. The belt-like arrangement of the Lys/Arg 
residues generates a region of strong positive electrostatic potential (in blue) that favors strong 
interaction with the negatively charged PIP2 lipids. Energy-guided docking of this face of the N-
terminus to the membrane model and solving for the steady state distributions of the charged 
lipid species (PIP2) under the influence of the electrostatic forces it generates (Khelashvili et al., 
2008, Khelashvili et al., 2009, Khelashvili et al., 2012) produces a quantitative estimate of the 
electrostatic component of the interaction energy. Thus, the rearrangement of the PIP2 lipids in 
the electrostatic field of the N-terminal segment is predicted to result in a significantly increased 
concentration of PIP2 near the Lys/Arg belt (Fig. 16c, color coding on the membrane shows the 
segregation of PIP2 (blue) to be 2.5 times larger than the PIP2 ambient concentration 
(yellow/green)). Particularly notable is the strength of the PIP2 interaction mediated by DAT 
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residues Lys3 and Lys5. Together, these in silico studies suggest that the interactions between 
the hDAT N-terminus and PIP2 lipids are driven by electrostatic forces.  
 
Disrupting DAT-PIP2 interaction inhibits reverse transport 
We hypothesized that the functional consequence of DAT-PIP2 interaction is to support 
reverse transport of DA. Thus, we disrupted DAT-PIP2 associations in hDAT cells while 
recording AMPH-induced DA efflux with amperometry. The amperometric electrode, a carbon 
fiber electrode juxtaposed to the cell membrane, measures DA efflux by oxidation/reduction 
reactions, with DA efflux represented as a positive current. To simultaneously record DA efflux 
while delivering compounds to the intracellular milieu, we combined amperometry with the 
whole cell patch clamp (APC) technique (Khoshbouei et al., 2004, Hamilton et al., 2013). The 
whole cell patch electrode controls the intracellular ionic composition, which includes DA 
(Khoshbouei et al., 2004) (see Methods).  
 
First, we perfused hDAT cells through the whole cell electrode with DA and the basic 
peptide pal-HRQKHFEKRR (positively charged at physiological pH and tethered to the plasma 
membrane through the fatty acid moiety, palmitic acid (Robbins et al., 2006)) while recording DA 
efflux with the amperometric electrode (Fig. 17a). We used this peptide to compete against the 
DAT N-terminus for PIP2 interactions as determined in Fig. 16a. Pal-HRQKHFEKRR (3 µM, 10 
minutes of intracellular perfusion) was effective in reducing AMPH-induced DA efflux with 
respect to the efflux obtained with the control peptide pal-HAQKHFEAAA, in which four positive 
residues were substituted with Ala (Fig. 17a, top). Quantitation of the peak amperometric 
currents demonstrates that intracellular perfusion of pal-HRQKHFEKRR significantly reduced 
DA efflux (Fig. 17a, bottom). These data underscore the importance of DAT-PIP2 interactions in 
the regulation of DA efflux and point to the type of interactions as electrostatic in nature. We 
next assessed whether DAT-PIP2 association regulates other DAT functions (e.g. DAT- 
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Figure 17. Sequestration or depletion of PIP2 inhibits AMPH-induced DA efflux. 
(a) Sequestering PIP2 with pal-HRQKHFEKRR decreases AMPH-induced DA efflux. 
Top: representative traces from stably transfected hDAT cells after patch delivery of 3 
µM control peptide (pal-HAQKHFEAAA) or PIP2 sequestering peptide (pal-
HRQKHFEKRR) to the cytoplasm of the cell. Arrows indicate the application of 10 µM 
AMPH. Bottom: quantitation of amperometric peak currents for the two different 
treatments. Data are expressed as percentage of vehicle control (*** = p ≤ 0.0001 by 
Student’s t-test; n = 7; mean ± s.e.m.). (b) Depleting PIP2 levels reduces AMPH-
induced DA efflux. Top: representative trace of responses to 1 µM AMPH in stably 
transfected hDAT cells, co-expressing the human muscarinic acetylcholine receptor 1 
(hM1R), before and after exposure to 100 µM acetylcholine (ACh). Bottom: 
quantitation of the amperometric peak currents representing AMPH-induced DA efflux 
before and after ACh-dependent PIP2 depletion (* = p ≤ 0.05 by Student’s t-test; n = 
11).  
49 
mediated inward currents). We recorded hDAT-mediated inward currents from hDAT cells 
voltage clamped at -60 mV with a whole-cell electrode containing either pal-HRQKHFEKRR or 
the control peptide pal-HAQKHFEAAA (3 µM, 10 minutes of intracellular perfusion). We 
stimulated the hDAT-mediated currents by perfusion of either 10 µM AMPH or DA, respectively. 
In contrast to DA efflux, pal-HRQKHFEKRR failed to inhibit hDAT-mediated inward currents, 
with respect to the control peptide, either for AMPH (109 ± 4.9% of control; p ≥ 0.8 by Student’s 
t-test; n = 4) or for DA (98 ± 16% of control; p ≥ 0.9 by Student’s t-test; n = 4).  
 
To further investigate the role of DAT-PIP2 interactions in AMPH regulation of DAT 
function, we transfected hDAT cells with the human muscarinic acetylcholine (ACh) receptor M1 
(hM1R), a Gαq coupled receptor. Activation of hM1R activates phospholipase C (PLC), 
stimulating hydrolysis of PIP2 and effectively depleting PIP2 stores (Kadamur and Ross, 2013). 
Live imaging was adopted utilizing mRFP tagged PLC-δ1 PH domain (see Fig. 14a) to detect 
changes of PIP2 levels at the plasma membrane induced by ACh, a potent hM1R agonist (Balla 
et al., 2009). In hDAT cells, 5 minutes of ACh (100 µM) decreased surface RFP tagged PLC-δ1 
PH domain levels to 64 ± 9% of vehicle control (p ≤ 0.009 by Student’s t-test comparing ACh to 
vehicle; n = 16). In cells loaded with DA (see Methods), we next quantified the magnitude of 
AMPH-induced DA efflux before and after bath perfusion of ACh (5 minutes, 100 µM) (Fig. 17b, 
top). Quantitation of the change in AMPH-induced DA efflux induced by PIP2 depletion within 
the same cell (Fig. 17b, bottom) demonstrates that ACh exposure significantly decreased DA 
efflux. This decrease was not due to a trafficking phenomenon, since exposure of ACh (5 
minutes, 100 µM) in hM1R-expressing hDAT cells did not cause significant trafficking of hDAT 
away from the plasma membrane as compared to vehicle-treated control (Fig. 18). We next 
determined whether providing an excess of intracellular PIP2 reduces the ability of hM1R 
agonism to decrease DA efflux. For this, we adopted the APC technique (Khoshbouei et al., 
2004, Hamilton et al., 2013). Inclusion of PIP2 (50 µM) in the whole cell patch pipette solution  
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Figure 18. ACh treatment does not affect hDAT surface expression. 
Representative immunoblots for biotinylated (surface) and total hDAT protein 
fractions from stably transfected hDAT cells, co-expressing the human muscarinic 
acetylcholine receptor 1 (hM1R), treated either with vehicle or 100 µM ACh for 5 min. 
Surface fractions were quantitated, normalized to total hDAT, and expressed as a 
percent of vehicle treated hDAT cells (p ≥ 0.7 by Student’s t-test; n = 3 in duplicate; 
mean ± s.e.m.). 
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(10 minutes of intracellular perfusion) impaired the ability of ACh (5 minutes, 100 µM) to 
significantly decrease AMPH-induced DA efflux with respect to vehicle control (Fig. 19). 
Collectively, these data demonstrate that impairing the electrostatic interaction between PIP2 
and DAT selectively inhibits the ability of AMPH to cause DA efflux. 
 
N-terminal lysine residues mediate DAT-PIP2 association 
Since our in silico modeling of the hDAT N-terminus indicated residues Lys3 and Lys5 to 
be essential in facilitating the electrostatic interaction of PIP2 with DAT (Fig. 16c), we 
hypothesized that substitution of these residues with uncharged amino acids (e.g. alanine or 
asparagine) would disrupt DAT-PIP2 associations. To probe this inference in silico, Lys3 and 
Lys5 were both substituted computationally with either Ala (hDAT K/A) or with Asn (hDAT K/N), 
and the resulting constructs (N-terminus of hDAT K/A and hDAT K/N) were evaluated for any 
conformational rearrangements due to the mutations. The constructs were used in the same 
computational protocols described for the hDAT model. The results for the mutant constructs 
show significantly reduced electrostatic interactions with PIP2-containing membranes for both 
hDAT K/A (Fig. 20a, compare to Fig. 16c) and hDAT K/N (Fig. 21, compare to Fig. 16c). 
 
The inferences from the computational evaluation of the N-terminus association with 
PIP2 lipids in silico were probed biochemically by determining the effect of charge neutralizing 
mutations of Lys3 and Lys5. In hDAT K/A cells, we immunoprecipitated PIP2 and immunoblotted 
the immunoprecipitates for DAT (IB: anti-DAT). The amount of DAT recovered in the PIP2 
immunoprecipitates was reduced in the hDAT K/A cells compared to the hDAT cells (Fig. 20b, 
top lane). In the absence of antibody against PIP2, no signal was detected for DAT in the 
immunoprecipitates (Fig. 20b, middle lane, IP: beads). The total DAT in the hDAT K/A cells was 
not decreased with respect to hDAT cells (Fig. 20b, bottom lane; Total DAT). These data 
demonstrate that substitution of Lys3 and Lys5 decreases DAT-PIP2 interaction, as predicted  
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Figure 19. Excess intracellular PIP2 levels prevents the ability of ACh to 
decrease AMPH-induced DA efflux. Top: representative traces of AMPH responses 
obtained with the APC technique in stably transfected hDAT cells, co-expressing 
hM1R, perfused intracellularly with 50 µM PIP2. Cells were pre-exposed to either 100 
µM ACh or vehicle for 5 minutes and DA effluxes induced by 10 µM AMPH were 
recorded in the continuous presence of ACh or vehicle. Bottom: quantitation of the 
amperometric peak currents normalized to vehicle control, and expressed as a 
percent of vehicle treated hDAT cells (p ≥ 0.9 by Student’s t-test; n = 4; mean ± 
s.e.m.). 
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Figure 20. hDAT N-terminal Lys regulate!DAT-PIP2 interaction. (a) Mutating hDAT 
N-terminal residues Lys3 and Lys5 to uncharged Ala (hDAT K/A) disrupts PIP2 
segregation to the N-terminus. View from the intracellular side of the N-terminus of 
hDAT K/A adsorbing on the lipid membrane. The level of PIP2 segregation by the N-
terminus residues is expressed as the ratio of local and ambient lipid fraction values 
and illustrated in color code, with cold colors representing an enrichment of PIP2. (b) 
N-terminal Lys residues mediate hDAT-PIP2 interaction. Top: PIP2 
immunoprecipitates from hDAT and hDAT K/A cells were immunoblotted for DAT (top 
lane). The beads fraction supports absence of non-specific binding (middle lane). 
Bottom lane shows total DAT proteins. Full blot is in Supplementary Figure 9. Bottom: 
quantitation of PIP2 pulldown band intensities normalized to the respective total DAT 
and expressed as a percentage hDAT (*** = p ≤ 0.001 by Student’s t-test; n = 4; 
mean ± s.e.m.). Inset: Representative blot for GST-64 hDAT and GST-64 hDAT K/A 
in pull downs with liposomes containing PIP2. 
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Figure 21. Mutation of hDAT N-terminal residues Lys3 and Lys5 to uncharged 
Asn (hDAT K/N) disrupts PIP2 segregation to the N-terminus. View from the 
intracellular side of the N-terminus of hDAT K/N adsorbing on the lipid membrane. 
The level of PIP2 segregation by the N-terminus is expressed as the ratio of local and 
ambient lipid fraction values, and illustrated in color code with cold colors 
representing an enrichment of PIP2. 
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from the computational modeling. Quantitation of multiple experiments (n = 4) is shown in figure 
20b (bottom). Next, we determined whether substitution N-terminal Lys3 and Lys5 to Ala impairs 
the direct interaction of DAT with PIP2 in vitro. We generated a purified recombinant GST-fused 
N-terminal DAT fragment comprising the first 64 N-terminal amino acids of hDAT with Lys3 and 
Lys5 substituted to Ala (GST-64 hDAT K/A). The lipid binding analysis of the GST-fusion 
proteins (either GST-64 hDAT or GST-64 hDAT K/A) was conducted utilizing liposome-pull 
down as in figure 16. The inset in figure 20b shows the pull down of the GST fusion proteins by 
liposomes containing PIP2. Quantitation of immunoblots obtained from multiple experiments 
demonstrated that pull down of GST-64 hDAT was significantly inhibited by Lys to Ala 
substitution (GST-64 hDAT K/A was 45 ± 20% of GST-64 hDAT; p ≤ 0.037 by Student’s t-test; n 
= 4). 
 
In order to assess whether DAT physiological function is altered by disrupting DAT-PIP2 
association, we examined radioactive [3H]DA uptake in both hDAT and hDAT K/A cells. In hDAT 
K/A cells, the maximal velocity of DA influx (Vmax) and the apparent DA affinity (Km) were not 
significantly different from those of hDAT (Fig. 22a, top). A representative plot of DA uptake 
kinetics (in triplicate) for hDAT and hDAT K/A is shown in Figure 22a (bottom), demonstrating 
that the uptake of substrate is not regulated by the interaction with PIP2. Consistent with the 
uptake data, no significant difference was found in the whole-cell DAT-mediated inward current 
(recorded at -60 mV) between hDAT and hDAT K/A cells upon stimulation with 10 µM DA. The 
hDAT K/A inward currents were expressed as a percent of hDAT-mediated currents (103 ± 20% 
of hDAT; p ≥ 0.97 by Student’s t-test; n = 4). 
 
Our pharmacological manipulations (Fig. 17) indicate that disrupting DAT-PIP2 
association has no effect on DAT-mediated DA uptake or DA-induced inward currents but 
inhibits the ability of AMPH to cause DA efflux. Consistent with this, hDAT K/A cells were found  
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Figure 22. N-terminal Lys3 and Lys5 regulate specific modalities of hDAT 
function. (a) hDAT K/A exhibits normal DA uptake function. Top: kinetic parameters 
(Vmax and Km) for hDAT and hDAT K/A (Vmax: p ≥ 0.92 by Student’s t-test; n = 3, in 
triplicate; Km: p ≥ 0.62 by Student’s t-test; n = 3, in triplicate; mean ± s.e.m.). Bottom: 
representative plot of [3H]DA uptake kinetics in hDAT (filled squares) and hDAT K/A 
(empty squares) cells (p ≥ 0.05, by two-way ANOVA followed by Bonferroni post-test; 
in triplicate; mean ± s.e.m.). (b) hDAT K/A has reduced AMPH-induced DA efflux. 
Top: representative AMPH-induced amperometric currents recorded from hDAT and 
hDAT K/A cells. Arrows indicate application of 10 µM AMPH. Bottom: quantitation of 
AMPH-induced DA efflux. Data are represented as maximal DA efflux expressed as 
percent of the DA efflux recorded in hDAT controls (* = p ≤ 0.05 by Student’s t-test; n 
= 7-8; mean ± s.e.m.).  
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to display strikingly reduced AMPH-induced DA efflux (Fig. 22b, top). Quantitation of the 
amperometric recordings demonstrate that the Lys to Ala substitution not only decreased DAT-
PIP2 association (Fig. 20), but also decreased the ability of AMPH to cause DA efflux (Fig. 22b, 
bottom). The reduced AMPH-induced DA efflux was not associated with a reduction in either 
total or DAT surface expression as assessed by measuring changes in DAT proteins in the total 
and biotinylated fraction, respectively. Surface fractions were quantitated, normalized to total 
DAT, and expressed as a percent of hDAT (hDAT K/A was 122 ± 31% of hDAT; p ≥ 0.53 by 
Student’s t-test; n = 7-8). The findings in the hDAT K/A cells were mirrored by those obtained in 
the hDAT K/N cells in terms of both DAT-PIP2 association and hDAT cell surface expression 
(Fig. 23a and 23b). The hDAT K/N also displayed normal uptake (Fig. 23c) and, like the hDAT 
K/A, had a significant reduction in AMPH-induced DA efflux (Fig. 23d). Furthermore, AMPH 
uptake assays revealed that hDAT, hDAT K/A, and hDAT K/N cells displayed comparable 
AMPH transport (see Methods) (hDAT K/A: 101 ± 4.9% and hDAT K/N: 93.9 ± 17% relative to 
hDAT; p ≥ 0.88 by one-way ANOVA; n = 3, in triplicate). These results demonstrate that the 
reduced ability of AMPH to cause DA efflux promoted by the Lys to Ala substitutions does not 
involve changes in the surface expression or changes in ability of the DAT mutants to transport 
AMPH. Another possibility for this decrease in DA efflux is that the N-terminal Lys substitution 
(hDAT K/A) perturbs the potential AMPH-induced phosphorylation of the Ser2 and Ser4 
adjacent to these Lys residues by altering primary sequence requirements for phosphorylation. 
To explore this, we substituted Ser2 and Ser4 with Asp (to mimic phosphorylation) in the hDAT 
K/A background (hDAT K/A-S/D). Cells expressing hDAT K/A-S/D exhibited significantly 
reduced AMPH-induced DA efflux, similar to hDAT K/A cells (Fig. 24a, top). Quantitation of the 
amperometric recordings demonstrated that Ser to Asp substitution at positions 2 and 4 in the 
hDAT K/A background did not rescue the ability of AMPH to cause DA efflux (Fig. 24a, bottom). 
The reduced AMPH-induced DA efflux was not associated with a reduction in DA uptake (Fig. 
24b). These data demonstrate that the reduction in DA efflux caused by substitution of Lys3 and  
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Figure 23. hDAT K/A findings mirrored in hDAT K/N. (a) Top: PIP2 
immunoprecipitates from hDAT and hDAT K/N cells were immunoblotted for DAT (top 
lane). The beads fraction supports absence of non-specific binding (middle lane).  
Bottom lane shows total DAT proteins. Bottom: quantitation of PIP2 pull down band 
intensities normalized to the respective total DAT and expressed as a percentage 
hDAT (*** = p ≤ 0.0001 by Student’s t-test; n = 3; mean ± s.e.m.). (b) Representative 
immunoblots for biotinylated (surface) and total protein fractions from hDAT and 
hDAT K/N cells. Immunoblots for surface NaK-ATPase and total ERK are shown as 
well. Surface fractions were quantitated, normalized to total DAT, and expressed as a 
percentage of hDAT (p ≥ 0.41 by Student’s t-test; n = 4-5; mean ± s.e.m.). (c) [3H]DA 
uptake (50 nM) in hDAT and hDAT K/N cells was expressed as a percent of uptake in 
hDAT cells (p ≥ 0.16 by Student’s t-test; n = 3, in quadruplicate; mean ± s.e.m.). (d) 
Representative AMPH-induced amperometric currents recorded from hDAT and 
hDAT K/N cells. Arrows indicate application of 10 µM AMPH. Bottom: quantitation of 
AMPH-induced DA efflux. Data are represented as maximal DA efflux expressed as a 
percent of the DA efflux recorded in hDAT cells (* = p ≤ 0.02 by Student’s t-test; n = 
6-7; mean ± s.e.m.). 
59 
 
  
!
Figure 24. hDAT K/A-S/D displays reduced DA efflux and normal DA uptake. (a) 
hDAT K/A-S/D has reduced AMPH-induced DA efflux. Top: representative AMPH-
induced amperometric currents recorded from hDAT and hDAT K/A-S/D cells. Arrows 
indicate application of 10 µM AMPH. Bottom: quantitation of AMPH-induced DA 
efflux. Data are represented as maximal DA efflux expressed as a percent of DA 
efflux recorded in hDAT cells (* = p ≤ 0.03 by Student’s t-test; n = 5-6; mean ± 
s.e.m.). (b) hDAT K/A-S/D exhibits normal [3H]DA uptake (50 nM) function. Data 
expressed as a percent of the uptake measured in hDAT cells (p ≥ 0.2 by Student’s t-
test; n = 4-8; mean ± s.e.m.). 
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Lys5 with uncharged amino acids cannot be attributed to impaired phosphorylation of adjacent 
Ser residues. 
 
Reduced DAT-PIP2 interaction impairs psychomotor behavior 
Locomotion is an elemental behavior regulated by DA across species, including 
Drosophila melanogaster (Pendleton et al., 2002, Wicker-Thomas and Hamann, 2008, Hamilton 
et al., 2013, Pizzo et al., 2013). Recently, locomotion in flies has been adopted to evaluate 
molecular discoveries of AMPH actions mechanistically in vivo (Hamilton et al., 2013, Pizzo et 
al., 2013). Thus, Drosophila offer a powerful model for elucidating the impact of altered DAT-
PIP2 interactions on locomotion and on the psychomotor stimulant effects of AMPH. 
 
To generate fly lines expressing either hDAT or hDAT K/A selectively in DA neurons, we 
used the Gal4/UAS system to express a single copy of either hDAT or hDAT K/A in flies with a 
Drosophila DAT (dDAT) null background (dDAT KO; flies are homozygous for the dDAT null 
allele, DATfmn) (Kume et al., 2005). Using phiC31-based integration, we generated transgenic 
flies expressing comparable mRNA levels for hDAT or hDAT K/A. Locomotion of flies was 
quantified by beam crossing detection over a >24 hour period (data binned in 15 minute 
intervals) including both the light (horizontal white bar) and the dark (horizontal black bar) cycle. 
While dDAT KO flies were hyperactive (Kume et al., 2005), dDAT KO flies expressing hDAT in 
DA neurons displayed reduced basal locomotion in comparison to dDAT KO (Fig. 25a, compare 
hDAT to dDAT KO). These data demonstrate the validity of expressing hDAT in Drosophila for 
behavioral studies.  
 
We hypothesized that flies harboring the hDAT K/A would demonstrate comparable 
locomotion with respect to hDAT expressing flies, since no difference in DA uptake was 
observed. Figure 25a demonstrates that Drosophila expressing hDAT and hDAT K/A displayed  
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Figure 25. Expression of hDAT K/A in Drosophila dopaminergic neurons does 
not affect circadian locomotor activity yet impairs AMPH-induced locomotion 
and neuronal DA efflux. hDAT or hDAT K/A was expressed in DA neurons of dDAT 
KO flies. (a) Locomotion was assayed over 32 hours during the light (horizontal white 
bars) or dark (horizontal black bars) cycle. Flies expressing dDAT KO (blue squares) 
were hyperactive with respect to flies expressing wild type hDAT (black squares) and 
flies expressing hDAT K/A (red squares) (beam breaks binned in 15 minute intervals; 
n = 31-42; mean ± s.e.m.). (b) Quantitation of total beam crosses over 24 hours for 
hDAT, hDAT K/A, and dDAT KO flies (*** = p ≤ 0.001 by one-way ANOVA followed by 
Bonferroni post-test; n = 31-42; mean ± s.e.m.). (c) AMPH did not cause a significant 
increase in locomotion in hDAT K/A flies compared to vehicle control (p ≥ 0.05 by 
one-way ANOVA followed by Bonferroni post-test; n = 25-49; mean ± s.e.m.). In 
hDAT flies, AMPH induced a significant increase in locomotion compared to vehicle 
control (*** = p ≤ 0.001 by one-way ANOVA followed by Bonferroni post-test; n= 25-
60; mean ± s.e.m.). (d) hDAT K/A Drosophila DA neurons show reduced AMPH-
induced DA efflux. Dopaminergic neurons were selected by fluorescence microscopy 
since the expression of mCherry was driven by TH-GAL4. Top: representative 
amperometric currents from hDAT and hDAT K/A neurons. Arrows indicate 
application of 1 µM AMPH. Bottom: quantitation of total AMPH-induced DA efflux. 
Data represented as cumulative DA efflux expressed as percent of DA efflux from 
hDAT neurons (** = p ≤ 0.01 by Student’s t-test; n = 4-5; mean ± s.e.m.).  
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comparable basal locomotion, whereas dDAT KO flies exhibited chronically elevated 
locomotion. Total circadian locomotor activities (24 hour) of hDAT and hDAT K/A flies were not 
significantly different, while total locomotor activity of dDAT KO flies was significantly higher 
than hDAT and hDAT K/A (Fig. 25b). 
 
Encouraged by the lack of hyperactivity of hDAT K/A flies under basal conditions, we 
hypothesized that these flies would have blunted AMPH-induced locomotive behaviors resulting  
from reduced ability of AMPH to stimulate DA efflux. While AMPH caused a significant increase 
in locomotion in flies expressing hDAT, this increase was significantly reduced in flies 
expressing hDAT K/A (Fig. 25c). These data demonstrate, for the first time, the behavioral 
importance of the interaction of PIP2 with a plasma membrane protein. This discovery is further 
enhanced by our ability to associate blunted AMPH-induced behaviors with a decreased ability 
of AMPH to cause DA efflux in isolated DA neurons from flies expressing hDAT K/A. Ex vivo 
cultures of Drosophila DA neurons were investigated with amperometry to quantify the 
magnitude of the AMPH-induced DA efflux in the different fly lines. The DA efflux recorded from 
hDAT K/A expressing neurons was significantly reduced compared to hDAT expressing neurons 
(Fig. 25d), suggesting that the reduced AMPH-induced locomotion in flies expressing hDAT K/A 
is due to diminished DA efflux in response to AMPH.  
 
It is possible that this PIP2 regulation of DA efflux is an evolutionarily conserved 
mechanism that controls DAT function across phylogeny. To test this possibility, we utilized the 
APC technique in Chinese hamster ovary (CHO) cells expressing the dDAT (dDAT cells). In 
dDAT cells, intracellular perfusion of pal-HRQKHFEKRR (3 µM, 10 minutes) was effective in 
reducing AMPH-induced DA efflux with respect to the efflux obtained with the control peptide 
pal-HAQKHFEAAA (34.9 ± 12.9% of control peptide; p ≤ 0.01 by Student’s t-test; n = 3). These 
results parallel those obtained in hDAT cells (Fig. 17). In this study, we provide the first 
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behavioral evidence for the relevance of the interaction of PIP2 with a plasma membrane 
protein, associating AMPH behaviors to altered neuronal DAT function within the same 
organism. 
 
Discussion 
We recently demonstrated that disrupting the localization of DAT in lipid rafts impairs the 
ability of AMPH to cause both DA efflux (without altering DA uptake) (Cremona et al., 2011), 
and associated behaviors (Pizzo et al., 2013). This led us to hypothesize that the molecular 
underpinnings required for AMPH actions reside in lipid rafts. Raft microdomains are considered 
scaffolds for PIP2 signaling, enabling PIP2 to selectively regulate different cellular processes 
(Pendleton et al., 2002, van Rheenen et al., 2005). Yet, partitioning of PIP2 into lipid rafts has 
been criticized as energetically improbable, since PIP2 consists of a polyunsaturated acyl side 
chain (arachidonic acid) that is unlikely to spontaneously partition into cholesterol-rich rafts 
(McLaughlin and Murray, 2005). Therefore, it is theorized that the partitioning of PIP2 into rafts is 
facilitated by interactions with raft-localized proteins (McLaughlin and Murray, 2005). Here we 
demonstrate that PIP2 directly interacts with hDAT, a protein that localizes to the rafts (Cremona 
et al., 2011, Gabriel et al., 2013, Sorkina et al., 2013). 
 
We found that the DAT N-terminus (a domain of functional importance) (Khoshbouei et 
al., 2004, Fog et al., 2006) is engaged in direct electrostatic interactions with PIP2, described by 
both computational and biochemical analysis. We demonstrate that this interaction is direct and 
distinct from the recently described association of PIP2 with SERT (Buchmayer et al., 2013). 
This DAT-PIP2 interaction, which occurs in brain tissue, involves the two most distal N-terminal 
Lys (Lys3 and Lys5). These data, combined with the regulatory nature of DAT localization to 
PIP2 enriched lipid rafts, led us to hypothesize that PIP2 participates in coordinating the complex 
molecular events underlying specific DAT activities. This includes AMPH-induced DA efflux. 
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Notably, this interaction does not regulate the physiological function of DAT (DA uptake), DAT 
surface expression, and AMPH uptake. Other functions of the DAT include AMPH- or DA-
stimulated inward currents that represent inward movements of ions associated with the 
transport of substrate. Therefore, we expected that substrate-induced inward currents would not 
be affected by disruption of DAT-PIP2 interaction, in the same way that DA or AMPH uptake is 
not affected. We show that disrupting DAT-PIP2 interaction by substitution of Lys3 and Lys5 with 
Ala did not impair the ability of hDAT to sustain electrical inward currents stimulated by either 
DA or AMPH. The regulatory nature of the direct DAT-PIP2 interaction on DAT-mediated DA 
efflux is underscored by our results demonstrating that “sequestering” PIP2, with our palmitoyl-
positively charged peptide, or depleting PIP2, by stimulating PLC activity, results in diminished 
reverse transport of DA. Consistent with these findings is the notable result that intracellular 
perfusion of the palmitoyl-positively charged peptide did not impair hDAT-mediated inward 
currents stimulated by either AMPH or DA relative to control peptide. These data underscore the 
interaction between DAT and PIP2 as a key regulator of the specific DAT function of DA efflux.  
 
N-terminal phosphorylation is a requirement for the ability of AMPH to cause a robust DA 
efflux (Khoshbouei et al., 2004). The results of our specific molecular manipulations support the 
notion that Lys to Ala substitution did not impair DA efflux by altering primary sequence 
requirements for phosphorylation of Ser2 and Ser4. Indeed, pseudophosphorylation of these 
Ser residues in the hDAT K/A background failed to rescue DA efflux. Consistent with this notion, 
palmitoyl-positively charged peptide (which does not alter the N-terminus primary sequence) 
disrupts both the direct interaction of the N-terminus with PIP2 as well as DA efflux. However, 
the computational modeling reveals the possibility that the strength of the association of Lys3 
and Lys5 with PIP2 regulates the proper conformation of the DAT N-terminus and affects the 
transporter N-terminus as a whole. Therefore, we cannot exclude the possibility that the 
observed DAT-PIP2 association regulates N-terminal phosphorylation of non-adjacent Ser by 
65 
coordinating suitable conformations. Nevertheless, this possibility does not diminish the 
importance of the discovery that DAT-interaction with PIP2 is a key determinant of AMPH-
induced DA efflux and behaviors. On the contrary, it highlights an opportunity, in future studies, 
to understand whether the DAT N-terminal interaction with PIP2 supports N-terminal 
phosphorylation and/or the importance of phosphorylation for N-terminal conformations and 
DAT-PIP2 association.  
 
The Ser-Lys-Ser-Lys N-terminal sequence of the DAT is conserved across several 
species, including Drosophila, suggesting that the DAT-PIP2 association is a possible 
evolutionarily conserved mechanism that regulates specific DAT functions. Our data 
demonstrate that disruption of the dDAT-PIP2 interaction impairs DA efflux, which parallels our 
results in the hDAT. It is tempting to speculate that this mechanism of N-terminal regulation of 
transporter function through electrostatic interactions with PIP2 is a potential mode of regulation 
for other neurotransmitter transporters as well. Examination of sequences of the N-terminal 
regions of four major neurotransmitter transporters (hDAT, hSERT, hNET, and hVMAT2) 
reveals that the positively charged residues are not only abundant in this region, but are also 
often clustered. In the hDAT, we revealed the consequences of this clustering in a structural 
context, where one of these clusters contains Lys3 and Lys5, which enables this region to 
attract PIP2 lipids. Therefore, a mechanism of PIP2 regulation, similar to the one outlined here 
for DAT function, may apply to other neurotransmitter transporters with charged clusters in their 
N-terminal sequences.  
 
Recently we discovered that the AMPH-induced 5-HT efflux mediated by SERT also 
relies on PIP2 interactions with positively-charged residues (Buchmayer et al., 2013). However, 
these residues are not localized to the N-terminus of SERT. These data do not exclude a 
possible role of SERT N-terminus basic residues in SERT-PIP2 interaction and AMPH-induced 
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5-HT efflux. In contrast, in DAT, mutation (to Ala) of the corresponding SERT-PIP2 binding sites 
causes substantial trafficking of DAT away from the plasma membrane, disrupting its membrane 
expression. Thus, this trafficking phenomenon prevents our ability to determine the significance 
of these residues in the mechanistic aspects of the DAT transport cycle. However, it is clear that 
they do not functionally replace Lys3 and Lys5 in terms of DA efflux. 
 
Prior to this work, it was unclear whether the association and/or dissociation of plasma 
membrane proteins with PIP2 played a role in the regulation of behaviors of complex organisms. 
Here, we took advantage of an animal model (Drosophila melanogaster) to determine the 
behavioral consequences of disrupting direct interactions of DAT with PIP2. Drosophila 
expressing hDAT K/A solely in DA neurons did not display altered circadian locomotor activity. 
This is not surprising, since the cells expressing hDAT K/A have both normal DA uptake and DA 
affinity. However, hDAT K/A flies exhibit significant reductions in the behavioral psychomotor 
responses to AMPH. These data convey the significance of the interaction between PIP2 and 
plasma membrane proteins (i.e. DAT) in fundamental organismal behaviors, such as 
locomotion. The discovery of this PIP2 regulation of the psychomotor actions of AMPH is further 
enhanced by our ability to record DA efflux (for the first time) directly from DA neurons cultured 
from the same Drosophila lines utilized in our behavioral assays. DA neurons expressing hDAT 
K/A have a significant reduction in DA efflux with respect to neurons expressing hDAT. This 
enhances our molecular discoveries outlining the DAT-PIP2 interaction as required for DA efflux 
and obligatory in the ability of AMPH to cause psychomotor behaviors. These data promote 
PIP2 and its synthetic pathway from its canonical role as a modulator of cell function and 
metabolism to a new role as a regulatory agent of both elemental behaviors, such as 
locomotion, and maladaptive behaviors, such as psychostimulant abuse. 
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Materials and methods 
Cell culture and transfection  
The GFP-hDAT-pCIHygro expression vectors containing hDAT, hDAT K/A (Lys3 and 
Lys5 to Ala), hDAT K/N (Lys3 and Lys5 to Asn), or hDAT K/A-S/D (Lys3 and Lys5 to Ala and 
Ser2 and Ser4 to Asp) sequence were generated, confirmed and transiently transfected into 
Chinese hamster ovary (CHO) cells. The Drosophila DAT cDNA was generously provided by 
the laboratory of Dr. Satinder Singh (Yale University). In some experiments (noted in figure 
legend), stably transfected hDAT CHO cells were used. These cells were generated as 
previously described (Bowton et al., 2010). Cells were maintained in a 5% CO2 incubator at 
37°C and maintained in Ham’s F-12 medium supplemented with 10% fetal bovine serum (FBS), 
1 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin. Stably transfected hDAT 
CHO cells were kept under selection with 250 µg/mL hygromycin B (Corning Cellgro). Fugene-6 
(Roche Molecular Biochemicals) in serum-free media was used to transfect cells using a 6:1 
transfection reagent:DNA ratio. Assays were conducted 24-48 hours post transfection.  
 
Drosophila neuron culture  
Drosophila neurons were cultured from 1-3 day old males. Brains were dissected in 
Schneider’s medium with 1.5% bovine serum albumen (BSA) and optic lobes were removed. 
Brains were washed with Schneider’s medium and incubated for 40 minutes in collagenase 
(0.3%) and trypsin (0.125%). They were washed in Schneider’s medium supplemented with 
10% heat inactivated FBS. Dissociated cells were obtained by brain trituration in medium. Cells 
from each brain were plated on one poly-D-lysine coated MatTek® dish treated with collagen 
(type IV). Assays were performed the next day. 
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Cell imaging 
We used the pleckstrin homology (PH) domain from phospholipase Cδ (PHPLCδ-mRFP) 
that binds to PIP2 at the plasma membrane and has been used to monitor pools of PIP2 at the 
plasma membrane(Varnai and Balla, 1998). Cells on poly-D-lysine coated MatTek® dishes were 
co-transfected with GFP-DAT and PHPLCδ-mRFP and, after 48 hours, were deprived of serum 
overnight. Single confocal image sections were generated by using a LSM 510 inverted 
confocal microscope (Zeiss) by sequential imaging of live cells.  
 
Co-immunoprecipitations  
Cells were grown to confluence in 25 cm2 culture flasks and serum deprived overnight 
prior to assay. On the day of the assay, cells were washed three times with 4˚C phosphate-
buffered saline (Gibco) containing 1 mM EGTA and 1 mM EDTA and lysed in RIPA buffer (100 
mM NaCl, 1.0% IGEPAL CA-630 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, 
pH = 8.0, supplemented with a protease inhibitor cocktail (Sigma Aldrich)). Lysates were passed 
twice through a 27.5 gauge needle and centrifuged at 15,000 x g for 30 minutes. With a portion 
of the total cell lysate (TCL) collected to run as the totals, 1 mL of the remaining supernatant 
was incubated at 4°C for 4 hours with Sepharose-G beads (Fisher Scientific), previously 
washed with 1% BSA in RIPA buffer and preincubated with 2.5 µg PIP2 antibody (mouse 
monoclonal, Enzo Life Sciences). For the negative control, TCL supernatant was incubated with 
BSA-blocked Sepharose-G beads alone. Beads were spun down, washed with cold RIPA 
buffer, and samples eluted with Laemmli sample buffer at 95˚C for 5 minutes. TCL and eluates 
were analyzed by SDS-PAGE and immunoblotting (see below for antibody details). Band 
intensity was quantified using ImageJ software (National Institutes of Health). The association 
between PIP2 and hDAT variants was represented as the ratio of eluate:TCL band intensity, 
normalized to the eluate:TCL ratio observed in hDAT and expressed as a percent. For the 
mouse DAT-PIP2 co-immunoprecipitations from striatum, the same protocol was used with the 
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following modifications: striatum was dissected from either wild-type or DAT KO mice, 
solubilized in RIPA buffer (1:10 weight/volume), homogenized, lysed on ice for 30 minutes and 
then centrifuged. The remaining protocol was performed as described above. The mice used for 
these experiments were handled in compliance with IACUC protocols. 
 
Cell surface biotinylation and protein immunoblot 
Cells were cultured in 6-well plates. For cell surface biotinylation assays, cells were 
labeled with sulfo-NHS-SS-biotin (1.0 mg/ml; Pierce) before purification and analysis via SDS-
PAGE/immunoblots (Mazei-Robison et al., 2008). hDAT was detected using a rat monoclonal 
primary antibody to the N-terminus of hDAT (1:1000) (Millipore Bioscience Research Reagents) 
and a goat-anti-rat-HRP-conjugated secondary antibody (1:5000; Jackson ImmunoResearch). 
 
Gluthathione transferase (GST) fusion proteins 
GST and GST fused to the first 64 N-terminal amino acids of hDAT were purified as 
described previously (Binda et al., 2008) with some modifications. Briefly, GST and the GST 
fusion proteins were produced in Escherichia coli BL21 DE3 LysS. The culture was grown at 
30°C, expression induced by the addition of 1 mM isopropylβ-d-1-thiogalactopyranoside at 
18°C, and the culture was harvested 8 hours after induction. The frozen pelleted bacteria was 
thawed in Tris-buffered saline (TBS) containing 10% glycerol and a Bacterial Protease inhibitor 
cocktail (Roche Diagnostics)(pH 7.4) and treated with 1 mg/mL lysozyme followed by 15 mM 
CHAPS. It was then sonicated and cleared by centrifugation. The lysate was passed over 
glutathione Sepharose 4B beads (GE Healthcare) and washed several times with TBS, followed 
by 10 mM Tris containing 10% glycerol and eluted with TBS containing 10 mM gluthathione. 
The quality, size, and amount (relative to BSA) of GST fusions were determined by SDS-PAGE 
and Bio-Safe Coomassie G-250 Stain. The amount was determined by analysis of imaged gels 
using ImageQuantTL. 
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Liposome binding 
GST and GST fusion proteins where incubated with or without liposomes for 10 minutes 
at room temperature, centrifuged at 100,000 x g for 20 minutes at 4°C, and analyzed by 
immunoblot analysis using anti-GST antibodies (The Vanderbilt Antibody and Protein Resource 
Core). Liposomes were formed by extrusion of synthetic lipids at a final concentration of 1 mM. 
Liposomes were formed in 10 mM HEPES/TRIS, 100 mM NaCl with 95% phosphatidylcholine 
(DOPC; Echelon) and 5% PIP2 (Phosphatidylinositol 4,5-bisphosphate diC16) at a pH of 7.4. 
 
Amperometry and patch clamp electrophysiology  
Cells were plated at a density of ~20,000 per 35-mm culture dish. To preload cells with 
DA, dishes were washed with KRH assay buffer (130 mM NaCl, 1.3 mM KCl, 1.2 mM KH2PO4, 
10 mM HEPES, and 2.2 mM CaCl2, pH 7.4) containing 10 mM dextrose, 100 µM pargyline, 1 
mM tropolone, and 100 µM ascorbic acid, and incubated with 1 µM DA in KRH assay buffer for 
20 minutes at 37°C. To preload Drosophila neurons, dishes were washed with KRH assay 
buffer (as above) containing 100 nM raclopride, and incubated with 1 µM DA in KRH assay 
buffer for 20 minutes at 26°C. All dishes were washed three times with the external bath solution 
(130 mM NaCl, 10 mM HEPES, 34 mM dextrose, 1.5 mM CaCl2, 0.5 mM MgSO4, 1.3 mM 
KH2PO4, adjusted pH to 7.35, and 300 mOsm).  
 
To deliver DA (2 mM, Sigma Aldrich), PIP2 inhibitory/control peptides (3 µM pal-
HRQKHFEKRR or pal-HAQKHFEAAA), and/or PIP2 (50 µM, phosphatidylinositol 4,5-
bisphosphate diC8, Echelon Biosciences), a programmable puller (model P-2000, Sutter 
Instruments, Novato CA) was used to fabricate quartz recording pipettes with a resistance of 3-5 
MΩ. These pipettes were filled with an internal solution containing: 120 mM KCl, 10 mM 
HEPES, 0.1 mM CaCl2, 2 mM MgCl2, 1.1 mM EGTA, 30 mM dextrose, pH 7.35, and 275 mOsm. 
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Upon gaining access to the cells, the internal solution was allowed to diffuse into the cell for 10 
minutes.  
 
Experiments involving perfusion of AMPH or DA (Fig. 17b and inward current 
experiments) utilized double-barrel quartz tubing with an inner diameter of 250 µm (Polymicro 
Technologies, Phoneix AZ) placed ~80 µm from the cell. DAT-mediated inward currents were 
recorded at -60 mV.  
 
To record DA efflux, a carbon fiber electrode (ProCFE; fiber diameter of 5 µm; obtained 
from Dagan Corporation) juxtaposed to the plasma membrane and held at +700 mV (a potential 
greater than the oxidation potential of DA) was used to measure DA flux through oxidation 
reactions. Amperometric currents in response to the addition of AMPH were recorded using an 
Axopatch 200B amplifier (Molecular Devices, Union City, CA) with a low-pass Bessel filter set at 
1 kHz; traces were digitally filtered offline at 1 Hz using Clampex9 software (Molecular Devices, 
Union City, CA). DA efflux was quantified as the peak value of the amperometric current for all 
experiments except for recordings from Drosophila neurons. For Drosophila neurons, total DA 
efflux was quantified as the integral of the trace for a fixed 15 minute window. Dopaminergic 
neurons were recognized by fluorescence microscopy since the TH-GAL4 drives the expression 
of mCherry in dopaminergic neurons. 
 
[3H]DA uptake 
Cells were plated on poly-D-lysine coated, 24-well plates and grown to ~90% 
confluence. On the day of the experiment, cells were washed once with 37°C KRH buffer 
containing 10 mM dextrose, 100 µM pargyline, 1 mM tropolone, and 100 µM ascorbic acid, and 
equilibrated for 5 minutes at 37°C. Saturation kinetics of DA uptake was determined using a 
mixture of [3H]DA (PerkinElmer Life Sciences, Waltham, MA) and unlabeled DA diluting to final 
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DA concentrations of 0.01 µM - 10 µM. Uptake was initiated by bath addition of the dilution row 
mixture. Uptake was terminated after 10 minutes by washing twice in ice-cold KRH buffer. 
Scintillation fluid (Optiphase HiSafe 3, PerkinElmer Life Sciences) was added to the wells and 
the plates were counted in a Wallac Tri-Lux β-scintillation counter (Wallac). Nonspecific binding 
was determined in the presence of 10 µM cocaine. Km and Vmax values were derived by fitting 
Michaelis-Menten kinetics to the background corrected uptake data, using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA). All determinations were performed in triplicates.  
 
Computational modeling  
To evaluate the interactions between PIP2-enriched membranes and the N-terminal 
region of the hDAT (residues 1-59), as well as the hDAT K/A and hDAT K/N mutants, molecular 
models were constructed with the knowledge-based structure-prediction tool Rosetta (Das and 
Baker, 2008). 1,000 different structures obtained from the structure prediction protocols in 
Rosetta were filtered through clustering according to a criterion of maximization of common 
structure conservation implemented in the in-house algorithm RMSDTT, which has been 
introduced into the molecular graphics program, visual molecular dynamics (VMD) (Humphrey 
et al., 1996). Clusters with the largest numbers of conformations (usually 2−3 top clusters for 
each construct) were selected for further refinement with atomistic molecular dynamics (MD) 
simulations, to find the motifs within each cluster that were most frequently found in the Rosetta 
prediction. Predicted structures of the hDAT N-terminus, incorporating these most frequent 
motifs, were then subjected to both unbiased MD and replica exchange MD (Earl and Deem, 
2005) simulations to assess the stability of the overall fold of the N-terminus, as well as of the 
individual structural elements identified with Rosetta.  
 
The top structures that underwent the filtering process, described above, were further 
examined for suitability in the complete model of the hDAT transmembrane bundle (TMB) 
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(Beuming et al., 2008, Kniazeff et al., 2008, Bisgaard et al., 2011). The structures were 
embedded into a compositionally-asymmetric lipid membrane model (5:45:50 mixture of 
PIP2/POPE (phosphatidylethanolamine) / POPC (phosphatidylcholine) on the intracellular 
leaflet, and 30:70 mixture of sphingomyelin / POPC on the extracellular leaflet (Kiessling et al., 
2009). Docking of the N-terminus (1-59 residues) to the TMB (residues 57-590) was carried out 
with Modeller (Sali and Blundell, 1993). Specific poses for the N-terminal constructs, relative to 
the TMB, were selected based on the criterion of positioning the largest positive electrostatic 
potential isosurfaces (EPIs) towards the membrane surface. As shown before (Khelashvili et al., 
2012), such configurations not only result in the strongest electrostatic interactions between the 
protein and the PIP2-containing membrane, but also produce the highest levels of concomitant 
PIP2 sequestration by the N-terminal peptide. These juxtamembrane poses of the N-terminus 
served as starting configurations for subsequent studies of the dynamics of PIP2 lipids near the 
hDAT N-terminus, as detailed below.  
 
The protocol used to evaluate the interaction of the hDAT N-terminus with PIP2-
containing membranes is based on the application of the self-consistent mean-field model 
(SCMFM) that evaluates the steady state distributions of charged lipid species (PIP2, in this 
case) under the influence of electrostatic forces from a membrane-adsorbing macromolecule 
(here, the hDAT N-terminus) and quantifies the corresponding adsorption energies. As 
described in detail (Khelashvili et al., 2008, Khelashvili et al., 2009, Khelashvili et al., 2012), the 
SCMFM is a mesoscale approach, based on the non-linear Poisson-Boltzmann (NLPB) theory 
of electrostatics (Sharp and Honig, 1990) and Cahn-Hilliard dynamics, in which the protein is 
considered in 3-dimensional full atomistic detail, and the lipid membrane is considered as a 2-
dimensional, tensionless, incompressible low-dielectric elastic slab in which the equilibrium 
distribution of different lipid species around adsorbing protein is obtained by self-consistent 
minimization. The governing free energy function contains contributions from electrostatic 
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interactions, lipid mixing entropy, and mixing entropy of mobile salt ions in the solution. The 
SCMFM calculation of the membrane interaction of the hDAT N-terminus constructs (hDAT and 
the hDAT K/A or hDAT K/N mutants) considered in full atomistic detail (with partial charge and 
atomic radii taken from the all-atom CHARMM27 force field with CMAP corrections for proteins 
(Mackerell et al., 2004), was carried out with the N-terminus positioned 2Å away from the lipid 
surface with average surface charge density of -0.0031e (corresponding to a lipid mixture 
with 5% PIP2). The NLPB equation was then solved numerically as described (Khelashvili et al., 
2008, Khelashvili et al., 2009, Khelashvili et al., 2012), in a 0.1 M ionic solution of monovalent 
counterions (corresponding to λ=9.65Å Debye length), and using a dielectric constant of 2 for 
membrane interior and protein, and 80 for the solution. 
 
AMPH uptake  
Plated hDAT, hDAT K/N, and hDAT K/A cells, as well as untransfected cells (to account 
for non-specific AMPH uptake) were washed with KRH assay buffer and incubated for 5*min at 
37*°C with 10*nM AMPH. Cells were washed three times with ice-cold KRH and AMPH was 
extracted with acidic organic solvent. AMPH was quantified by reversed-phase HPLC using the 
Waters AccQ·Tag® method which uses pre-column derivatized reagents that help separate and 
easily detect fluorescence adducts (Waters Corporation, Milford, MA). AMPH uptake (with non-
specific uptake subtracted) was normalized to hDAT levels and expressed as a percent. 
 
Drosophila genetics, molecular biology, and construction of UAS hDAT  
Flies lacking the Drosophila dopamine transporter (DATfmn) (Kume et al., 2005) and flies 
harboring TH-Gal4(Friggi-Grelin et al., 2003) were outcrossed to a control line (Bloomington 
Indiana (BI) 6326) and selected by PCR or by eye color. TH-GAL4 (Bl 8848) and M{vas-
int.Dm}ZH-2A, M{3xP3-RFP.attP'} ZH-22A (Bl 24481) were obtained from the BI stock center 
and outcrossed to flies lacking the Drosophila DAT (DATfmn) and carrying the white (w1118) 
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mutation (BI stock number 6236) for 5–10 generations. Transgenes (hDAT or hDAT K/A) were 
cloned into pBI-UASC(Wang et al., 2012), and constructs were injected into embryos from 
M{vas-int.Dm}ZH-2A, M{3xP3-RFP.attP'}ZH-22A (Bl 24481). Initial potential transformants were 
isolated by selecting for red eyes and lack of GFP signal in the head. Transformants were also 
verified by RFP fluorescence and outcrossed 5-8 times to DATfmn flies. The presence of DATfmn 
lesion was verified by PCR. Flies were maintained on a standard cornmeal/molasses/yeast 
media at 25°C and 65% humidity with a 12 hour/12hour light/dark cycle. Lights came on at 8 AM 
and off at 8 PM.  
 
Behavioral analysis  
Three-day-old males were collected and placed into tubes with food for three days. After 
three days locomotion was recorded for 32 hours by beam breaks and analyzed using 
equipment/software from Trikinetics (www.trikinetics.com). For the AMPH-induced locomotion, 
males were starved for 6*hours and then fed sucrose (10*mM) containing either AMPH (1*mM) or 
vehicle.  
 
Statistical analysis  
Compiled data are expressed as normalized mean values ± standard error. For 
statistical analysis, we used either a Student’s t-test or one-way ANOVA depending on the n of 
the experimental groups. P < 0.05 was considered statistically significant.  
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CHAPTER 3 
 
PUTATIVE PHOSPHATIDYLINOSITOL (4,5)-BISPHOSPHATE BINDING  
SITES ON DOPAMINE TRANSPORTER INTRACELLULAR LOOP REGIONS  
CONTROL TRANSPORTER FUNCTION 
 
Introduction 
To date, direct interactions between phosphotidylinositol (4,5)-bisphosphate (PIP2) and 
the hDAT have been documented to occur via electrostatic interactions between PIP2 and Lys 
residues of the hDAT N-terminus (Hamilton and Belovich et al., 2014).  However, studies 
conducted with the hSERT have shown that PIP2 also interacts with positive residues in the 
intracellular loop regions of the transporter, specifically Lys residues K352 and K460 in IL3 and 
IL4, respectively (Buchmeyer et al., 2013).  Mutating both of these residues to Ala (hSERT 
K352A-K460A) results in an impaired ability of the hSERT to interact with PIP2 compared to WT 
hSERT, as demonstrated in vitro using PIP2-coated beads to pull down lysates from HEK 293 
cells (Buchmeyer et al., 2013).  Additional in vitro experiments have shown that the hSERT 
K352A-K460A has an impaired ability to pass efflux currents induced by para-
chloroamphetamine (pCA), while substrate uptake capability is unaffected (Buchmeyer et al., 
2013).  Thus, these data suggest that PIP2 interaction with non-N-terminal residues is important 
for substrate efflux by the hSERT.  Intriguingly, the interactions of PIP2 with the hSERT appear 
to have an asymmetric regulation of transporter function (e.g., affecting substrate efflux, but not 
substrate uptake), similar to what has been reported for the hDAT N-terminal K/A constructs 
with impaired PIP2 interactions (Hamilton and Belovich et al., 2014).  Thus, the work described 
in this chapter aims to investigate the hypothesis that PIP2 also regulates hDAT function 
(specifically AMPH-induced DA efflux) via interactions with hDAT intracellular loops. 
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The focus of this chapter is to determine whether the homologous hDAT residues of the 
hSERT/PIP2 binding sites also have a significant role in transporter function, specifically in DA 
uptake and AMPH-induced DA efflux.  The homologous residues for the hSERT/PIP2 interaction 
sites in the hDAT are K337 and R443 (Yamashita et al., 2005).  Simultaneous mutation of these 
putative PIP2 binding site residues to Ala (hDAT K337A-R443A) results in an impaired ability of 
the transporter to be expressed at the cell surface in CHO cells, hindering functional 
investigation of hDAT K337A-R443A (Hamilton and Belovich et al., 2014).  However, mutation 
of each residue individually does not impair surface expression, allowing for in vitro investigation 
of functional properties (discussed below).  When expressed in CHO cells, hDAT K337A shows 
an impairment in AMPH-induced DA efflux, as well as an impairment in DA uptake ability, but 
with normal total and surface expression levels.  CHO cells expressing hDAT R443A, on the 
other hand, display a reduction in AMPH-induced DA efflux only, with DA uptake comparable to 
WT hDAT as well as normal total and surface expression.  Individual mutation of both of these 
putative PIP2 binding sites results in functional deficiencies compared to  WT hDAT, although 
they do not display the same phenotypic profile.  These data indicate that K337 and R443 may 
be essential for hDAT function via distinct molecular mechanisms and invites further study into 
the diverse roles that PIP2 may play in regulating neurotransmitter transporter function. 
 
Results 
hDAT K337A shows impairments in both AMPH-induced DA efflux and DA uptake  
To determine the ability of hDAT K337A to respond to AMPH, CHO cells were transiently 
transfected with either WT hDAT or hDAT K337A and bath loaded with DA (bath concentration: 
10 µM DA).  AMPH was added to the bath solution and DA efflux was measured as 
amperometric current detected with a carbon fiber electrode (Hamilton and Belovich et al., 
2014).  In comparison to WT hDAT cells, K337A hDAT cells show a significant impairment in 
peak amplitude of the AMPH-induced amperometric current, as seen in both the representative 
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traces (Fig. 26a) and the quantitated average peak amplitudes (Fig. 26b).  Peak amplitude of 
WT hDAT is 100.0%  ± 19.7% compared to hDAT K337A peak amperometric current of 45.36 % 
± 10.7% (Fig. 26b).   
 
To rule out decreased surface expression of hDAT K337A as a cause for the impaired 
AMPH response, biotinylation assays as previously described were conducted with WT hDAT 
and hDAT K337A cells (Mazei-Robison et al., 2008).  For each genotype, the surface fraction 
(Fig. 26c, top) was quantitated and normalized to the mature glycosylated total hDAT (Fig. 26c 
middle) and represented as % WT hDAT.  There were no significant changes in hDAT K337A 
surface expression compared to WT hDAT (Fig. 26d). Additionally, there was no change in the 
ratio of mature glycosylated and immature unglycosylated forms of the hDAT K337A compared 
to WT hDAT (Fig. 26c, middle). 
   
In order to assess whether hDAT K337A has an impairment in uptake capacity, hDAT 
K337A cells (open squares) and WT hDAT cells (filled squares) were incubated with varying 
concentrations of [3H]DA to assess uptake capacity of the hDAT K337A (Fig. 26e).  Figure 26e 
represents an average of all data points (12) gathered across four different trials.  hDAT K337A 
(Fig. 26e, open squares) shows a decrease in Vmax compared to WT hDAT (WT hDAT Vmax = 
1.019 ± 0.07 pmols/min/105 cells; hDAT K337A Vmax = 0.6992 ± 0.04 pmols/min/105 cells), but 
has an unchanged apparent affinity for DA compared to WT hDAT (WT hDAT Km = 0.6437 ± 
0.17 µM; hDAT K337A Km = 0.6053 ± 0.14 µM) (Fig. 26f).   
 
hDAT R443A shows impaired AMPH-induced DA efflux, but normal DA uptake 
Similar to hDAT K337A, hDAT R443A shows impaired response to AMPH in vitro.  CHO 
cells transiently transfected with either WT hDAT or hDAT R443A were bath-loaded with DA 
and exposed to a final concentration of 10 µM AMPH.  As seen in the representative traces,  
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Figure 26. hDAT K337A shows decreased AMPH-induced DA efflux and DA uptake, 
but no decrease in trafficking and surface expression ratios compared to WT 
hDAT. (a) Representative traces of amperometric currents from WT hDAT and K337A 
hDAT cells in response to 10 µM AMPH indicated by arrows. (b) Quantitation of peak 
amplitude of AMPH-induced amperometric current normalized to WT hDAT peak 
amperometric current. (*p = 0.0269 by Two-tailed Student’s T-test; n = 9). (c) 
Representative immunoblots of biotinylated surface fractions of WT hDAT and K337A 
hDAT (top), total lysates, including mature glycosylated and immature non-glycosylated 
forms (middle), and actin as loading control (bottom). (d) Quantification of surface 
expression is represented by normalization of surface band to glycosylated total hDAT 
band and is expressed as a Surface/Total ratio. Data are normalized to WT hDAT 
Surface/Total ratios, and presented as % WT hDAT Surface/Total. (p = 0.3626 by Two-
tailed Student’s T-test; n = 10). (e) Substrate saturation uptake curve, cumulative results 
from 4 experiments, each data point collected in triplicate for 12 replicates total. (*p < 
0.05, **p <0.01 by Two-way ANOVA with Bonferonni’s multiple comparison’s test; n = 4, 
12 replicates total). (f) Vmax and apparent Km values were obtained using the Michaelis-
Menten equation using all available data points. 
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AMPH-induced DA efflux is reduced in hDAT R443A compared to WT hDAT (Fig. 27a).  On 
average, the peak AMPH-induced amperometric current amplitude of hDAT R443A cells was 
observed to be 57.5 ± 10% of WT hDAT (100 ± 15.5%) (Fig. 27b).   
 
Again, as with hDAT K337A, hDAT R443A’s impairment of AMPH-induced DA efflux is 
not due to alterations in total or surface protein expression (Fig. 27c-d).  The surface fraction for 
each genotype (Fig. 27c, top) was quantitated and normalized to the mature glycosylated total 
hDAT (Fig. 27c middle) and expressed as a percent of WT hDAT (Fig. 27d).  hDAT  R443A 
surface expression does not significantly differ from WT hDAT surface expression, nor does 
R443A hDAT display differences in glycosylation (Fig. 27c, middle). !
Finally, hDAT R443A’s uptake capabilities were tested using [3H]DA.  hDAT R443A cells 
(open squares) and WT hDAT cells (filled squares) were incubated with varying concentrations 
of [3H]DA (Fig. 27e).  Figure 27e represents an average of all data points (11-12) gathered 
across four different trials.  hDAT R443A shows no change in Vmax compared to WT hDAT (WT 
hDAT Vmax = 1.39 ± 0.10 pmols/min/105 cells; hDAT R443A Vmax = 1.275 ± 0.12 pmols/min/105 
cells) and has an unchanged apparent affinity for DA compared to WT hDAT (WT hDAT Km = 
0.938 ± 0.25 µM; hDAT R443A Km = 1.028 ± 0.34 µM) (Fig. 27f). 
 
Discussion 
The results in Figure 26 show that hDAT K337A has severe deficiencies in both DA 
uptake and AMPH-induced DA efflux functions.  The K337 residue is located is located two 
amino acid residues away from Y335, which has previously been shown to be important for the 
hDAT’s ability to change its conformation towards an inward-facing conformation (Norregaard et 
al., 1998, Loland et al., 2002).  As confirmed by the 2013 dDATcryst structure showing the 
intracellular gate (Fig. 28), the dDAT’s homologous residue of hDAT Y335, dDAT Y334  
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Figure 27. hDAT R443A shows decreased AMPH-induced DA efflux, but no 
decrease in trafficking and surface expression ratios and DA uptake compared to 
WT hDAT. (a) Representative traces of amperometric currents, arrows indicate addition 
of AMPH. (b) Quantitation of peak current amplitudes, normalized to peak WT hDAT 
current amplitudes. (*p < 0.03 by two-tailed paired Student’s t-test; n = 14). (c) 
Representative immunoblots of biotinylated (surface) hDAT (top), total glycosylated hDAT 
and total non-glycosylated hDAT (middle), and actin as loading control (bottom). (d) 
Quantification of surface expression is represented by normalization of surface band to 
glycosylated total hDAT band and is expressed as a Surface/Total ratio. Data are 
normalized to WT hDAT Surface/Total ratios, and presented as % WT hDAT 
Surface/Total (p = 0.6232 by two-tailed Student T-test; n = 20). (e) Curves represent 
averaged uptake data from 3 trials in triplicate and 1 trial in duplicate (11 data points 
total) at 10 minutes at the specified DA concentrations. (No significance by Two-way 
ANOVA with Bonferonni Post test). (f) Vmax and apparent Km values were obtained using 
the Michaelis-Menten equation. 
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Figure 28. Structure of the dDATcryst intracellular gate in closed conformation.  
Structure is viewed from cytoplasm.  A network of polar interactions on the cytoplasmic 
face of the transporter stabilizes the closed conformation of the intracellular gate. 
Residue Y334 (hDAT Y335) appears positioned to form interactions with IL1 and TM8.  
IL4 residue D435 (hDAT 436) forms a salt bridge with N-terminus residue R27 (hDAT 
R60).  Figure modified from Penmatsa et al., 2013.  
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coordinates a salt bridge between dDAT R27 (hDAT R60) and dDAT D435 (hDAT D436) 
(Penmatsa et al., 2013).  Therefore, if PIP2 does indeed interact with K337, this interaction may 
help coordinate the hDAT’s conformational change towards the inward facing state.  Direct 
interaction between hDAT K337 and PIP2 has not yet been established, but could possibly be 
investigated via GST-pulldown experiments as previously published (Hamilton and Belovich et 
al., 2014).  Furthermore, as Zn2+ has previously been used to rescue the ability of hDAT Y335A 
to adopt an inward-facing conformation and restore uptake function (Loland et al., 2002), it 
should be investigated whether Zn2+ can also rescue hDAT K337A function.  
 
hDAT K337A also shows an impairment in AMPH-induced DA efflux (Fig. 26).  One 
possible explanation for this observation is that K337’s proximity to Y335 influences inward vs. 
outward facing conformation of the transporter.  If true, this would suggest the hDAT must adopt 
specific conformations before AMPH-induced DA efflux can occur.  This idea could be 
experimentally addressed by the application of Zn2+ to rescue AMPH-induced DA efflux.  This 
concept has been demonstrated with the ASD-associated variant, hDAT T356M, which prefers 
an outward facing conformation and has impaired AMPH-induced DA efflux susceptible to Zn2+  
rescue (Hamilton and Campbell et al., 2013, Hamilton and Shekar et al., 2015, see Chapter 5 of 
this thesis for detailed discussion).  If Zn2+ does rescue AMPH-induced DA efflux (along with DA 
uptake as discussed above), this would support the hypothesis that hDAT K337A’s impaired 
AMPH-induced DA efflux is due to an altered conformational equilibrium.  An alternative 
explanation for hDAT K337A’s impaired AMPH-induced DA efflux is that PIP2 interacts with both 
K337 and the hDAT N-terminus to coordinate the conformational changes required for efflux.  
However, since there is limited functional data on the K337 residue, this concept will be 
discussed in the context of the R443 residue (below). 
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In contrast to hDAT K337A, hDAT R443A does not show any indication of impaired DA 
uptake, instead showing only an impairment in AMPH-induced DA efflux (Fig. 27).  This 
asymmetric functional profile is the same as that of hDAT constructs with impaired N-terminal 
PIP2 interactions (Hamilton and Belovich et al., 2014).  Computational modeling studies support 
the notion that the R443 residue interacts with both PIP2 and the hDAT N-terminus (Khelashvilli 
et al., 2015).  As represented in Figure 29a, PIP2 is predicted to form close associations with 
R443 and with other positive residues in the N-terminus, specifically K3, K5, K27, K35, and R51 
(Khelashvilli et al., 2015).  In turn, R443 is also predicted to form close associations with N-
terminal residues K3, K35, and R51 (Fig. 29b) (Khelashvilli et al., 2015).  Overall, this model 
suggests that PIP2 interacts with the positive residues on the hDAT N-terminus and R443, 
essentially bringing the N-terminus into proximity with R443 and surrounding residues in IL4 and 
TM9 (Khelashvilli et al., 2015).   
 
In the context of AMPH-induced DA efflux, this model is especially intriguing, as the 
hDAT N-terminus and its phosphorylation are both essential for this mechanism (Khoshbouei et 
al., 2003, Khoshbouei et al., 2004), as well as PIP2 interactions (Hamilton and Belovich et al., 
2014).  The idea that PIP2 can simultaneously interact with both the N-terminus and R443 
supports the hypothesis that PIP2 brings the negative charges of the phosphorylated N-terminus 
into proximity with positively charged R443, possibly triggering the conformational changes 
required for DA efflux.  As Figure 27 shows, removing the positive charge at residue R443 
(hDAT R443A) significantly impairs AMPH-induced DA efflux, indicating that R443 does indeed 
play a vital role in this mechanism.  However, more studies will need to be conducted with 
phosphomimetic mutation of the hDAT N-terminus in an hDAT R443A background to determine 
whether R443 interaction with the phosphorylated N-terminus is necessary for AMPH-induced 
DA efflux. 
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Figure 29. Computational model of DAT IL4 and DAT N-terminus interactions, 
coordinated by PIP2. (a) The DAT N-terminus (N-term, mauve) is predicted to be 
brought into proximity with residue R443 (space-filling model, green) by interactions with 
PIP2 (stick models; hydrophobic region is rendered in teal and phospho-head groups are 
rendered in red).  Teal space-filling residues are N-terminus residues predicted to interact 
with PIP2.  Blue and red space-filling residues represent components of the intracellular 
gating region. (b) N-terminus residues (blue) and R443 (green) are predicted to be in 
close proximity.  Peptide backbone of N-terminus is rendered in red.  DNt indicates distal 
N-terminus (indicated by black arrow).  Images adapted from Khelashvilli et al., 2015. 
 
86 
Of further interest is the fact that R443 is located on the same intracellular loop (IL4) as  
D460, which forms a salt bridge between R60 and E428, residues that compose part of the 
intracellular gate (Khleashvilli et al., 2015).  R443 is also two amino acids away from R445, 
which has been predicted to interact with E428 in the dDATcryst structure and during dynamic 
molecular simulations (Penmatsa et al., 2013, Khelashvilli et al., 2015).  These interactions 
stabilize the inward-closed state of the transporter, and are predicted to be disrupted by the 
hDAT N-terminus interacting with IL4 (Khelashvilli et al., 2015).  Furthermore, PIP2 enriched 
membranes are modeled to induce the transporter to favor an inward facing conformation 
(Khelashvilli et al., 2015).  Using these statements as background, it would be reasonable to 
assume that hDAT R443A would have impaired ability to adopt an inward-facing conformation, 
like hDAT Y335A, and would therefore show reduced ability to uptake DA.  However, hDAT 
R443A does not show impairments in DA uptake in vitro (Fig. 27).  This suggests that R443 
plays a different role other than that modeled  computationally.  Instead, it may be more fruitful 
to examine the role of the phosphorylated N-terminus, PIP2, and the interactions with R443 
during AMPH-induced DA efflux.  However, as with K337, R443 remains a putative PIP2 binding 
site, and the direct interaction between this residue and PIP2 must be established in future 
studies. 
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CHAPTER 4 
 
DE NOVO MUTATION IN THE DOPAMINE TRANSPORTER GENE ASSOCIATES 
DOPAMINE DYSFUNCTION WITH AUTISM SPECTRUM DISORDER2 
 
Abstract 
De novo genetic variation is an important class of risk factors for autism spectrum 
disorder (ASD). Recently, whole exome sequencing of ASD families has identified a novel de 
novo missense mutation in the human dopamine (DA) transporter (hDAT) gene, which results in 
a Thr to Met substitution at site 356 (hDAT T356M). The dopamine transporter (DAT) is a 
presynaptic membrane protein that regulates dopaminergic tone in the central nervous system 
by mediating the high-affinity re-uptake of synaptically released DA, making it a crucial regulator 
of DA homeostasis. Here, we report the first functional, structural, and behavioral 
characterization of an ASD-associated de novo mutation in the hDAT. We demonstrate that the 
hDAT T356M displays anomalous function, characterized as a persistent reverse transport of 
DA (substrate efflux). Importantly, in the bacterial homolog leucine transporter, substitution of 
A289 (the homologous site to T356) with a Met promotes an outward-facing conformation upon 
substrate binding. In the substrate-bound state, an outward-facing transporter conformation is a 
required for substrate efflux. In Drosophila melanogaster, expression of hDAT T356M in DA 
neurons lacking Drosophila DAT leads to hyperlocomotion, a trait associated with DA 
dysfunction and ASD. Taken together, our findings demonstrate that alterations in DA 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!
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Hansen,"C."Saunders,"A."N."Belovich,"NIH"ARRA"Autism"Sequencing"Consortium,"M."Sahai,"E."H."Cook,"U."Gether,"H."
S." Mchaourab," H." J." G." Matthies#," J." S." Sutcliffe#" and" A." Galli#" (2013)." “De" novo" mutation" in" the" dopamine"
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homeostasis, mediated by aberrant DAT function, may confer risk for ASD and related 
neuropsychiatric conditions. 
 
Introduction 
Genetic factors have been implicated as important components in the etiology of autism 
spectrum disorder (ASD). It is now accepted that rare genetic variation affecting single 
nucleotides of protein-coding DNA, as well as rare genomic copy number variants (CNVs), are 
significant ASD risk factors (Sebat et al., 2007, Sanders et al., 2011, Devlin and Scherer, 2012, 
Sanders et al., 2012). In particular, increasing evidence suggests that de novo genetic variation 
is a risk factor in ASD and other neuropsychiatric diseases (Cook and Scherer, 2008, Pinto et 
al., 2010, Levy et al., 2011, Sanders et al., 2011, Devlin and Scherer, 2012). Several groups 
have conducted whole exome sequencing (WES) on ASD families, and collectively, these 
studies indicate that discrete de novo mutation (single nucleotide variation (SNV) or small 
indels) contribute to the overall genetic risk of ASD (Iossifov et al., 2012, Neale et al., 2012, 
O'Roak et al., 2012, Sanders et al., 2012). Among these variations is the first ASD-associated, 
de novo mutation found in the human dopamine (DA) transporter (hDAT) gene (SLC6A3) (Neale 
et al., 2012). This mutation results in a Thr to Met substitution at position 356 (hDAT T356M). 
The consequences of this de novo mutation and its impact on DA neurotransmission have yet to 
be elucidated.  
 
The neurotransmitter DA plays an important role in the central nervous system by 
regulating a variety of functions, including motor activity, motivation, attention, and reward 
(Carlsson, 1987, Giros and Caron, 1993, Bjorklund and Dunnett, 2007, Palmiter, 2008).!
Disrupted DA function is implicated in a number of neuropsychiatric disorders, including bipolar 
disorder, schizophrenia, attention-deficit hyperactivity disorder (ADHD) (Seeman and Niznik, 
1990, Volkow et al., 2007, Cousins et al., 2009) and, more recently, ASD (Nieminen-von Wendt 
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et al., 2004, Anderson et al., 2008, Nakamura et al., 2010, Tassone et al., 2011, Makkonen et 
al., 2011). The dopamine transporter (DAT) is a presynaptic membrane protein that regulates 
DA neurotransmission via the high-affinity reuptake of synaptically released DA (Kristensen et 
al., 2011). It is the major molecular target of cocaine, amphetamine (AMPH; Adderall™), and 
methylphenidate (Ritalin™)(Giros et al., 1996, Jones et al., 1998, Khoshbouei et al., 2004, 
Kahlig et al., 2005, Sulzer et al., 2005). Due to DAT’s role in DA neurotransmission, SLC6A3 
variants have been a focus of genetic association studies linking the etiology of brain disorders 
to dysregulated DA neurotransmission (Kurian et al., 2009, Kurian et al., 2011). Recent studies 
have identified a rare, inherited, functional missense SLC6A3 variant, hDAT A559V 
(rs28364997) (Grunhage et al., 2000, Mazei-Robison et al., 2005), that has been associated 
with ADHD, which is commonly comorbid in ASD subjects (Roman et al., 2004, Leyfer et al., 
2006, de Bruin et al., 2007, Ronald et al., 2008). These studies point to a contribution of DAT 
genetic variants in complex brain disorders.  
 
While the role of DA in ADHD has been established (Nemoda et al., 2011), DA’s role in 
ASD is poorly understood (Dichter et al., 2012). Many individuals with ASD exhibit co-
occurrence of ADHD symptoms (~20-45%)(Goldstein and Schwebach, 2004, Sturm et al., 2004, 
Yoshida and Uchiyama, 2004, Gadow et al., 2006). The comorbid nature of ADHD with ASD 
points to dysregulation of common signaling pathways (e.g. DA) as a mechanism underlying 
these neuropsychiatric disorders (Di Martino et al., 2013). 
 
Here, we characterized the first ASD-identified, de novo mutation in hDAT by presenting 
structural, functional, and behavioral analysis of this de novo variant. These results implicate 
altered DA homeostasis as a potential liability in ASD risk. 
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Results 
T356M de novo DAT variant has impaired function 
A recent study assessed the role of de novo variation in ASD by using WES in 175 ASD 
parent-child trios (Neale et al., 2012). In this study, a de novo SLC6A3 variant was identified, 
resulting in a Thr to Met substitution at site 356 (Neale et al., 2012). Given the rarity of non-
synonymous de novo events, it is not surprising that this mutation was absent in the ~1,000 
unrelated ASD cases and controls (Neale et al., 2012) and has not been deposited in 1,000 
genomes (Genomes Project et al., 2012), dbSNP (build 137) (Sherry et al., 2001), or the NHLBI 
Exome Sequencing Project. The subject carried no other coding de novo mutations. The T356 
is completely conserved across several species (Fig. 30a). Importantly, the T356 residue is 
located in the seventh transmembrane domain of hDAT and resides in a highly conserved 
region implicated in ion binding (Yamashita et al., 2005). The molecular modeling of hDAT and 
in silico mutagenesis of T356 is shown in Figure 30b. 
 
The subject harboring this de novo mutation is the elder male child of healthy 
nonconsanguineous Caucasian parents (proband has a healthy younger sibling). There is no 
immediate family history of ASD or related psychiatric conditions. The subject has a normal IQ 
(94) and has no history of seizures or other co-morbidities. By the age of 6 years-old, the 
proband was diagnosed with ASD (see supplemental material for full clinical reports). 
 
To evaluate whether the T356M variant may be a risk factor in the proband’s ASD, we 
compared the activities of hDAT and hDAT T356M in a heterologous expression system. We 
examined radioactive [3H]DA uptake and affinity. In hDAT T356M cells, the maximal velocity of 
DA influx (Vmax) was significantly reduced, whereas the apparent DA affinity (Km) of hDAT 
T356M was not significantly different from that of hDAT (Fig. 31a, top). A representative plot of 
DA uptake kinetics for hDAT and hDAT T356M is shown in Figure 31a (bottom). The reduced 
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Figure 30. Cross-species conservation and in silico mutagenesis of T356. (a) 
Alignment of the DAT amino acid sequence across multiple species. Threonine 356 is 
represented in red. (b) In an equilibrated three-dimensional homology model of 
hDAT, the T356M mutation is located on transmembrane domain 7 (TM7). Top: 
Schematic views representing a 180° rotation show T356M with respect to the TM 
helices. TM7 is shown in dark blue. Bottom: Critical residues that interact with 
DA{18568020}{20816875} are shown, as well as the bound Na+ and Cl- ions. The 
methionine is rendered together at position 356 with the wild type threonine (green). 
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Figure 31. hDAT T356M has impaired function. (a) Top: Kinetic parameters (Vmax 
and Km) for hDAT and hDAT T356M (Vmax: p ≤ 0.005; by Student’s t-test; n = 3, in 
triplicate; Km: p ≥ 0.20; by Student’s t-test; n = 3, in triplicate). Bottom: Representative 
plot of [3H]DA uptake kinetics in hDAT (filled squares) or hDAT T356M (empty 
squares) cells (** = p ≤ 0.01, *** = p ≤ 0.001; by two-way ANOVA followed by 
Bonferroni post-test; n = 3, in triplicate). (b) Representative immunoblots for 
biotinylated (surface) and total protein fractions from hDAT and hDAT T356M cells. 
Surface fractions were quantitated, normalized to total DAT (Glycosylated), and 
expressed as a percent of hDAT (p ≥ 0.05; by Student’s t-test; n = 8-11). 
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[3H]DA transport capacity was not associated with a reduction in either total or DAT surface 
expression (Fig. 31b, top), as assessed by measuring changes in DAT proteins in the total and 
biotinylated fraction, respectively. The total fraction for hDAT and hDAT T356M contained both 
glycosylated and non-glycosylated forms of the DAT. Surface fractions were quantitated, 
normalized to total DAT (glycosylated), and expressed as a percent of hDAT (Fig. 31b, bottom). 
Furthermore, normalizing the total DAT fraction (glycosylated) to actin loading control yielded no 
significant differences between hDAT and hDAT T356M total expression (data are expressed as 
a percentage of hDAT; hDAT 100 ± 17.6% versus hDAT T356M 96.4 ± 13.7%; p ≥ 0.87 by 
Student’s t-test; n = 8-11).  
 
hDAT T356M displays ADE 
 Although hDAT T356M displays similar surface expression to that of hDAT, it 
demonstrates reduced ability to accumulate intracellular DA. One possibility is that constitutive 
DA efflux, here referred to as anomalous DA efflux (ADE), contributes to this reduced DA 
uptake in the hDAT T356M cells. This efflux would impede the intracellular accumulation of DA.  
 
To determine whether hDAT T356M exhibits ADE, cells were whole cell patch clamped 
and perfused for 10 minutes with an internal solution containing 2 mM DA (Bowton et al., 2010).  
The electrode, in current clamp configuration, allows the cell to control its membrane voltage. In 
addition, this technique ensures that cells expressing either hDAT or hDAT T356M were equally 
loaded with DA. DA efflux was quantified through amperometry (Bowton et al., 2010). We have 
previously shown that, in the presence of ADE, cocaine decreases the amperometric signal 
through blockade of DAT (Mazei-Robison et al., 2008). In hDAT cells, amperometric currents 
were unaffected by application of cocaine (Fig 32a, top, hDAT, COC), indicating no ADE. In 
contrast, amperometric signals from hDAT T356M cells were significantly reduced by the 
application of cocaine (Fig. 32a, top, hDAT T356M, COC), revealing ADE. hDAT T356M-  
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Figure 32. hDAT T356M exhibits robust anomalous DA efflux (ADE). (a) Top: 
representative amperometric currents recorded from hDAT and hDAT T356M cells. 
Arrows indicate application of 10 µM cocaine (COC). Bottom: quantitation of the 
cocaine-induced reduction in the amperometric current (ADE). Data are reported as 
maximal current (*** = p ≤ 0.001 by Student’s t-test; n = 4-5). (b) hDAT T356M cells 
do not display altered resting membrane potential with respect to hDAT cells (p ≥ 0.05 
by Student’s t-test, n = 9-25). (c) Representative AMPH-induced amperometric 
currents recorded from hDAT and hDAT T356M cells. Arrows indicate application of 
10 µM AMPH. Bottom: quantitation of AMPH-induced DA efflux. Data are represented 
as maximal current expressed as percent of the current recorded in hDAT cells (** = p 
≤ 0.01 by Student’s t-test; n = 5-7).  
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expressing cells displayed a significant increase in ADE, compared to hDAT transfected cells 
(Fig. 32a, bottom).  
 
Cell membrane depolarization has been shown to support DA efflux (Khoshbouei et al., 
2003). Figure 32b reveals that there is not a significant difference in resting membrane potential 
(measured in current clamp) between cells expressing hDAT or hDAT T356M. This indicates 
that differences in the function of hDAT and hDAT T356M are not due to resting membrane 
potential. 
 
Next, we determined possible changes in the ability of AMPH to cause DA efflux by 
patch delivering DA into hDAT or hDAT T356M cells while recording DA efflux with 
amperometry. AMPH dose-response assays (measuring the peak of the amperometric current 
at different AMPH concentrations) revealed that hDAT T356M and hDAT cells have comparable 
AMPH EC50 (EC50; hDAT: 0.15 ± 0.05 µM; hDAT T356M: 0.16 ± 0.07 µM; n = 4; p ≥ 0.95 by 
Student’s t-test). Then, using a saturating AMPH concentration (10 µM) we determined DA 
efflux in either hDAT or hDAT T356M cells (Fig. 32c, top). AMPH-induced DA efflux was 
significantly reduced in hDAT T356M cells in comparison to hDAT cells (Fig. 32c). These 
results strongly suggest that ADE does not share common mechanisms with AMPH-induced DA 
efflux.  
 
In LeuT, substitution of Ala289 with a Met promotes an outward-facing conformation 
To investigate the structural consequences of the T356M de novo mutation in a DAT 
homolog with a known crystal structure, we analyzed changes in the conformational cycle of the 
leucine transporter (LeuT). We substituted A289 (the homologous amino acid to T356) with a 
Met (LeuT A289M). We measured distances between pairs of spin labels (r (Å)) and the 
distance distribution (P(r), the probability of a given distance between the two labels) monitoring 
96 
the intra- and extracellular gates by double electron electron resonance (DEER) (McHaourab et 
al., 2011). First, we examined the pair 309/480 (Fig. 33a, left) that monitors the relative 
movement of the extracellular loop 4 (EL4) in LeuT. This loop obstructs the permeation pathway 
in the Apo conformation (Claxton et al., 2010), as indicated by the close proximity of the pair 
309/480 (Fig. 33a, middle, Apo black line). Upon Na+ binding, the distance between EL4 and 
TM12 increases (Claxton et al., 2010), indicating opening of the extracellular vestibule and 
enabling substrate access (data not shown) (Claxton et al., 2010). Subsequent Leu binding 
resets the closed EL4 conformation in the occluded conformation of the transporter (Na+ and 
Leu bound in the vestibule) (Fig. 33a, right; +Na/L black line). The extracellular Apo state (Fig. 
33a, middle; Apo; compare red and black lines) as well as Na+ bound state (data not shown) are 
similar in LeuT and LeuT A289M. Yet, LeuT A289M with Na+ and Leu bound in the vestibule 
has a destabilized bound structure with fluctuations on the extracellular side (Fig. 33a, right; 
+Na/L; compare red and black lines). The probability distribution in the Na/Leu bound state 
contains distinct populations of conformations that indicate fluctuations of LeuT A289M to a 
permeation pathway that has increased probability to be open to the outside, relative to LeuT 
(Fig. 33a, right; red line, arrows).  
 
We then examined the pair 7/86 (Fig. 33b, left), to determine the distance between the 
N-terminus and intracellular loop 1 (IL1) and to monitor fluctuation dynamics on the intracellular 
side (McHaourab et al., 2011). This is necessary to describe changes in the population of 
transporters with an inward facing conformation (McHaourab et al., 2011). In the LeuT 
background, distance distributions between spin (McHaourab et al., 2012) or fluorescent probes 
(Zhao et al., 2011) in the Apo state are bimodal, reflecting the equilibrium of this intracellular 
gate between closed and open conformations (Fig. 33b, middle; Apo; black lines). Introduction 
of the A289M leads to a shift in the equilibrium to favor the closed conformation side (Fig. 33b, 
middle; Apo; compare red and black lines, arrow). Na+ binding does not alter the equilibrium 
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Figure 33. In the leucine transporter (LeuT), substitution of Ala289 with a Met 
supports an outward-open facing conformation. Distance distributions of 
extracellular and intracellular spin labeled Cys pairs in LeuT reveal changes in the 
conformational equilibrium caused by mutating Ala289 to a Met. (a) Left: extracellular 
reporter pairs (309-480) tagged on three-dimensional structure of LeuT. Right: 
distance of the extracellular reporter pair for LeuT (black) and A289M (red), in the 
Apo conformation (Apo) and in the presence of Na+ and Leu (+NaL). (b) Left: 
intracellular reporter pairs (7-86) tagged on the three-dimensional structure of LeuT. 
Right: distance of the intracellular reporter pair for LeuT (black) and A289M (red), in 
the Apo conformation (Apo) and in the presence of Na+ and Leu (+NaL). The LeuT 
structure was obtained from PDB 2A65. The structures were generated using 
PyMOL. 
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between the two conformations (data not shown), while Na+ and Leu binding resets this shift to 
LeuT-like conformations (Fig. 33b, middle; +Na/L; compare red and black lines). 
 
Our results demonstrate that, because of the A289M, the presence of substrate and Na+ 
fails to completely close the extracellular pathway as in LeuT, inducing fluctuations on the 
extracellular side. These fluctuations to an open-to-the-outside permeation pathway persist, 
possibly enabling substrate release. This is in contrast to LeuT, where substrate binding closes 
the extracellular permeation pathway.  
 
Drosophila expressing hDAT T356M in DA neurons are hyperactive 
 Locomotion is an elemental behavior regulated across species, including Drosophila 
melanogaster, by DA (Pendleton et al., 2002, Wicker-Thomas and Hamann, 2008, Pizzo et al., 
2013). Thus, locomotion in flies offers a powerful model for elucidating the behavioral impact of 
ADE associated with hDAT T356M. 
 
We expressed hDAT or hDAT T356M in flies homozygous for the Drosophila DAT null 
allele, DATfmn (dDAT KO)(Kume et al., 2005), by using the Gal4/UAS system to express a single 
copy of hDAT or hDAT T356M in a dDATfmn mutant background, selectively in DA neurons 
(Matthies and Broadie, 2003). To generate the transgenic flies, we used phiC31 based 
integration, which leads to the expression of comparable levels of mRNA for the relevant 
transgenes (hDAT or hDAT T356M). Locomotion was quantitated by beam crossing detection 
over a >24 hour period (data binned in 15 minute intervals) during both the light (horizontal 
white bar) and dark (horizontal black bar) cycle. While dDAT KO are hyperactive (Kume et al., 
2005), flies expressing hDAT in DA neurons have reduced locomotion as compared to dDAT 
KO, demonstrating the behavioral significance of our approach (Fig. 34a, compare hDAT to 
dDAT KO).  
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Figure 34. Expression of hDAT T356M in Drosophila leads to hyperactivity. hDAT or 
hDAT T356M was expressed in DA neurons of dDAT KO flies. (a) Locomotor activity was 
assayed over 32 hours during the light (horizontal white bars) or dark (horizontal black 
bars) cycle. Flies expressing hDAT T356M (red squares), as well as dDAT KO flies (blue 
squares), were hyperactive throughout the 32 hour period with respect to flies expressing 
wild type hDAT (black squares) (n = 32; beam breaks binned in 15 minute intervals). (b) 
Quantitation of total beam crosses over 24 hours for hDAT, hDAT T356M, and dDAT KO 
flies (**** = p ≤ 0.0001; n = 32). 
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We hypothesized that flies harboring the hDAT T356M would be hyperactive with 
respect to hDAT expressing flies due to an increase in extracellular DA promoted by ADE. This 
is shown in figure 34a. Figure 34b shows total (24 hour) locomotor activity in the different fly 
lines. Total activity (24 hours) of hDAT T356M and dDAT KO flies is significantly higher than 
hDAT flies (Fig. 34b).  
 
hDAT T356M cells display compromised AMPH-induced DA efflux (Fig. 32c). This 
suggests a reduced ability of AMPH to increase locomotion in flies expressing hDAT T356M. 
Changes in locomotion were determined upon AMPH or vehicle exposure (15 minutes) and 
calculated as beam crosses. We observed no significant increase in locomotion in hDAT T356M 
flies when exposed to AMPH as compared to vehicle control (hDAT T356M (vehicle) 9.7 ± 0.7 
beam breaks versus hDAT T356M (AMPH) 12.7 ± 1.6 beam breaks; n = 24; p ≥ 0.05). This is in 
contrast to flies expressing hDAT, where AMPH induced a significant increase in locomotion 
(hDAT (vehicle) 6.2 ± 0.9 beam breaks versus hDAT (AMPH) 18.2 ± 1.0 beam breaks; n = 24; p 
≤ 0.001). Moreover, in the dDAT KO flies, similar to the hDAT T356M flies, AMPH failed to 
induce a significant increase in locomotion (data not shown). 
 
Discussion 
Alterations in DA tone underlie multiple neuropsychiatric disorders, including bipolar 
disorder, schizophrenia, and ADHD (Seeman and Niznik, 1990, Volkow et al., 2007, Cousins et 
al., 2009). With respect to ADHD, altered DA signaling, including changes in DAT function, may 
contribute to the cognitive and hyperactive traits of the disorder (Mazei-Robison et al., 2008, 
Bowton et al., 2010). ASD, like ADHD, is phenotypically and etiologically complex. However, 
there is mounting evidence that risk for ASD resides, at least in part, in dopaminergic factors. 
Variants in DA receptor (DRD) sub-type genes, including DRD1, DRD3, and DRD4, have been 
associated with increased risk for ASD (Hettinger et al., 2008) as well as with specific 
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phenotypic behavior within ASD. These include repetitive or stereotyped behaviors (de Krom et 
al., 2009, Gadow et al., 2010, Staal et al., 2012), oppositional defiant disorder, and separation 
anxiety disorder (Gadow et al., 2010). Male children carrying four tandem repeats in the 
promoter region of the MAOA gene (the gene product responsible for degrading amine 
neurotransmitters, including DA) showed elevated risk for developing ASD (Tassone et al., 
2011). It must be noted that none of these genes are significant in genome-wide association 
studies of ASD. However, in positron emission tomography (PET) studies in adults with ASD, 
DAT binding was significantly elevated in the orbitofrontal cortex (Nakamura et al., 2010). 
 
Genes harboring de novo events are highly significant for understanding the etiology of 
ASD (Neale et al., 2012). This is not surprising since rate of reproduction is typically low in 
individuals with autism. Consequently, genetic variants would be subject to negative selection 
(Devlin and Scherer, 2012). This suggests that the biological networks identified from these de 
novo events, and the broader pathways they function within, are candidate risk factors for ASD. 
In this study, we examine the functional, structural, and behavioral consequences of the first 
identified de novo hDAT missense variant associated with ASD.  
 
Our amperometric recordings demonstrate that the de novo hDAT T356M mutation 
confers cocaine sensitive ADE. We also show that ADE does not share common mechanisms 
with AMPH-induced DA efflux since hDAT T356M has an impaired AMPH response. It is 
intriguing to speculate that anomalous transporter-mediated neurotransmitter efflux may be an 
unappreciated source of risk for mental illness, especially in disorders associated with altered 
DA signaling. It is possible that ADE, driven by DAT variants or variants in other genes in the 
DAT regulatory network (such as DRD subtypes), could impact risk for ASD. A similar point for 
ADE has been argued previously, in the context of ADHD, for the hDAT variant A559V, in its 
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functional identification (Mazei-Robison et al., 2008) and original characterization (Bowton et al., 
2010). 
 
The question remains as to how the hDAT T356M de novo mutation perturbs transporter 
structure to trigger ADE. Since the crystal structure of hDAT is unavailable, we analyzed 
changes in the conformational cycle of the hDAT bacterial homolog, LeuT. In LeuT A289M, we 
measured the distances between pairs of spin labels monitoring the intra- and extracellular 
gates by DEER. The spin labels monitoring the extracellular gate clearly show that in LeuT 
A289M, in contrast to LeuT, the presence of Na+ and leucine promotes a permeation pathway 
unoccluded to the outside. In terms of transporter function, it is difficult to draw parallels 
between hDAT T356M and LeuT A289M. Nevertheless, it is compelling to speculate that the 
mechanism by which the substrate promotes an outward open conformation in LeuT A289M, 
could also support the ability of hDAT T356M to promote ADE when cytoplasmic DA is 
available. This would suggest that the mechanism of ADE for hDAT T356M is distinct from that 
of hDAT A559V, which is a result of a tonic activation of DRD2 and the downstream kinase 
CaMKII (Bowton et al., 2010). Thus, there may be multiple mechanistic routes to promote 
hDAT-mediated ADE, and yet ADE might support the comorbid nature of ASD with ADHD.  
 
In an in vivo context, hDAT T356M may alter extracellular DA levels and, as a 
consequence, increase locomotion (Kume et al., 2005). We selectively expressed hDAT T356M 
specifically in DA neurons of dDAT KO flies. Drosophila expressing hDAT T356M exhibited 
prominent hyperactivity as compared to Drosophila expressing hDAT. In addition, AMPH has an 
impaired ability to increase locomotion in hDAT T356M and dDAT KO flies. This might stem 
from the decreased ability of AMPH to cause DA efflux in hDAT T356M cells.  
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Here, we report novel and profound functional abnormalities associated with the hDAT 
de novo mutation T356M, resulting in enhancement of non-vesicular, DAT-dependent DA 
release, referred to as ADE. Our data raise the possibility that ADE could impact the risk for 
ASD. 
 
Materials and methods 
Subjects and clinical assessment  
Subjects from this family included the proband, unaffected sibling, and both parents 
(AC04-0029-01, AC04-0029-02, AC04-0029-03, AC04-0029-04), who were recruited by the 
Boston-based Autism Consortium as described previously (Wolfson, 2007, Neale et al., 2012). 
Clinical assessment followed standard research criteria for ASD diagnosis. The proband was 
classified as having a comparatively “narrow” diagnosis (as opposed to a “broader ASD”) based 
on diagnostic algorithms from the Autism Diagnostic Interview Revised (ADI-R) (Lord et al., 
1994) using criteria described by Risi et al. (Risi et al., 2006), and classification resulting from 
the diagnostic algorithm of the Autism Diagnostic Observational Session (ADOS) (Lord et al., 
2000). Proband IQ was assessed at age 5 years, 9 months using the Wechsler Preschool and 
Primary Scale of Intelligence (WPPSI; Wechsler, D. (1967)). The Social Responsiveness Scale 
(SRS; Western Psychological Services) was performed on both parents to index the presence 
and severity of broader autism phenotype traits, followed by medical and family history provided 
by the biological mother.  
 
SLC6A3 T356M de novo discovery  
Methodological details and validation of the de novo mutation are published (Neale et 
al., 2012). Briefly, DNA derived from whole blood of both parents and the probands was 
subjected to whole exome sequence analysis. The T356M variant, identified as a heterozygote 
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in the proband and absent in both parents, was experimentally validated and confirmed to be a 
de novo mutation that does not appear in the unaffected sibling.  
 
Cell culture and transfection  
The GFP-hDAT-pCIHygro expression vectors containing either hDAT or hDAT T356M 
sequence were generated, confirmed and transiently transfected into Chinese hamster ovary 
cells using FuGENE-6 (Promega). Assays were conducted 24-48 hours post transfection. 
 
Amperometry and patch clamp electrophysiology  
hDAT and hDAT T356M cells were plated at a density of ~30,000 per 35-mm culture 
dish and experiments conducted as previously described (Mazei-Robison et al., 2008, Bowton 
et al., 2010). 
 
[3H]DA uptake  
hDAT and hDAT T356M cells were seeded (50,000 cells/well) into polyornithine coated, 
24-well plates, 48 hours before assaying. Uptake kinetic assays were performed as described in 
the supplementary information of Rickhag et al. (Rickhag et al., 2013) and in Rasmussen et al. 
(Rasmussen et al., 2009). 
 
AMPH uptake  
Plated hDAT and hDAT T356M cells were washed with KRH buffer and incubated for 5 
min at 37°C with 10 nM AMPH. Cells were washed three times with ice-cold KRH. AMPH was 
quantified using a HPLC system previously described (Siuta et al., 2010). 
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Cell surface biotinylation and western blot  
For cell surface biotinylation assays and Western blots, hDAT and hDAT T356M cells 
were cultured in 6-well plates and experiments conducted as in Mazei-Robinson et al. (Mazei-
Robison et al., 2008).  
 
Homology modeling of hDAT and construction of the T356M simulation system  
As the template, the homology model uses the known crystal structure for the cognate 
and homologous structure of the recent outward-open crystal structure of LeuT (Krishnamurthy 
and Gouaux, 2012). The substrate DA, two Na+ ions and a Cl- ion were positioned as described 
in Shan et al. (Shan et al., 2011). To model the mutant hDAT construct with T356M, the 
mutation was introduced using the free energy perturbation (FEP) method (Guptaroy et al., 
2009).  
 
Double Electron Electron Resonance  
Cysteine residues were introduced using site directed mutagenesis into LeuT and LeuT 
A289M constructs (Claxton et al., 2010). Experiments were conducted as in Claxton et al. 
(Claxton et al., 2010). In Figure 33, Apo refers to ion Na+ and leucine-free transporter while the 
+NaL state was obtained by addition of 200 mM NaCl and 4-fold molar excess of Leu relative to 
LeuT. Double Electron Electron Resonance (DEER) (Jeschke and Polyhach, 2007) was 
performed at 83K on a Bruker 580 pulsed EPR spectrometer operating at Q-band frequency 
using a standard 4-pulse sequence (Zou and McHaourab, 2010). DEER echo decays were 
analyzed to obtain distance distributions (Jeschke et al., 2002).  
  
Drosophila genetics  
Drosophila homozygotes for the DAT null allele DATfmn (dDAT KO)(Kume et al., 2005) 
and flies harboring TH-Gal4 (Friggi-Grelin et al., 2003) were outcrossed to a control line 
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(Bloomington Indiana (BI) 6326) and selected by PCR or eye color. TH-GAL4 (Bl 8848) and 
M{vas-int.Dm}ZH-2A, M{3xP3-RFP.attP'} ZH-22A (Bl 24481) were obtained from the BI stock 
center and outcrossed to dDAT KO flies carrying the white (w1118) mutation (BI stock number 
6236) for 5–10 generations. Transgenes (hDAT or hDAT T356M) were cloned into pBI-UASC 
(Wang et al., 2012) and constructs were injected into embryos from M{vas-int.Dm}ZH-2A, 
M{3xP3-RFP.attP'}ZH-22A (Bl 24481). Initial potential transformants were isolated and selected.  ! 
Behavioral analysis  
Three-day-old males were collected and placed into tubes with food for 72 hours. 
Locomotion was recorded by beam breaks and analyzed using equipment/software from 
Trikinetics (www.trikinetics.com). For the AMPH-induced locomotion, males were starved for six 
hours and then fed sucrose (5 mM) containing either AMPH (10 mM) or vehicle. Data were 
analyzed by One-way ANOVA followed by a Newman-Keuls Multiple Comparison Post-test. 
 
Clinical information 
 Proband (male) is the eldest of two children and heterozygous for the mutation described 
herein. 
 
Patient ID: AC04-0029-01 (proband) 
Event: SLC6A3 de novo missense (T356M) mutation  
 At the time of testing, patient was a 66-69-month-old non-Hispanic male Caucasian 
diagnosed with autism (on both ADOS and ADIR). Maternal interview on pregnancy provided 
the following details: Mother experienced anemia during pregnancy (gestational age = 39 
weeks). Labor was induced (use of Pitocin) because of failure to progress (Note: no C-section 
was done). Child was born 8 lbs 6 oz (134 ounces), with no other delivery issues.  
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Subset and composite scores on the Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI) indicate normal intelligence. Full Scale IQ was Average (94), and the 
subsets of Verbal-IQ and Performance-IQ was scored as Average (101) and Low Average (86) 
respectively, indicating normal intelligence.  
 
ADIR revealed deficits across all four subsets: (1) Reciprocal Social Interaction 
(score=13; cutoff=10); (2) Abnormalities in Communication (score=13; cutoff=8); (3) Restricted, 
Repetitive and Stereotyped Patterns of Behavior (score=4; cutoff=3); (4) Development Evident 
at or before 36 Months (score=1; cutoff=1). 
 
Patient experienced a delay in speech requiring therapy. No history of seizures, 
gastrointestinal conditions, sleep deficits, and no diet restrictions. Currently taking multivitamins, 
with no use of other medications (besides amoxicillin, Tylenol, and Benadryl).  
 
No family history for psychiatric illness requiring hospitalization. Known history of 
Asperger’s Disorder (Mother’s cousin’s son), and depression (Father’s paternal uncle). 
 
Patient ID: AC04-0029-02 (father) 
Father is an adult non-Hispanic Caucasian male. Age at conception of proband is 36. 
Slightly above normative range of intelligence (IQ=118; Wechsler Adult Intelligence Scale). No 
presence of broader autism phenotype, and no psychiatric medication use current or past. No 
co-morbid diagnoses. He holds a postgraduate degree and reports an annual household income 
of $81-101k.  
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Patient ID: AC04-0029-03 (mother) 
Mother is an adult non-Hispanic Caucasian female. Age at conception of proband is 32. 
Above normative range of intelligence (IQ=131; Wechsler Adult Intelligence Scale); no presence 
of broader autism phenotype, and no psychiatric medication use current or past. No co-morbid 
diagnoses. She holds a postgraduate degree and reports an annual household income of $81-
101k. No medication use reported for mother before, during, or after pregnancy except for 
epidural during labor. 
 
Patient ID: AC04-0029-04 (sibling) 
Sibling is a non-Hispanic Caucasian 3 year old (37 months) of unspecified sex. 
Normative intelligence (IQ=118; WPPSI). No behavioral problems reported. No medication use 
endorsed for current or past. No comorbid diagnoses. 
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CHAPTER 5 
 
ZN2+ REVERSES FUNCTIONAL DEFECITS IN A DE NOVO DOPAMINE TRANSPORTER 
VARIANT ASSOCIATED WITH AUTISM SPECTRUM DISORDER3 
 
Abstract 
Our laboratory recently characterized a novel autism spectrum disorder (ASD)-
associated de novo missense mutation in the human dopamine transporter (hDAT) gene 
SLC6A3 (hDAT T356M). This hDAT variant exhibits dysfunctional forward and reverse transport 
properties that may contribute to DA dysfunction in ASD. Here, we report that Zn2+ reverses, at 
least in part, the functional deficits of ASD-associated hDAT variant T356M. These data suggest 
that the molecular mechanism targeted by Zn2+ to restore partial function in hDAT T356M may 
be a novel therapeutic target to rescue functional deficits in hDAT variants associated with ASD. 
 
Introduction 
The dopamine (DA) transporter (DAT) tunes DA neurotransmission by active re-uptake 
of DA from the synapse (Kristensen et al., 2011). Our laboratory has recently characterized the 
first de novo mutation in the human dopamine transporter (hDAT) reported in a patient 
diagnosed with autism spectrum disorder (ASD), which results in a Thr to Met substitution at site 
356 (hDAT T356M). We reported novel and profound functional abnormalities associated with 
the hDAT de novo mutation T356M, resulting in enhancement of non-vesicular, DAT-dependent 
DA release, referred to as anomalous DA efflux. Our data raise the possibility that anomalous 
DA efflux (or other disturbances in DA neurotransmission) may represent a complication !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!
3"The"work"presented"in"this"chapter"is"in#press#as"Hamilton,"P."J.*,"A."Shekar*,"A."N."Belovich,"N."Bibus"Christianson,"
N."G."Campbell,"J."S."Sutcliffe,"A."Galli,"H."J.G."Matthies*"and"K."Erreger*"(2015)."“Zn2+"reverses"functional"deficits"in"a"
de"novo"dopamine"transporter"variant"associated"with"autism"spectrum"disorder.”"Molecular#Autism"6:8""*"denotes"
equal"contributions."
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relevant for behavioral abnormalities in ASD. Extracellular zinc (Zn2+) inhibits DA uptake 
(Norregaard et al., 1998). Three amino acid side chains have been identified in DAT which 
coordinate zinc: H193 in extracellular loop 2 (EL2), H375 in the first helical part of extracellular 
loop 4 (EL4A), and E396 in the second helix of extracellular loop 4 (EL4B) (Norregaard et al., 
1998, Loland et al., 1999). Structural data from the DAT-homolog LeuT in the inward- and 
outward-facing conformation suggest that the relative orientation of H375 and E396 shifts during 
the transport cycle (Krishnamurthy et al., 2012). 
 
hDAT T356M displays decreased forward and reverse-transport function compared with 
wild-type hDAT (Hamilton and Campbell et al., 2013). The reduced transport capacity of the 
mutant was not associated with a reduction in hDAT surface expression. Amphetamine (AMPH) 
is a psychostimulant that targets the hDAT causing reverse transport of DA (DA efflux) (Sulzer 
et al., 2005). hDAT T356M exhibits impaired AMPH-induced DA efflux. Here, we show that the 
presence of Zn2+ partially rescues both DA uptake and the AMPH-induced DA efflux 
impairments of hDAT T356M. Zn2+ diminishes the anomalous DA efflux property of the hDAT 
T356M, which might account for its ability to partially rescue transporter functions. Rescue of 
hDAT function by Zn2+ might reveal a new molecular mechanism to target for pharmacological 
intervention in patients with ASD. 
 
Results 
Zn2+ enhances [3H]DA uptake in hDAT T356M 
CHO cells were transiently transfected with either wild-type hDAT or hDAT T356M. Cells 
were incubated with 50 nM [3H]DA at 37 °C for 5 min in the presence of varying concentrations 
of Zn2+. Consistent with previous reports (Norregaard et al., 1998, Loland et al., 1999), Zn2+ 
decreases the DA uptake rate for wild-type hDAT (Fig. 35A, filled squares). In contrast, for  
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Figure 35. Zn2+ partially reverses the hDAT T356M deficits in [3H]DA uptake and 
AMPH-mediated efflux. Methods were as previously described in Hamilton and 
Campbell et al., 2013. (a) [3H]DA uptake counts (cpm) are plotted for hDAT and hDAT 
T356M over a range of Zn2+ concentrations. While Zn2+ inhibits hDAT [3H]DA uptake, 
Zn2+ instead increases hDAT T356M [3H]DA uptake (* = p < 0.05 by one-way ANOVA 
followed by Dunnett's test compared to 0 Zn2+ control; n = 4). (b) (Top) 
Representative AMPH-induced amperometric currents (reflecting DA efflux) are 
displayed in the presence or absence of 100 µM Zn2+. Arrows indicate application of 
10 µM AMPH. Bottom: maximal DA efflux amperometric current recorded in the 
presence of Zn2+ normalized to maximal current recorded in the presence of vehicle. 
(* = p < 0.05 by Student’s t-test; n = 5). 
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hDAT T356M cells, Zn2+ increases DA uptake, partially reversing the functional deficit of this 
variant (Fig. 35A, open circles). 
 
Zn2+ enhances AMPH-induced DA efflux in hDAT T356M 
To specifically measure reverse transport, DA was loaded into the cytoplasm of hDAT 
T356M cells by a whole-cell patch clamp pipette held in current-clamp mode. This configuration 
supplies intracellular DA directly to the cell independent of forward transport by hDAT and 
allows the cell to control its membrane voltage. The whole-cell patch pipette was filled with an 
internal solution containing 2 mM DA as described previously (Hamilton and Campbell et al., 
2013). DA efflux in response to 10 µM AMPH was measured by amperometry in the presence of 
100 µM Zn2+ or vehicle control (Hamilton and Campbell et al., 2013). Representative 
amperometric traces are shown in Figure 35B (top). The peak of DA efflux normalized to 
vehicle control is shown in Figure 35B (bottom). Zn2+ increases AMPH-induced DA efflux in 
hDAT T356M compared to vehicle control (Fig. 35B), indicating an enhancement of reverse 
transport DA in the presence of Zn2+. For comparison, Zn2+ partially rescues AMPH-induced DA 
efflux for hDAT T356M to a level of 48%*±*12% of wild-type hDAT AMPH-induced DA efflux 
(Hamilton and Campbell et al., 2013). 
 
Zn2+ decreases baseline anomalous DA efflux in hDAT T356M 
Using the whole-cell patch clamp technique coupled to amperometry, the effect of 
100 µM Zn2+ on the baseline (anomalous) DA efflux of hDAT T356M was studied. The whole-
cell patch pipette delivered intracellular DA into the cell in current-clamp mode. To determine 
the effect of Zn2+ on baseline DA efflux, the change in amperometric current was compared 
following the application of 100 µM Zn2+ or vehicle control. Baseline DA efflux decreased 
significantly in the presence of Zn2+ in comparison with that of vehicle, indicating that Zn2+ 
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inhibits the constitutive DA efflux by hDAT T356M. Representative amperometric traces are 
shown in Figure 35C (top), and mean values are plotted in Figure 35C (bottom). 
 
Discussion 
Here, we explore the potential for Zn2+ in rescuing the biophysical abnormalities in the 
hDAT variant T356M, which we recently reported in Hamilton et al. (Hamilton and Campbell et 
al., 2013). These functional deficits in hDAT T356M may contribute to the dysfunction in DA 
neurotransmission associated with ASD. Zn2+ was previously shown to partially restore DA 
uptake function in DAT mutant Y335A, which exhibits low uptake under basal conditions (Kahlig 
et al., 2006). Here, we demonstrate that Zn2+ reverses deficits in both forward and reverse 
transport in the T356M variant. Additionally, Zn2+ decreases baseline anomalous DA efflux of 
the hDAT T356M de novo mutation, possibly providing an explanation for the positive effects of 
Zn2+ on the uptake and efflux properties of this mutant transporter. This is a novel and intriguing 
finding in terms of ameliorating irregularities in DAT function in a de novo ASD-associated 
mutation. 
 
T356 is located in transmembrane domain 7, and the hDAT Zn2+ binding site spans the 
spatial micro-environment between the transmembrane helices 7 and 8 and extracellular loop 2 
(EL2) (Loland et al., 2002, Stockner et al., 2013). Binding of Zn2+ to DAT alters the 
conformational equilibrium between the inward- and outward-facing state of the DAT (Loland et 
al., 2002, Stockner et al., 2013). However, mutation of an intracellular tyrosine to alanine 
(Y335A) converts the inhibitory Zn2+ switch into an activating Zn2+ switch, whereby Zn2+ rescues 
functions of the Y335A mutant transporter (Kahlig et al., 2006, Loland et al., 2002). Therefore, 
the functional impact of Zn2+ binding to mutant transporters can be different than for wild-type 
hDAT as we observe here for T356M (Fig. 35A). Whereas Zn2+ has been suggested to promote 
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the outward facing conformation of wild-type hDAT, the structural effect of Zn2+ binding to hDAT 
T356M is unknown and remains an interesting topic for future investigation. 
 
Clinical data have previously established that mean serum Zn2+ levels are significantly 
lower in children diagnosed with ASD compared to unaffected children and that there exist 
disturbances in Zn2+ metabolism in patients diagnosed with ASD (Jackson et al., 1978, Faber et 
al., 2009, Li et al., 2014). hDAT T356M is the first de novo DAT mutation found in a patient with 
ASD, and hDAT T356M functional deficits can partially be rescued by Zn2+. Whether or not Zn2+ 
regulation of hDAT may be directly relevant for the etiology of ASD is presently unknown. 
However, our work suggests that the molecular mechanism engaged by Zn2+ to partially restore 
function in hDAT T356M may be a novel therapeutic target to rescue, at least in part, functional 
deficits in hDAT variants associated with ASD. 
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CHAPTER 6 
 
RARE AUTISM-ASSOCIATED VARIANTS IMPLICATE SYNTAXIN 1 (STX1 R26Q) 
PHOSPHORYLATION AND THE DOPAMINE TRANSPORTER (HDAT R51W) IN DOPAMINE 
NEUROTRANSMISSION AND BEHAVIORS4 
 
Abstract 
Syntaxin 1 (STX1) is a presynaptic plasma membrane protein that coordinates synaptic 
vesicle fusion. STX1 also regulates the function of neurotransmitter transporters, including the 
dopamine (DA) transporter (DAT). The DAT is a membrane protein that controls DA 
homeostasis through the high-affinity re-uptake of synaptically released DA. We adopt newly 
developed animal models and state-of-the-art biophysical techniques to determine the 
contribution of the identified gene variants to impairments in DA neurotransmission observed in 
autism spectrum disorder (ASD). Here, we characterize two independent autism-associated 
variants in the genes that encode STX1 and the DAT. We demonstrate that each variant 
dramatically alters DAT function. We identify molecular mechanisms that converge to inhibit 
reverse transport of DA and DA-associated behaviors. These mechanisms involve decreased 
phosphorylation of STX1 at Ser14 mediated by casein kinase 2 as well as a reduction in 
STX1/DAT interaction. These findings point to STX1/DAT interactions and STX1 
phosphorylation as key regulators of DA homeostasis. We determine the molecular identity and 
the impact of these variants with the intent of defining DA dysfunction and associated behaviors 
as possible complications of ASD. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!
4"The" work" presented" in" this" chapter" is" in# press# as" Cartier" E.*," P." J." Hamilton*," A." N." Belovich," A." Shekar," N." G."
Campbell,"C."Saunders,"T."F."Andreassen,"U."Gether,"J."Veenstra_Vanderweele,"J."S."Sutcliffe,"P."G."Ulery_Reynolds,"K."
Erreger#,"H."J.G."Matthies#"and"A."Galli#"(2014)."“Rare"Autism_Associated"Variants"Implicate"Syntaxin"1"(STX1"R26Q)"
Phosphorylation" and" the" Dopamine" Transporter" (hDAT" R51W)" in" Dopamine" Neurotransmission" and" Behaviors."
EBioMedicine#(Lancet)#2(2): 135-146.#*"and"#"denote"equal"contributions."
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Introduction 
Autism spectrum disorder (ASD) is defined by deficits in social communication and by 
the presence of restricted and repetitive behaviors, which are often the first signs of ASD 
(Rowberry et al., 2014, Wolff et al., 2014). Increased striatal size is among the most consistent 
neuroimaging findings in ASD, and increased size and growth of the striatum, a dopamine (DA) 
enriched brain region, have been associated with severity of repetitive behaviors (Langen et al., 
2007, Langen et al., 2009, Langen et al., 2014, Hollander et al, 2015). Consistent with the 
involvement of striatal dysfunction in ASD, recent studies have found that individuals with ASD 
display diminished response to reward (Dichter et al., 2012, Damiano et al., 2012, Lin et al., 
2012) which stems from striatal hypofunction (Kohls et al., 2013, Kohls et al., 2014). Striatal DA 
input has important roles in reward, movement, and habit (Zald et al., 2004, Howe et al., 2011, 
Howe et al., 2013). Importantly, excessive striatal dopaminergic signaling results in repetitive 
behavior (Fasano and Petrovic, 2010). 
 
The DA transporter (DAT) shapes striatal DA signaling via re-uptake of synaptically 
released DA (Kristensen et al., 2011). In addition to its role in vesicular fusion, the plasma 
membrane protein syntaxin 1 (STX1) plays a pivotal role in regulating DAT functions (Binda et 
al., 2008), and it has been observed to regulate other neurotransmitters: sodium symporters 
(NSS) (Quick, 2002, Quick, 2003, Quick, 2006, Dipace et al., 2007). Therefore, at the 
dopaminergic synapse, in addition to synaptic release, the actions of STX1 may regulate DAT 
functions and, as a consequence, DA neurotransmission and associated behaviors. 
 
ASD is associated with variants in several genes of the DA network, including those 
encoding STX1 (Nakamura et al., 2008, Nakamura et al., 2011, Durdiakova et al., 2014), the 
DAT (Hamilton et al., 2013, Bowton et al., 2014), DA receptors, as well as enzymes involved in 
DA metabolism (Hettinger et al., 2012, Qian et al., 2013, Reiersen and Todorov, 2011, Yoo et 
117 
al., 2013, Nguyen et al., 2014). Altered gene expression of STX1A has also been described in 
post-mortem brain and in lymphocytes from people with ASD (Nakamura et al., 2008, Nakamura 
et al., 2011). These data point to DA dysfunction as a potential complication and possible risk 
factor for ASD, but without a clear understanding of the underlying mechanisms. 
 
Here, we have identified rare, inherited, functional missense variants in the gene that 
encodes STX1 (STX1A; resulting in an Arg to Gln substitution at site 26) and in the gene that 
encodes DAT (SLC6A3; resulting in an Arg to Trp substitution at site 51) in separate individuals 
with ASD. Among the different DAT functions, reverse transport of DA has emerged as a 
contributing factor in DA neurotransmission and remains incompletely understood (Leviel, 
2011). Both of these variants disrupt the molecular mechanisms of reverse transport of DA, 
resulting in DA dysfunction and associated behavioral abnormalities. To mechanistically 
characterize these variants, we identify novel molecular events involved in the STX1 regulation 
of DAT. Our results suggest a coordinated molecular network, including STX1 and DAT that 
might contribute to disruption of dopaminergic signaling in individual with ASD. 
 
Results 
Autism-related hDAT and STX1 variants alter DA transport 
Exome capture and sequencing analysis identified two families harboring separate rare 
and inherited SNPs. One family harbors a single nucleotide variant (SNV) in the gene that 
encodes hDAT (SLC6A3; resulting in an Arg to Trp substitution at site 51; hDAT R/W) (Fig. 36a, 
left panel). The other family harbors a SNV in the gene that encodes STX1A (STX1A; resulting 
in an Arg to Gln substitution at site 26; STX1 R/Q) (Fig. 36a, right panel). Neither of these SNVs 
were found in control samples (n = 1463) and were not deposited in the NHLBI Exome 
Sequencing Project (URL: http://evs.gs.washington.edu/EVS/) [3 (November, 2014) accessed]. 
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Figure 36. Pedigree and cross-species conservation of hDAT R/W and STX1 R/Q. 
(a) Variant inheritance is shown for the families harboring the hDAT R/W and the STX1 
R/Q genotypes. Filled symbols indicate individuals with an ASD diagnosis, while open 
symbols reflect individuals without an ASD diagnosis. (b) Alignment of the DAT amino 
acid sequence across multiple species. Arginine 51 is represented in red. (c) Alignment 
of the STX1 amino acid sequence across isoforms and multiple species. Arginine 25 is 
represented in red. 
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The family harboring the STX1A R/Q variant is in a cohort of families belonging to the 
Simons Simplex Collection (SSC), a well-characterized ASD collection. The family harboring the 
SLC6A3 R/W variant is in the cohort of families studied by the Autism Sequencing Consortium 
(ASC). Details on ASC samples and characteristics have been previously published (Neale et 
al, 2012). The ADIR scores are presented in table format in Table 3. Thus, we are classifying 
these variants as ASD-specific. The hDAT Arg51 is located at the N-terminus in a region highly 
conserved across multiple species (Fig. 36b). STX1A Arg26 is located at the N-terminus and is 
also conserved across several species as well as in other STX1 isoforms, including STX1B  
(Fig. 36c). The two redundant neuronaThil STX1 isoforms (STX1A and STX1B) are 84% 
identical. Both isoforms are present in DA neurons and striatal DA terminals and colocalize with 
DAT (Fig. 37). In this study we utilize STX1B, here simply referred as STX1. 
 
To evaluate whether the STX1 R/Q variant promotes DA dysfunction, we determined the 
impact of this variant on a key STX1 regulatory site (Ser14) implicated in neuropsychiatric 
disorders (Castillo et al., 2010) and hDAT function. hDAT cells (see Methods) expressing STX1 
R/Q show reduced STX1 phosphorylation at Ser14 (Fig. 38a). One function of STX1 is to 
regulate the DAT-mediated reverse transport of DA in response to AMPH (Binda et al., 2008) 
Therefore, we used AMPH as a tool to probe whether STX1 R/Q has an altered ability to 
regulate DA efflux, measured by amperometry in hDAT cells. The amperometric probe, a 
carbon fiber electrode juxtaposed to the cell membrane, measures DA efflux by 
oxidation/reduction reactions, with DA efflux represented as a positive current. hDAT cells 
expressing STX1 R/Q display a significantly reduced AMPH-induced DA efflux as compared to 
hDAT cells expressing STX1 (Fig. 38b). It is important to point out that in hDAT cells expressing 
STX1 R/Q, the Vmax of DA uptake was significantly increased, whereas the Km of DA was not 
significantly different from that of hDAT cells expressing STX1 (Fig. 38c, top). A representative
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Table 1: Autism Diagnostic Interview-Revised (ADI-R) algorithm domain scores   
ASD collection Identifier Sex Diagnosis Y.O.B. Social (cutoff=10) Communication (cutoff=8) 
Repetitive 
(cutoff=3) 
Evident before 36 
months Verbal 
Autism Sequencing 
Consortium AU078103 Female Spectrum 1993 9 6 6 yes yes 
Autism Sequencing 
Consortium AU078104 Male Autism 1995 20 22 8 yes yes 
Autism Sequencing 
Consortium AU078105 Male Autism 1997 21 15 7 yes yes 
Simons Simplex Collection 13344.p1 Male Autism 1998 24 14 11 yes yes 
Simons Simplex Collection 13344.s1 Female Designated sibling 2000 N/A N/A N/A N/A N/A 
Supplemental Table 1:. Autism Diagnostic Interview-Revised (ADI-R) algorithm domain scores. Trained clinicians conducted the ADI-R and algorithm 
scores were calculated. ADIR subdomain scores with diagnostic cutoffs are shown along with the autism cohort, subject identifier, sex, year of birth and verbal 
capabilities of the individuals. Individuals received a diagnosis of “autism” or “spectrum” based on measures from the ADIR and Autism Diagnostic Observation 
Schedule (ADOS). 
 
Table 3. Autism Diagnostic Interview-Revised (ADI-R) algorithm domain scores.  
T ained clinicians co ducted the ADI-R and algorithm score  were cal ulated.  ADIR 
subdomain scores with diagnostic cutoffs are shown along with the autism cohort, subject 
identifier, sex, year of birth and verbal capabilities of the individuals.  Individuals received 
a diagnosis of “autism” or “spectrum” based on measures from the ADIR and Autism 
Diagnostic Observation Schedule (ADOS). 
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Figure 37. STX1A, STX1B and p-STX1 colocalize with DAT in the striatum. Striatal 
slices were reacted with anti-DAT antibodies (green) and the appropriate anti-STX1 
antibodies (red) as indicated, processed, and imaged by confocal microscopy. 
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Figure 38. STX1 R to Q missense mutation decreases STX1 phosphorylation and 
reverse   transport of DA without decreasing DA uptake. (a) Top: stably transfected 
hDAT cells expressing either STX1 or STX1 R/Q were immunoblotted with a phospho-
specific antibody directed against STX1 at Ser14 (top lane).  The mock transfection of 
GFP alone (mock) supports absence of non-specific binding.  Bottom lane shows total 
STX1 proteins. Bottom: quantitation of band intensities of phospho-STX1 (p-STX1) 
normalized to the respective total STX1 and expressed as a percentage STX1 (** = p < 
0.01 by Student’s t-test; n = 5, in triplicate). (b) Top: representative AMPH-induced DA 
efflux recorded from stably transfected hDAT cells expressing either STX1 or STX1 R/Q. 
Arrows indicate application of 10 µM AMPH. Bottom: quantitation of AMPH-induced DA 
efflux. Data are represented as maximal current expressed as percent of the current 
recorded in hDAT cells expressing STX1 (* = p < 0.05 by Student’s t-test; n = 7). (c) 
STX1 R/Q enhances DAT-mediated DA uptake. Top: kinetic parameters (Vmax and Km) for 
stably transfected hDAT cells expressing either STX1 or STX1 R/Q (Vmax: p < 0.05 by 
Student’s t-test; n = 3, in triplicate; Km: p > 0.46 by Student’s t-test; n = 3, in triplicate). 
Bottom: representative plot of [3H]DA uptake kinetics in stably transfected hDAT cells 
expressing STX1 (filled squares) and STX1 R/Q (empty squares) cells (*** = p < 0.001, 
by two-way ANOVA followed by Bonferroni post-test; in triplicate). 
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plot of DA uptake kinetics is shown in Figure 38c (bottom). These data indicate that the STX1 
R/Q variant asymmetrically regulates hDAT function by selectively impairing DA efflux. 
 
In order to determine whether other ASD-associated variants can disrupt DAT function 
by parallel mechanisms to those of STX1, we explored changes in hDAT function in cells 
expressing hDAT R/W. The AMPH-induced reverse transport of DA was reduced in hDAT R/W 
cells with respect to hDAT cells (Fig. 39a). These data parallel the reduction in DA efflux 
observed in hDAT cells expressing the STX1 R/Q variant (Fig. 38b). This reduction in AMPH-
induced DA efflux in the hDAT R/W is not mirrored by a significant reduction in DA uptake or DA 
apparent affinity (Fig. 39b), indicating the hDAT R/W variant also asymmetrically regulates 
hDAT function by selectively impairing DA efflux. 
 
Previously, we determined that reverse transport of DA induced by AMPH is tightly 
regulated by the interaction of STX1 at the DAT N-terminus (Binda et al., 2008). Therefore, we 
explored whether the reduced reverse transport of DA in hDAT R/W cells stemmed from a 
decreased association of STX1 to hDAT R/W. We immunoprecipitated hDAT and 
immunoblotted the immunoprecipitates for STX1 (Fig. 39c). The amount of STX1 recovered in 
the DAT immunoprecipitates was reduced in the hDAT R/W cells compared to the hDAT cells 
(Fig. 39c, IB: STX1). In the absence of antibody against DAT, no signal was detected for STX1 
in the immunoprecipitates (Fig. 39c, beads). The total STX1 and hDAT in the hDAT R/W cells 
was not decreased with respect to hDAT cells (Fig. 39c, total STX1 and total hDAT). These 
data demonstrate that the hDAT R/W variant has a reduced STX1/DAT interaction. Quantitation 
of multiple experiments is shown in the bar graph of Figure 39c. These data highlight that the 
ASD-associated hDAT and STX1 variants both impair reverse transport of DA without inhibiting 
DAT-mediated DA uptake functions. 
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Figure 39. hDAT R to W missense mutation has decreased STX1 association, 
reduced reverse transport of DA, but normal DA uptake. (a) Top: representative 
AMPH-induced DA efflux recorded from hDAT or hDAT R/W cells expressing STX1. 
Arrows indicate application of 10 µM AMPH. Bottom: quantitation of AMPH-induced DA 
efflux. Data are represented as maximal current expressed as percent of the current 
recorded in hDAT cells (* = p < 0.05 by Student’s t-test; n = 5). (b) hDAT R/W exhibits 
normal DA uptake function. Top: kinetic parameters (Vmax and Km) for hDAT and hDAT 
R/W (Vmax: p > 0.92 by Student’s t-test; n = 3, in triplicate; Km: p > 0.62 by Student’s t-test; 
n = 3, in triplicate). Bottom: representative plot of [3H]DA uptake kinetics in hDAT (filled 
squares) and hDAT R/W (empty squares) cells (p > 0.05, by two-way ANOVA followed by 
Bonferroni post-test; in triplicate). (c) Top: hDAT immunoprecipitates from either hDAT or 
hDAT R/W cells expressing STX1 were immunoblotted for STX1 (top lane).  The beads 
fraction supports the absence of non-specific binding.  Third lane shows an immunoblot 
for total STX1 proteins. Bottom lane shows an immunoblot for total hDAT proteins. 
Bottom: quantitation of hDAT pull down band intensities normalized to the respective total 
STX1 and total hDAT; expressed as a percentage hDAT cells (* = p < 0.05 by Student’s 
t-test; n = 5).  
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STX1 phosphorylation regulates STX1/DAT interaction 
STX1 is phosphorylated at Ser14 by the kinase CK2 (Hirling and Scheller, 1996, Foletti 
et al., 2000), a posttranslational modification involved in the functional regulation of STX1 
(Khelashvili et al., 2012, Dubois et al., 2002). Figure 38a shows that the STX1 R/Q variant has 
reduced phosphorylation at Ser14. Therefore, we sought to determine the functional 
consequences of impaired Ser14 phosphorylation. First, we demonstrated that the highly 
selective ATP/GTP-competitive inhibitor of CK2, 4,5,6,7-tetrabromobenzotriazole (TBB, 10 µM), 
effectively reduces p-STX1 in hDAT cells. p-STX1 levels were determined either upon TBB 
treatment or control conditions with a phospho-specific antibody that recognizes 
phosphorylation of Ser14 (Castillo et al., 2010) (Fig. 40a). TBB significantly decreases basal 
levels of p-STX1, demonstrating that CK2 regulates the phosphorylation state of STX1 at Ser14. 
Next, we investigated whether STX1 phosphorylation at Ser14 regulates the association of 
STX1 with the DAT. hDAT cells were treated with either TBB (10 µM for 20 min) or vehicle 
control, and the cell lysates were immunoprecipitated for DAT and subsequently immunoblotted 
for STX1. Inhibition of STX1 phosphorylation with TBB reduces STX1/DAT association (Fig. 
40b), demonstrating that phosphorylation promotes the STX1/DAT interaction. TBB (10 µM for 
20 min) did not change the level of DAT available at the cell surface (hDAT surface expression 
for TBB exposure was 89.0 ± 12.9% of vehicle control; p > 0.40 by Student's t-test; n = 4), 
indicating that the reduced STX1/DAT interaction following CK2 inhibition is not due to DAT 
trafficking away from the plasma membrane. Collectively, these results are consistent with a 
coordinated signaling complex whereby phosphorylation of STX1 at Ser14 promotes its 
association with DAT. 
 
STX1 can be phosphorylated at residues other than Ser14. For example, casein kinase 
1 can promote STX1 phosphorylation at Thr21 (Dubois et al., 2002). Therefore, we validated 
whether the level of phosphorylation of Ser14 alone supports STX1/DAT interactions. We 
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Figure 40. CK2-mediated phosphorylation of STX1 at S14 promotes STX1/DAT 
interaction. (a) Stably transfected hDAT cells transfected with STX1 were treated with 
either vehicle or 10 µM TBB for 20 minutes. STX1 proteins were immunoblotted for p-
STX1 (with a phospho-specific antibody directed against Ser14) and STX1. p-STX1 band 
densities were normalized to the corresponding total STX1 band densities and expressed 
as a percentage of vehicle control. CK2 inhibition with TBB significantly decreased the 
levels of p-STX1 (* = p < 0.05 by Student’s t-test; n = 4). (b) Stably transfected hDAT 
cells transfected with STX1 were treated with either vehicle or 10 µM TBB for 20 minutes. 
hDAT proteins were immunoprecipitated and immunoblotted for STX1 and DAT. STX1 
band densities were normalized to DAT and expressed as a percentage of vehicle 
control. CK2 inhibition significantly decreased STX1/DAT interaction (* = p < 0.05 by 
Student’s t-test; n = 4). (c) Stably transfected hDAT cells were transfected with either 
STX1, STX1 S14A, or STX1 S14D. hDAT immunoprecipitates were immunoblotted for 
either STX1 (top band) or hDAT (middle band). Input (bottom band) serves as loading 
control. All STX1 isoform band densities were normalized to hDAT and expressed as a 
percentage of STX1. STX1 S14A displays a significantly decreased association with DAT 
(* = p < 0.05 by one-way ANOVA followed by Newman-Keuls Multiple Comparison Test; 
n = 6). (d) Purified STX1ΔTM peptides (S14A or S14D) were incubated with a GST 
fusion protein of the first 64 amino acids of the hDAT N-terminus (N64) or with GST 
alone. The samples were then immunoblotted for STX1. STX1 band densities were 
expressed as a percentage of STX1ΔTM S14D. STX1ΔTM S14A displays reduced 
binding to the hDAT N-terminus (* = p < 0.05 by Student’s t-test; n = 5). 
127 
generated STX1 constructs that either prevent Ser14 phosphorylation, by mutating Ser14 to Ala 
(STX1 S14A), or mimic Ser14 phosphorylation, by mutating Ser14 to Asp (STX1 S14D). We 
performed immunoprecipitation experiments in hDAT cells transfected with the different STX1 
constructs. We observed that the STX1/DAT association is blunted in hDAT cells expressing 
STX1 S14A as compared to hDAT cells expressing STX1 (Fig. 40c). Furthermore, the pseudo-
phosphorylated STX1 S14D exhibits increased interaction with hDAT with respect to STX1 
S14A. Thus, phosphorylation of STX1 at Ser14 supports STX1/DAT association. Plasma 
membrane levels of hDAT, as measured by biotinylation, were not altered by the expression of 
either STX1 S14A or STX1 S14D when compared to STX1 (STX1 S14A: hDAT surface 
expression was 101 ± 39% and STX1 S14D: hDAT surface expression was 88 ± 16% relative to 
hDAT cells expressing STX1; p > 0.89 by one-way ANOVA; n = 5–6). 
 
To determine whether Ser14 phosphorylation regulates the direct association between 
STX1 and DAT, we used an in vitro GST pull-down assay modified from Binda et al. (2008). 
which previously demonstrated that the hDAT N-terminus directly interacts with STX1 (Binda et 
al., 2008). GST hDAT N-terminal fusion proteins (hDAT N64, see the Materials and Methods 
section) were used to pull down recombinant soluble constructs of STX1 lacking the 
transmembrane domain (STX1ΔTM) with Ser14 mutated to Ala (STX1ΔTM S14A) or Asp 
(STX1ΔTM S14D) (Fig. 40d). hDAT N64 robustly pulled down STX1ΔTM S14D. However, 
hDAT N64 pull down of STX1ΔTM S14A was dramatically blunted. GST alone did not pull down 
either STX1ΔTM construct. Quantitative analysis of band densities in Figure 40d demonstrates 
that the STX1ΔTM S14A peptide exhibits a significantly reduced direct association with the DAT 
N-terminus relative to the STX1ΔTM S14D peptide. Input bands show that the STX1ΔTM 
constructs were of expected size and exhibited minimal degradation. These data further support 
the notion that STX1 phosphorylation at Ser14 is a key regulator of the dynamic, direct 
interaction between STX1 and DAT. 
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STX1 phosphorylation supports reverse transport of DA 
Figure 38b shows that the STX1 R/Q variant promotes a reduction in DA efflux. 
Therefore, it is possible that the CK2-mediated phosphorylation of STX1 at Ser14 support 
reverse transport of DA. We first determined whether AMPH causes an increase in STX1 
phosphorylation. To test this, p-STX1 levels were measured in hDAT cells transfected with 
STX1 and treated either with vehicle, AMPH, or AMPH in the presence of TBB (Fig. 41a). 
AMPH treatment increased the level of p-STX1 with respect to vehicle control. Pre-treatment of 
cells with TBB (10 µM for 20 min) prevented the AMPH-induced phosphorylation of STX1 at 
Ser14, demonstrating that AMPH induces phosphorylation of STX1 in a CK2-dependent 
manner. Quantitation of the band density of p-STX1, normalized to total STX1 and expressed as 
a percent of control is shown in Figure 41a (bottom). 
 
These findings implicate CK2 and phosphorylation of STX1 at Ser14 as possible novel 
molecular mediators of reverse transport of DA. Thus, we investigated the role of CK2 function 
and STX1 phosphorylation at Ser14 in AMPH-induced DA efflux. DA efflux was quantified by 
amperometry in hDAT cells expressing STX1 under control conditions or pharmacological 
inhibition of CK2 with TBB (10 µM for 20 min). TBB reduced AMPH-induced DA efflux as 
compared to vehicle control treated cells (Fig. 41b). These data support our hypothesis that 
STX1 phosphorylation at Ser14 regulates reverse transport of DA. To further test this 
hypothesis, we determined if the ability of TBB to regulate DA efflux is altered by preventing or 
mimicking phosphorylation of STX1. We expressed STX1 S14A or STX1 S14D constructs in 
hDAT cells and measured AMPH-induced DA efflux in the presence or absence of TBB. In 
hDAT cells expressing STX1 S14A, AMPH-induced DA efflux was not sensitive to 
pharmacological inhibition of CK2, and the absolute DA efflux in vehicle control was comparable 
to hDAT cells expressing STX1 that were TBB treated (Fig. 41c, compare to Fig. 41b TBB 
treated). Further, in hDAT cells expressing STX1 S14D, AMPH-induced DA efflux was also not 
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Figure 41. STX1 phosphorylation promotes reverse transport of DA. (a) Top: stably 
transfected hDAT cells expressing STX1 were treated with either vehicle or 10 µM TBB 
for 20 minutes. This was followed by an additional treatment with vehicle or 10 µM AMPH 
for 15 minutes.  STX1 immunoprecipitates were immunoblotted for either p-STX1 (Ser14) 
or STX1. Bottom: the immunoprecipitated band densities were quantified, normalized to 
the corresponding density of total precipitated STX1, and expressed as a percentage of 
vehicle control (* = p < 0.05 by one-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test; n = 3). (b) Representative AMPH-induced DA efflux recorded from 
stably transfected hDAT cells expressing STX1 treated with either vehicle or 10 µM TBB 
for 20 minutes just before the amperometric recordings. Arrows indicate application of 10 
µM AMPH. Bottom: quantitation of AMPH-induced DA efflux. Data are represented as 
maximal oxidative current (* = p < 0.05 by Student’s t-test; n = 5). (c) Representative 
AMPH-induced amperometric currents recorded from stably transfected hDAT cells 
expressing STX1 S14A treated with either vehicle or 10 µM TBB for 20 minutes. Arrows 
indicate application of 10 µM AMPH. Bottom: quantitation of maximal oxidative current (p 
> 0.05 by Student’s t-test; n = 4-7). (d) Representative AMPH-induced amperometric 
currents recorded from stably transfected hDAT cells expressing STX1 S14D treated with 
either vehicle or 10 µM TBB for 20 minutes. Arrows indicate application of 10 µM AMPH. 
Bottom: quantitation of AMPH-induced DA efflux. Data are represented as maximal 
oxidative current (p > 0.05 by Student’s t-test; n = 6). 
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sensitive to TBB. However, the absolute DA efflux in the presence of TBB was comparable to 
vehicle treated hDAT cells expressing STX1 (Fig. 41d, compare to Fig. 41b vehicle treated). 
These results demonstrate that preventing STX1 phosphorylation (STX1 S14A) parallels 
pharmacological inhibition of CK2, and mimicking STX1 phosphorylation (STX1 S14D) obscures 
the ability of TBB to inhibit DA efflux. It also points to the phosphorylation state of STX1 at 
Ser14 as a determining factor in the magnitude of reverse transport of DA, further supporting 
our hypothesis that the STX1 R/Q variant alters DA neurotransmission via reduced 
phosphorylation. 
 
Cultured catecholamine neurons from the superior cervical ganglion (SCG) have large 
presynaptic boutons that are amenable to imaging approaches, allowing us to determine 
whether AMPH drives STX1 phosphorylation at these release sites. SCG neurons natively 
express the NET, which has 66% amino acid sequence homology with the DAT, as well as the 
accompanying catecholamine presynaptic machinery (Matthies et al., 2009). Here, we utilized 
confocal imaging of SCG presynaptic boutons coupled with immunofluorescence to reveal the 
presence of endogenous p-STX1, closely localized to the NET (Fig. 42a). Consistent with our 
findings in hDAT cells (see Fig. 41a), AMPH treatment (10 µM for 20 min) enhances STX1 
phosphorylation at Ser14 in SCG presynaptic terminals (Fig. 42b). SCG cultured neurons also 
express endogenous CK2α (Fig. 42c). Lastly and notably, in mouse striatal slices, there is a 
similar profile of endogenous STX1 and p-STX1 expression. (Fig. 42d). These data present 
SCG neurons as a biologically relevant preparation in which to observe the functional role of 
STX1 in reverse transport of DA. 
 
STX1 phosphorylation regulates reverse transport of DA at neuronal release sites 
Next, we explored the role of STX1 phosphorylation in DAT-mediated reverse transport 
of DA at the level of the SCG presynaptic boutons. Since SCG neurons do not natively express  
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Figure 42. AMPH treatment increases p-STX1 levels in boutons. (a) Mouse superior 
cervical ganglion (SCG) neurons were fixed and p-STX1 (green) was visualized by 
immunoflourescence. The norepinephrine transporter (NET, red) was used as a marker 
of presynaptic boutons. The merge shows that p-STX1 is present in presynaptic boutons 
of cultured catecholamine neurons. Inset: Confocal section of a single presynaptic bouton 
(arrow). (b) Top: SCG neurons were treated with either vehicle or 10 µM AMPH for 20 
minutes. Cells were fixed and immunostained for p-STX1 (green) and for the NET (red). 
AMPH increases the intensity of p-STX1 in presynaptic boutons. Bottom: p-STX1 levels 
were quantified by the ratio of p-STX1 pixel intensity normalized to NET pixel intensity. 
AMPH significantly increases the intensity of p-STX1 in presynaptic boutons (* = p < 0.05 
by Student’s t-test; n = 5-6). (c) In SCG neurons cultured from NET KO mice, p-Stx1 
colocalizes with CK2. (d) In mouse striatal slices, DAT co-localizes with STX1 and p-
STX1. 
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DAT, we used neurons cultured from NET knockout mice and transiently transfected with hDAT 
labeled with a GFP tag (Fig. 43a, inset). GFP fluorescence was used to identify neurons 
positive for hDAT expression. AMPH-induced DA efflux was recorded with amperometry from 
individual synaptic boutons (Fig. 43a). This DA efflux was cocaine sensitive, indicating its DAT 
dependence (data not shown). TBB (10 µM for 20 min) reduced AMPH-induced DA release as 
compared to vehicle control (Fig. 43a). These data demonstrate, at the level of a single bouton, 
that CK2 function and STX1 phosphorylation are critical mediators of AMPH-induced DAT-
mediated DA release. 
 
We then determined the importance of STX1 for reverse transport of DA in ex vivo 
preparations. In mouse striatal slices, pre-incubation in botulinum toxin serotype C (BoNT/C, 
100 nM for 60 min), a protein known to cleave STX1, inhibits AMPH-induced DA efflux as 
measured by high speed chronoamperometry (Fig. 43b). Importantly, this BoNT/C pre-
incubation paradigm was not effective in significantly altering DA uptake (Fig. 43c). These data 
demonstrate the pivotal role of STX1 in supporting DA efflux without altering forward transport of 
DA in brain tissues. 
 
STX1 phosphorylation and STX1/DAT association regulates dopaminergic behaviors 
In adult Drosophila males, we developed locomotor assays for an in vivo examination of 
DAT-mediated reverse transport of DA and the impact of ASD variants on this transport 
process. First, we explored how impairments in STX1 phosphorylation, which affects STX1/DAT 
associations, regulate DA-associated behaviors. In Drosophila, locomotion requires functional 
DA neurotransmission (Hamilton and Campbell et al., 2013, Hamilton and Belovich et al., 2014, 
Pizzo et al., 2013). To probe for changes in locomotion, adult males were fed a sucrose solution 
containing either AMPH (1 mM) or vehicle. We observed that AMPH significantly stimulated 
locomotion in wild-type (WT) Drosophila (Fig. 44a). However, AMPH did not significantly  
133 
 
 
  
!
Figure 43. Inhibition of either STX1 phosphorylation or cleavage of STX1 
inhibits DA efflux but not uptake. (a) Inset: Image of a single GFP-hDAT 
transfected SCG neuron; arrows indicate the site of amperometric recording (i.e. the 
presynaptic bouton). Top: representative AMPH-induced amperometric currents 
recorded from a single presynaptic bouton of SCG neurons expressing GFP-hDAT 
after treatment with either vehicle or 10 µM TBB for 20 minutes. Bottom: quantitation 
of the maximal oxidative current normalized to vehicle treatment (* = p < 0.05 by 
Student t-test; n = 5). (b) AMPH (10 µM)-induced DA efflux recorded in mouse striatal 
slices preincubated (1 hr) either with vehicle or BoNT/C (100 nM) (* = p < 0.05 by 
two-way ANOVA; n = 6). (c) [3H]DA uptake measure in striatal slices receiving 
identical treatment as in panel (c) (p > 0.05 by Student’s t-test; n = 4). 
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Figure 44. STX1 phosphorylation regulates AMPH-induced behaviors. (a) DAT knockout 
(KO) flies demonstrate that AMPH-induced locomotor behavior is DAT-dependent. Locomotor 
activity in response to vehicle (open symbols) or (1mM) AMPH (filled symbols) in either wild-
type (WT) (squares) or in DAT KO flies (triangles). WT flies exhibit a significant AMPH-
induced increase in locomotion while DAT KO flies do not exhibit this significant increase (* = 
p < 0.05 for vehicle vs AMPH, two-way ANOVA followed by Bonferroni post-test; n = 5). (b) 
Drosophila were generated expressing a dominant-negative (DN) version of CK2α expressed 
specifically in dopaminergic neurons. Locomotor activity in response to vehicle (open 
symbols) or AMPH (filled symbols) in either wild-type (WT) (squares) or in CK2 dominant 
negative flies (CK2DN) (triangles). WT flies exhibit a significant increase in AMPH-induced 
locomotion while CK2DN flies do not (* = p < 0.05 for vehicle vs AMPH, two-way ANOVA 
followed by Bonferroni post-test; n = 5). Inset: DA uptake in intact fly brains in the presence of 
10 µM TBB or vehicle. The absence of uptake in the dDAT KO fly brains shows the 
dependence of DA uptake on the dDAT (*** = p < 0.0001 by one-way ANOVA followed by 
Newman-Keuls Multiple Comparison Test; n = 3). (c) hDAT R/W expressing flies have 
blunted locomotor responses to AMPH. Changes in locomotion were determined upon AMPH 
or vehicle exposure over 30 minutes and calculated as beam crosses (counts). AMPH (1 mM) 
caused a significant increase in locomotion in both hDAT flies (p < 0.001 by one-way ANOVA 
followed by Newman-Keuls Multiple Comparison Test; n = 24) and hDAT R/W flies (p < 0.05 
by one-way ANOVA followed by Newman-Keuls Multiple Comparison Test; n = 24). However, 
in hDAT R/W flies, AMPH exposure led to a reduced increase in locomotion than in hDAT 
flies (* = p < 0.05 by one-way ANOVA followed by Newman-Keuls Multiple Comparison Test; 
n = 24). 
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increase locomotion in flies lacking dDAT (DAT KO) (Kume et al., 2005), indicating that AMPH-
induced locomotion is a DAT-dependent behavior (Fig. 44a). These data strongly support this 
assay as a model to test the multiple functions of DAT in vivo.  
 
CK2 function promotes STX1 phosphorylation at Ser14, STX1/DAT interaction, and 
reverse transport of DA. Thus, to probe the behavioral significance of impaired STX1 
phosphorylation at Ser14 and STX1/DAT interaction, we evaluated whether inhibited CK2 
function alters AMPH-induced locomotion. We expressed a dominant negative form of CK2 
(CK2DN) in flies by using the Gal4/UAS system to express a single copy CK2DN in a WT 
background, selectively in DA neurons. We compared the AMPH-induced behavioral responses 
of flies expressing CK2DN to WT flies. AMPH did not significantly increase locomotor activity in 
flies expressing dominant negative CK2 mutant (Fig. 44b). Furthermore, vehicle treatment did 
not modify locomotion of flies expressing CK2DN with respect to WT flies, suggesting that 
extracellular DA level did not change under basal conditions. Consistent with this, CK2 inhibition 
by TBB treatment (10 µM for 15 min) did not alter DA uptake in intact Drosophila brains (Fig. 
44b, inset). Importantly, brains obtained from dDAT KO flies show robustly reduced DA uptake, 
demonstrating the DAT dependence of DA uptake in our newly developed uptake assay. 
Collectively, these data point to CK2 activity, STX1 phosphorylation at Ser14, and STX1/DAT 
association as critical mediators of reverse transport of DA and associated behaviors. 
 
Next, we explored how the ASD-associated hDAT R/W variant that impairs STX1/DAT 
association affects DA-dependent behaviors in our Drosophila model system. We expressed 
hDAT or hDAT R/W in DA neurons of dDAT KO flies as described above. We fed male 
Drosophila a sucrose solution containing either AMPH (1 mM) or vehicle and quantified 
locomotion in 30-minute intervals. AMPH exposure induced a significantly smaller increase in 
locomotion in hDAT R/W expressing flies as compared to hDAT expressing flies (Fig. 44c, 
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compare hDAT + AMPH versus hDAT R/W + AMPH). These data are consistent with the 
reduced ability of AMPH to cause DA efflux in hDAT R/W expressing cells. Basal locomotion of 
flies expressing hDAT R/W did not significantly differ from hDAT expressing flies. 
 
Discussion 
Alterations in DA neurotransmission have been identified in several neuropsychiatric 
disorders, including ASD (Seeman et al., 1990, Volkow et al., 2007, Cousins et al., 2009, 
Nguyen et al., 2014). Recently, we demonstrated that an ASD-associated hDAT de novo variant 
displays dramatically altered DAT function, including constitutive reverse transport of DA, which 
leads to hyperlocomotion (Hamilton and Campbell et al., 2013). Thus, we hypothesized that 
novel DAT variants (or variant in the genes known to regulate the DAT) that affect DA 
neurotransmission might contribute to the pathology and/or complications of ASD. We identify 
and describe two independent gene variants that converge mechanistically to disrupt DAT 
function and associated behaviors, with distinct mechanisms regulating either STX1 
phosphorylation or STX1/DAT interaction. 
 
We found that the STX1 R/Q variant has decreased phosphorylation of Ser14, a key 
residue involved in the functional regulation of STX1 (Dubois et al., 2002, Khelashvili et al., 
2012). STX1 in this hypo-phosphorylated state fails to support DAT-mediated reverse transport 
of DA without inhibiting DA uptake function. Interestingly, in hDAT cells expressing STX1 R/Q, 
we observe a significantly increased Vmax of DA uptake. In parallel experiments in mouse striatal 
slices, cleaving STX1 with BoNT/C promotes a decrease in reverse transport of DA with a trend 
towards increased DA uptake. These data suggest that STX1 function asymmetrically regulates 
reverse transport of DA and DA uptake. Therefore, to define how hypo-phosphorylation of STX1 
R/Q impairs DA reverse transport, we studied the regulatory effects of CK2 function on DA 
efflux. 
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CK2 phosphorylates STX1 at Ser14 to regulate STX1 function and protein interactions 
(Hirling and Scheler, 1996, Foletti et al., 2000, Dubois et al., 2002). Here, we discovered that 
CK2-mediated phosphorylation of STX1 at Ser14 increases the direct association between 
STX1 and the hDAT N-terminus. Consistently, pharmacological inhibition of CK2 strongly 
reduces reverse transport of DA without altering DA uptake. Thus, CK2 is a key player involved 
in DA efflux. It is possible that this mechanism is important in a broader array of DA-associated 
neuropsychiatric disorders, since the expression of CK2, as well as the phosphorylation state of 
STX1 at Ser14, is decreased in post-mortem brain tissue from patients with schizophrenia 
(Aksenova et al., 1991, Castillo et al., 2010). To have a more complete understanding of how 
genetic variants within the DA network discovered in ASD patients alter behaviors, we 
translated our molecular discoveries in vivo. First, we inhibited CK2 function by selectively 
expressing CK2DN specifically in DA neurons of WT flies. Drosophila expressing CK2DN 
exhibited a robust reduction in AMPH-induced hyperlocomotion as compared to WT flies. These 
data underscore the importance of CK2 function and STX1 phosphorylation in regulating 
behaviors sustained by reverse transport of DA. Interestingly, inhibiting CK2 function did not 
regulate basal locomotion or DA uptake in intact Drosophila brains. 
 
Parallel to STX1 R/Q, we found that the hDAT R/W variant displays inhibited reverse 
transport of DA without impairments in uptake function. It is important to note that CK2 function, 
in addition to phosphorylating STX1 at Ser14, also promotes STX1/DAT interactions. Here, we 
show that hDAT R/W has reduced association with STX1, resulting in reduced reverse transport 
of DA and DA-related behaviors. Drosophila expressing hDAT R/W selectively in DA neurons 
demonstrate reduced sensitivity to the psychomotor effects of AMPH. Interestingly, basal 
locomotion remained unaltered in hDAT R/W flies, indicating normal DAT-mediated DA 
clearance as supported by our uptake data. These data suggest that the phosphorylation state 
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of STX1 at Ser14 and STX1/DAT interaction asymmetrically regulate reverse transport of DA 
and DAT-mediated uptake. 
 
Mounting evidence demonstrates that reverse transport of DA and associated behaviors 
can be promoted by changes in the association between the N-terminus of DAT and STX1 
(Binda et al., 2008). Additionally, it has been suggested that reverse transport of DA might 
participate in shaping DA neurotransmission (Leviel, 2011). Here, we used AMPH as a tool to 
induce reverse transport of DA to determine whether ASD-associated variants disrupt this 
event. We show that AMPH promotes phosphorylation of STX1 at Ser14 and, as a 
consequence, STX1/DAT interaction to cause reverse transport of DA. Therefore, we felt that it 
was important to demonstrate these discoveries at the level of a single active site, the SCG 
bouton. 
 
Several ASD-associated hDAT variants have now been found to impact reverse 
transport of DA. The STX1 R/Q variant reported here ablates AMPH-induced efflux similarly to 
hDAT R/W. Interestingly, two other variants were previously found to cause dysregulation of DA 
efflux, including a de novo DAT T356M variant and the recurrent DAT A559V variant seen in 
two boys with ASD, as well as in individuals with bipolar disorder and ADHD. These findings 
demonstrate diverging mechanisms by which reverse transport of DA can be disrupted. They 
align with other examples of neurodevelopmental risk emerging from genetic variants causing 
opposite effects on gene expression or signaling cascades (Cook et al., 1997, Sanders et al., 
2011).   
 
Here, we characterize two independent autism-associated variants in the genes that 
encode STX1 and the DAT. We demonstrate that each variant dramatically alters DAT function. 
We identify molecular mechanisms that converge to inhibit reverse transport of DA and DA-
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associated behaviors. The physiological importance of reverse transport of DA has only recently 
emerged and remains incompletely understood. However, defining the molecular identity and 
the impact of these variants on DA efflux may further shape our understanding of the etiology of 
ASD. Therefore, large genotyping studies aimed at uncovering other variants of the hDAT and 
STX1A genes in ASD cases and matched controls would be worthwhile. 
 
Materials and methods 
All human subjects provided informed consent and the research was approved by 
institutional human subjects boards. All experiments, procedures, and surgeries involving mice 
were performed in compliance with and were approved by the Institutional Animal Care and Use 
Committee of Vanderbilt University. 
 
Subjects and clinical assessment  
All ASD cases were ascertained using the Autism Diagnostic Interview—Revised 
(ADIR), the Autism Diagnostic Observation Schedule—Generic (ADOS), and the DSM-IV 
diagnosis of pervasive developmental disorder (Neale et al., 2012, Lim et al., 2013, Liu et al., 
2013). Clinical assessment of families harboring either variant is dependent on which collection 
they belong to. In brief, families that contain the SLC6A3 R/W or STX1A R/Q variant belong to 
the Autism Sequencing Consortium (ASC) and the Simons Simplex Collection (SSC) 
respectively, and have been previously reported (Neale et al., 2012, De Rubeis et al., 2014, 
Iossifov et al., 2014). 
 
ADIR is an extensive, semi-structured parent/guardian interview that queries both 
historical and current information on the development, behavior, and skills of a child. The ADOS 
is a structured observational assessment administered directly to participants. It is employed to 
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confirm behaviors reported on the ADIR and consists of modules adapted for differing language 
abilities. When used together, the ADIR and ADOS are deemed the “gold-standard” instruments 
for validating and ASD diagnosis.  
 
SLC6A3 R/W and STX1A R/Q discovery and validation  
Methodological details on SLC6A3 R/W and STX1A R/Q discovery are published (Neale 
et al., 2012, De Rubeis et al., 2014, Iossifov et al., 2014) and validation of the variant was 
performed as described in Bowton et al. (2014). DNA derived from both parents, the probands, 
and siblings were subjected to sequence analysis. In all instances, each variant was predicted 
to be heterozygous at their respective site and experimentally validated and confirmed via 
Sanger sequencing.  
 
Cell culture and transfection  
STX1 constructs in the pcDNA3.1(−) expression vector and the GFP-hDAT-pCIHygro 
expression vectors containing hDAT or hDAT R/W (Arg51 to Trp) sequence were generated, 
confirmed and transiently transfected into Chinese hamster ovary (CHO) cells. In some 
experiments (noted in figure legend), stably transfected hDAT CHO cells were used. These cells 
were generated as described in Bowton et al. (2010). Cells were maintained in a 5% CO2 
incubator at 37 °C and maintained in Ham's F-12 medium supplemented with 10% fetal bovine 
serum (FBS), 1 mM l-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin. Stably 
transfected hDAT CHO cells were kept under selection with 250 µg/mL hygromycin B (Corning 
Cellgro). Fugene-6 (Roche Molecular Biochemicals) in serum-free media was used to transfect 
cells using a 6:1 transfection reagent:DNA ratio. Assays were conducted 24–48 h post-
transfection. 
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Superior cervical ganglion neuron culture and transfection  
SCG neurons were cultured from 1 to 3 day old male mouse pups. SCGs were dissected 
in complete Ultraculture medium (Lonza) supplemented with 20 ng/mL nerve growth factor 
(NGF). SCGs were washed with PBS and incubated for 20 min in collagenase (3%) and trypsin 
(2.5%) at 37 °C. They were washed in complete Ultraculture medium with NGF. Dissociated 
cells were obtained by SCG trituration in medium. Cells were plated on poly-d-lysine coated 
MatTek® dish treated with collagen (type IV). 24 h post-plating, the media was replaced with 
Ultraculture medium with NGF and 10 µM 5-fluoro-2-deoxyuridine (FDU). SCGs were 
transfected via intranuclear microinjection of DNA. 
 
Cell surface biotinylation and protein immunoblot  
Cells were cultured in 6-well plates. For cell surface biotinylation assays, cells were 
labeled with sulfo-NHS-SS-biotin (1.0 mg/mL; Pierce) before purification and analysis via SDS-
PAGE/immunoblots. hDAT was detected using a rat monoclonal primary antibody to the N-
terminus of hDAT (1:1000) (Millipore Bioscience Research Reagents, catalog number MAB369) 
and a goat-anti-rat-HRP-conjugated secondary antibody (1:5000) (Jackson ImmunoResearch, 
catalog number sc-2006). The phosphorylation level of STX1 at Ser14 was detected using a 
rabbit polyclonal antibody against phospho-S14 either from Castillo et al. (2010) or with a 
commercially available antibody (1:2500) (Abcam, catalog number ab63571) and with a goat-
anti-rabbit-HRP-conjugated secondary antibody (1:5000) (Jackson ImmunoResearch, catalog 
number sc-3837). Total STX1 was detected using a mouse monoclonal antibody (1:5000) 
(Sigma, catalog number S 0664) and a goat-anti-mouse-HRP-conjugated secondary antibody 
(1:5000) (Jackson ImmunoResearch, catalog number sc-2005). 
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Immunostaining  
SCG neurons (at least 14 days in culture) were serum starved for 1 h in DMEM:F12 and 
treated with vehicle or AMPH for 20 min. Neurons were subsequently fixed with PBS plus 
Ca2 +/Mg2 + and 4% paraformaldehyde, washed three times with PBS plus Ca2 +/Mg2 +, 
permeabilized and blocked with PBS with 4% bovine serum albumin (BSA)/0.15% Tween 20, 
and immunostained with the appropriate antibody dissolved in PBS plus 4% BSA and 0.05% 
Tween 20. NET was detected using a mouse monoclonal antibody (1:5000) (Mab Technologies; 
NET05-2) and p-STX1 with an affinity purified rabbit polyclonal (1:1000), anti-pSTX at Ser14 
(Castillo et al., 2010). Primary antibodies were visualized with the appropriate Alexa-labeled 
secondary antibody from Invitrogen. 
 
Mouse brain slices were prepared as outlined in the High Speed Chronoamperometry 
section, except recovery was in aCSF for 1 h at 37 °C. Slices were fixed, permeabilized, 
washed, and blocked as outlined above. DAT was visualized using rat monoclonal against DAT 
and STX1A and STX1B were detected using rabbit polyclonal antiserum from SYSY. p-STX at 
Ser14 was detected using an affinity purified rabbit polyclonal(1:1000) (Castillo et al., 2010). 
Primary antibodies were visualized with the appropriate covalently Alexa-labeled secondary 
antibody from Invitrogen. 
 
Immunofluorescence was imaged by capturing Z-series using a Zeiss using a 63 × Plan-
APOCHROMAT oil lens (Vanderbilt University Medical Center Cell Imaging Shared Resource). 
All images shown are from single confocal sections, and image processing was performed using 
ImageJ and Adobe Photoshop. 
 !!
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Co-immunoprecipitations  
Cells were grown to confluence in 25 cm2 culture flasks and serum deprived for 1 h prior 
to assay. Cells were washed three times with 4 °C phosphate-buffered saline (Gibco) containing 
1 mM EGTA and 1 mM EDTA, and then lysed in RIPA buffer (100 mM NaCl, 1.0% IGEPAL CA-
630 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH = 7.4, supplemented with 
a protease inhibitor cocktail (Sigma)). Lysates were passed twice through a 27.5 gauge needle, 
and centrifuged at 15,000 ×g for 30 min. With a portion of the total cell lysate (TCL) collected to 
run as the totals, 1 mL of the remaining supernatant was incubated at 4 °C for 4 h with 
Sepharose-G beads (Fisher Scientific), previously washed with 1% BSA in RIPA buffer, and 
then preincubated with 2.5 µg DAT antibody (rat monoclonal, #MAB369, Millipore). For the 
control, supernatant was incubated with BSA-blocked Sepharose-G beads alone (no DAT 
antibody). After the 4-hour incubation, beads were spun down, washed with cold RIPA buffer, 
and eluted with Laemmli sample buffer at 37 °C for 30 min. TCL and bead eluates were 
analyzed by SDS-PAGE (10%) and immunoblotted for total STX1 and DAT. Band intensity was 
quantified using ImageJ software (National Institutes of Health). 
 
Expression and purification of STX1  
The cDNAs encoding STX, STX S14D and STX S14A lacking the transmembrane 
domain (STXΔTM, STX1ΔTM S14A and STX1ΔTM S14D) were inserted into the bacterial 
expression vector pGEX, thereby adding an N-terminal GST-tag followed by a thrombin 
cleavage site. The resulting fusion proteins were produced in Escherichia coli BL21 DE3 LysS. 
The culture was grown at 30 °C to OD 0.8 and expression was induced with 1 mM isopropylβ-d-
1-thiogalactopyranoside at 30 °C, and the culture was harvested 4 h after induction. The frozen 
pelleted bacteria were lyzed in buffer (PBS, 0.1% TX-100, 20 µg/mL DNAse I, 1 mM DTT, mix 
protease inhibitor (GE Healthcare)). The lysate was cleared by centrifugation followed by 
incubation with 100 µL glutathione sepharose beads (GE Healthcare, Uppsala, Sweden) at 4 °C 
144 
for 1.5 h. The beads were pelleted at 3000 rpm for 5 min and washed 3 times in buffer (PBS, 
0.1% TX-100, 1 mM DTT) before elution by cleavage with 1 µL thrombin (GE Healthcare, 
Uppsala, Sweden) O/N at 4 °C. PMSF (1 mM) was added, and the beads were filtered through 
a P200 tip. The concentration of the purified STX1B was measured by BCA assay (Thermo 
Fisher Scientific, Waltham, MA). 
 
GST pull-down assay  
A DAT GST fusion protein containing the 64 N-terminal residues of the transporter (GST 
hDAT 1–64) was expressed and bound to glutathione sepharose beads as described (Binda et 
al., 2008). For the pull-down, 20 µL beads with either GST or GST hDAT 1–64 bound were 
incubated with 2 µg of purified STXΔTM, STX1ΔTM S14A or STX1ΔTM S14D in 500 µL buffer 
(PBS, 0.1% TX-100, 0.1% BSA) for 30 min at 4 °C and washed three times in buffer without 
BSA. Bound protein was eluted by incubation of beads for 1 h at room temperature with 1 µL 
thrombin in 15 µL buffer (PBS, 0.1% TX-100) followed by addition of SDS loading 
buffer + 100 mM DTT and incubation for 25 min at 70 °C. Each sample was split in two and 
loaded in two different Any-kD precast gels (BioRad, Hercules, CA). One gel was used as a 
Coomassie loading control and the other was transfered to a PDVF membrane and 
immunoblotted with primary mouse STX1 antibody (Sigma Aldrich. St. Louis, MO) 1:1000 and 
anti-mouse HRP-conjugated secondary antibody (Thermo Fisher Scientific, Waltham, MA) 
1:5000. 
 
Amperometry  
Cells were plated at a density of ~ 20,000 per 35-mm culture dish. To load cells with DA, 
dishes were washed with KRH assay buffer (130 mM NaCl, 1.3 mM KCl, 1.2 mM KH2PO4, 
10 mM HEPES, and 2.2 mM CaCl2, pH 7.4) containing 10 mM dextrose, 100 µM pargyline, 
1 mM tropolone, and 100 µM ascorbic acid, and incubated with 1 µM DA in KRH assay buffer 
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for 20 min at 37 °C. To preload SCG neurons, dishes were washed with KRH assay buffer (as 
above) containing 100 nM raclopride. Dishes were washed three times with the external bath 
solution (130 mM NaCl, 10 mM HEPES, 34 mM dextrose, 1.5 mM CaCl2, 0.5 mM MgSO4, 
1.3 mM KH2PO4, adjusted pH to 7.35, and 300 mOsm). A carbon fiber electrode (ProCFE; fiber 
diameter of 5 µm; obtained from Dagan Corporation) juxtaposed to the plasma membrane and 
held at + 700 mV (a potential greater than the oxidation potential of DA) was used to measure 
DA flux through oxidation reactions. Amperometric currents in response to the addition of 10 µM 
AMPH were recorded using an Axopatch 200B amplifier (Molecular Devices, Union City, CA) 
with a low-pass Bessel filter set at 1 kHz; traces were digitally filtered offline at 1 Hz using 
Clampex9 software (Molecular Devices, Union City, CA). DA efflux was quantified as the peak 
value of the amperometric current for all experiments except for recordings from SCG neurons. 
For SCG neurons, total DA efflux was quantified as the integral of the trace for a fixed 15-minute 
window. 
 
High speed chronoamperometry  
Striatal hemislices (300 µm) from 6 to 10 week old C57BL/6 mice were prepared with a 
vibratome (Leica VT1000S) in an ice cold oxygenated (95% O2/5% CO2) sucrose cutting 
solution consisting of (in mM): 210 sucrose, 20 NaCl, 2.5 KCl, 1 MgCl2, 1.2 NaH2PO4, 10 
glucose, 26 NaHCO3. Slices were then transferred to oxygenated artificial cerebrospinal fluid 
(aCSF) at 28 °C for a minimum of 1 h. The aCSF consisted of (in mM): 125 NaCl, 2.5 KCl, 1 
MgCl2, 2 CaCl2, 1.2 NaH2PO4, 10 glucose, 26 NaHCO3, 0.25 ascorbic acid. Striatal slices were 
treated at 37 °C for 1 h with either 100 nM BONT/C or vehicle control. DA concentration was 
measured by chronoamperometry in striatal slices. Briefly, carbon fiber electrodes (100 µm 
length × 30 µm O.D.) coated with nafion for DA selectivity were lowered into the desired 
recording site or sites so that the tip of the recording electrode was positioned at a depth of 75–
100 µm. The voltage was stepped from 0 mV to 550 mV for 100 ms and then back to 0 mV and 
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the charging current of the carbon fiber electrode was allowed to decay for 20 msec before the 
signals were integrated. Data were collected at a frequency of 1 Hz with an Axopatch 200B 
amplifier. The integrated charge was converted to DA concentration based on in vitro calibration 
with DA. 
 
[3H]DA uptake  
For DA uptake in a heterologous expression system: cells were plated on poly-d-lysine 
coated, 24-well plates and grown to ~ 90% confluence. On the day of the experiment, cells were 
washed with 37 °C KRH buffer containing 10 mM dextrose, 100 µM pargyline, 1 mM tropolone, 
and 100 µM ascorbic acid, and equilibrated for 5 min at 37 °C. Saturation kinetics of DA uptake 
was determined using a mixture of [3H]DA (PerkinElmer Life Sciences, Waltham, MA) and 
unlabeled DA (Sigma Aldrich) diluting to final DA concentrations of 0.05 µM–10 µM. Uptake was 
initiated by bath addition of the dilution row mixture. Uptake was terminated after 10 min by 
washing twice in ice-cold KRH buffer. Scintillation fluid (Optiphase HiSafe 3, PerkinElmer Life 
Sciences) was added to the wells and the plates were counted in a Wallac Tri-Lux β-scintillation 
counter (Wallac). Nonspecific binding was determined in the presence of 10 µM cocaine. Km 
and Vmax values were derived by fitting Michaelis–Menten kinetics to the background corrected 
uptake data, using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). All 
determinations were performed in triplicates. 
 
For DA uptake in striatal slices: striatal hemislices (prepared as previously mentioned) 
were treated at 37 °C for 1 h with either 100 nM BONT/C or vehicle control. Slices were then 
exposed to 50 nM [3H]DA for 10 min. DAT-specific DA uptake was determined by subtracting 
the non-specific signal in the presence of 3 µM GBR12909. At the end of the [3H]DA treatment, 
the slices were washed with cold aCSF and the striatum dissected. Tissue samples were then 
homogenized in 200 µL of lysis buffer consisting of 150 mM NaCl, 25 mM HEPES, 2 mM 
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sodium orthovanadate, 2 mM sodium fluoride, 1% Triton-100. The homogenate was centrifuged 
at 13,000 ×g at 4 °C for 30 min and the supernatant added to 500 µL of buffer 150 mM NaCl, 
25 mM HEPES, 2 mM sodium orthovanadate, 2 mM sodium fluoride, 0.1% Triton-100. The 
protein concentration of each sample was measured and 500 µL of each sample was added to 
scintillation vials to count [3H]DA. Counts were expressed as a ratio to protein content and 
normalized to the mean value for the control condition within each experiment. 
 
For DA uptake in dissected Drosophila brains: 2–5 day old males were collected, 
anesthetized with CO2, and brains were dissected in Schneider's medium (GIBCO) with 1.5% 
BSA. The retina was removed, and four brains per condition were pooled in Millipore Millicell 
inserts in 24 well plates. Brains were washed with Schneider's medium, then washed in a 
standard fly saline solution (HL3) plus 1.5% BSA and 10 mM MgSO4. For 15 min at room 
temperature, brains were exposed to 200 nM [3H]DA in HL3 plus 1.5% BSA and 115 µM 
ascorbic acid. Brains were then washed six times with 1.4 mL HL3 plus 1.5% BSA at 4 °C. 
Brains were placed into scintillation vials in 100 µL 0.1% SDS. Scintillation fluid was added to 
count [3H]DA. 
 
Drosophila genetics, molecular biology, and construction of UAS hDAT 
Flies lacking the Drosophila dopamine transporter (DATfmn) (Kume et al., 2005) and flies 
harboring TH-Gal4 were outcrossed to a control line (Bloomington Indiana (BI) 6326) and 
selected by PCR or by eye color. TH-GAL4 (Bl 8848) and M{vas-int.Dm}ZH-2A, M{3xP3-
RFP.attP′} ZH-22A (Bl 24481) were obtained from the BI stock center and outcrossed to flies 
lacking the Drosophila DAT (DATfmn) and carrying the white (w1118) mutation (BI stock number 
6236) for 5–10 generations. Transgenes (hDAT or hDAT R/W) were cloned into pBI-UASC, and 
constructs were injected into embryos from M{vas-int.Dm}ZH-2A, M{3xP3-RFP.attP′}ZH-22A (Bl 
24481). Initial potential transformants were isolated by selecting for red eyes and lack of GFP 
148 
signal in the head. Transformants were also verified by RFP fluorescence and outcrossed 5–8 
times to DATfmn flies. The presence of DATfmn lesion was verified by PCR. To generate CK2-DN 
flies, we drove the expression of a severely functionally compromised dominant negative 
version of CK2α (UAS-Tik) (Bose et al., 2006) in dopaminergic neurons by using TH-Gal4. UAS-
Tik is based on a CK2α allele (Tik) that in a heterozygous condition, causes no obvious neural 
abnormalities (Lin et al., 2002). Tik has two substitutions, M161K and E165D. M161K is in the 
ATP-binding pocket preventing nucleotide-binding thereby eliminating catalytic activity (Lin et 
al., 2002, Rasmussen et al., 2005). Overexpression from the UAS-Tik construct to dominantly 
blocks CK2 function (Bose et al., 2006). Therefore, UAS-Tik can be used as a CK2-DN 
construct. Flies were maintained on a standard cornmeal/molasses/yeast media at 25 °C and 
65% humidity with a 12 hour/12 hour light/dark cycle. Lights came on at 8 AM and off at 8 PM. 
 
Behavioral analysis  
Three day old males were collected and placed into tubes with food for three days. After 
three days locomotion was recorded for 32 h by beam breaks and analyzed using 
equipment/software from Trikinetics (www.trikinetics.com). For the AMPH-induced locomotion, 
males were starved for 6 h and then fed sucrose (10 mM) containing either AMPH (1 mM) or 
vehicle. !
Statistical analysis  
Compiled data are expressed as normalized mean ± s.e.m. For statistical analysis, we 
used either a Student's t-test or ANOVA depending on the n of the experimental groups. 
p < 0.05 was considered statistically significant. 
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CHAPTER 7 
 
FUTURE DIRECTIONS 
 
The work presented in this dissertation lays the foundation for investigating the 
mechanism of AMPH-induced reverse transport of DA in two contexts: 1) structure-function 
studies of determining the conformational changes necessary for the transporter to enter an 
efflux-willing state, and 2) studies of the endogenous physiological role of the AMPH-induced 
DA efflux mechanism in behavioral models.  Both of these directions represent valuable 
avenues of exploration: the mechanistic studies may reveal future molecular targets for 
pharmacological therapies for AMPH abuse, while the behavioral studies may shed light on 
poorly understood modes of dopaminergic neurotransmission.   
 
The work in Chapter 2 established the electrostatic interaction between PIP2 and Lys 
residues 3 and 5 of the hDAT N-terminus hDAT as an important part of the AMPH-induced DA 
efflux mechanism.  Previous work has shown that the N-terminus is phosphorylated as a result 
of AMPH exposure, and that this phosphorylation event is necessary for AMPH-induced DA 
efflux to occur (Khoshbouei et al., 2004, Fog et al., 2006).  What remains unclear at this point is 
whether PIP2 interaction is required for phosphorylation, and/or whether PIP2 plays a more 
complex role in coordinating the conformations of the N-terminus with other regions of the 
transporter.   
 
Chapter 3 explores the possibility that other suspected PIP2 binding sites of the hDAT 
may be involved in the AMPH-induced DA efflux mechanism, such as R443 and K337.  Recent 
computational work has generated a visual model to show how PIP2 might coordinate the 
interaction between the N-terminus and residues involved in the intracellular gating mechanism 
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of the transporter (Khelashvilli et al., 2015).  However, the simulation does not address the 
conformation of the N-terminus when phosphorylated, although it is tempting to speculate that 
PIP2 coordination would bring a phospho-group into direct contact with positive charges near 
the intracellular gating region.   
 
Additionally, Chapters 4 and 5 not only placed ADE in the context of autism spectrum 
disorder, but also provided valuable insights into some of the steps that must occur for AMPH-
induced DA efflux to occur.  In Chapter 4, hDAT T356M was shown to have a preference for an 
outward-facing conformation (Fig. 33), which accounts for the inability to uptake DA and the 
constitutive “leak” of intracellular DA by this variant.  As established in Loland et al., 2002, a 
mutant hDAT construct, hDAT Y335A, with an impaired ability to change conformation towards 
an inward-facing state, was rescued by the addition of Zn2+.  Incidentally, Zn2+ impairs the ability 
of the WT hDAT to uptake DA, further suggesting that Zn2+ stabilizes an inward facing 
conformation.  The data from the hDAT T356M and Zn2+ studies (Chapter 5), shows that the 
addition of Zn2+ partially restores DA uptake function in the hDAT T356M, as well as diminishes 
ADE (Fig. 35), indicating that Zn2+ enables hDAT T356M to adopt an inward-facing 
conformation with greater frequency than without Zn2+.  Importantly, the hDAT T356M also 
shows an impaired ability to respond to AMPH, even when using whole-cell patch clamp pipette 
to establish intracellular DA concentrations sufficient for AMPH-induced DA efflux.  In the 
presence of Zn2+, however, hDAT T356M regains partial ability to respond to AMPH (Fig. 35), 
suggesting that the hDAT must be in an inward facing conformation in order to efflux DA.  
Although these chapters do not directly address the role of PIP2, they do underscore the 
importance of the intracellular conformational state of the transporter in the AMPH-induced DA 
efflux mechanism, lending credence to the idea that the intracellular gating region must be 
particularly aligned for efflux to occur.  However, future studies with hDAT K337A to assess (1)  
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direct PIP2 binding and (2) Zn2+ rescue of AMPH-induced DA efflux may provide a link between 
PIP2 binding and proper alignment of the intracellular gate as requirements for DA efflux. 
 
I propose two hypotheses to explain why PIP2 is necessary for AMPH-induced DA efflux: 
(1) PIP2 interaction with the N-terminus of the hDAT may be necessary to coordinate 
phosphorylation of the N-terminus, or (2) PIP2 may use the electrostatic interactions between 
positive residues of the N-terminus and positive residues near the intracellular gate to bring the 
phosphorylated N-terminus into proximity of the intracellular gate.  These hypotheses are not 
mutually exclusive, as PIP2 has been known to coordinate up to 5 positive charges 
(Rosenhouse-Dantsker and Logothetis, 2007), and data from proposed experiments might 
support the combined hypothesis that PIP2 both coordinates N-terminal phosphorylation and 
coordinating the phosphorylated N-terminus with the intracellular gating region.    
 
To begin addressing hypothesis (1), I propose P32 labeling experiments to be conducted 
on cells expressing the PIP2-impaired hDAT constructs (hDAT K/A).  If interaction with PIP2 is 
necessary for coordinating phosphorylation of the N-terminus, then I would expect hDAT K/A to 
show reduced P32 levels in response to AMPH treatment.  If hDAT K/A does not show reduced 
P32 levels in response to AMPH, then the N-terminus/PIP2 interaction may be necessary for 
coordinating interaction with intracellular gate, in support of hypothesis (2).  Furthermore, I 
propose to utilize the pseudophosphorylated hDAT construct, wherein all five Ser residues on 
the N-terminus are mutated to Asp (S/D hDAT), and examine whether the addition of the PIP2-
sequestering peptide, through a patch pipette, will prevent AMPH-induced DA efflux.  If the S/D 
hDAT AMPH response is impervious to PIP2 depletion, then it is likely that PIP2 does not play a 
role beyond coordinating phosphorylation of the N-terminus.  If, on the other hand, the S/D 
hDAT AMPH response is affected by PIP2 depletion, then it is likely that PIP2 may play a more 
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complex role in coordinating the phosphorylated N-terminus with other regions of the 
transporter. 
 
To address hypothesis (2), that PIP2 brings the phosphorylated N-terminus into proximity 
of the intracellular gate, evidence exists to show that a pseudophosphorylated, PIP2-impaired 
hDAT variant, K/A hDAT with N-terminal Ser residues mutated to Asp, has a reduced ability to 
respond to AMPH (Hamilton and Belovich et al., 2014).  This indicates that phosphorylation of 
the hDAT N-terminus alone is insufficient for the transporter to respond to AMPH-induced DA 
efflux mechanism and that PIP2 interactions with the phosphorylated hDAT N-terminus are also 
necessary for efflux to occur.  Since putative PIP2 binding sites are located near the hDAT 
intracellular gate (predicted residues K337 and R443), I propose to examine whether PIP2 
directly interacts with R443 or K337 to coordinate the phosphorylated N-terminus with other 
regions of the transporter.  Since mutation of K337 or R443 to Ala results in decreased AMPH-
induced DA efflux (Figures 26-27; Chapter 3), it is possible that disrupting the electrostatic 
interactions between PIP2 and these regions perturbs the ability of the N-terminus to come into 
proximity with the intracellular gate. 
 
I propose to first establish the direct interaction with R443 and K337.  As performed by 
Buchmayer et al., PIP2-coated beads can be incubated with lysate from hDAT R443A or hDAT 
K337A expressing heterologous cells (Buchmayer et al., 2013).  If no difference in PIP2 binding 
is observed, then perhaps the impairments in R443A and K337A are due to an impairment in 
interaction between the phosphorylated N-terminus.  In this case, I would test whether R443A or 
K337A in a S/D hDAT background responds to AMPH.  If S/D hDAT-R443A or S/D hDAT-
K337A show impaired AMPH response compared to S/D hDAT, then phosphorylated N-
terminus interactions with R443 and/or K337 are important for this process.  If they do not show 
impaired AMPH response compared to S/D hDAT, then it is possible that the phosphorylated N-
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terminus may interact with other residues in the intracellular gating regions, or interfere with salt 
bridges.  
 
Finally, Chapter 6 represents an important insight into the role of the AMPH-induced DA 
efflux mechanism in ASD and in behaviors in general.  Chapter 6 presents the first known 
examples of neuropsychiatric disease-associated hDAT variants possessing impaired AMPH-
induced DA efflux without concomitant impairments in uptake and/or a DA leak (ADE).  Although 
hDAT R51W was untested for ADE, the unchanged ability of the transporter to uptake substrate 
indicated that it was not a likely candidate for ADE (Fig. 39).  Similarly, WT hDAT cells co-
expressing STX1 R26Q showed an increase in DA uptake, making ADE further unlikely for that 
variant as well (Fig. 38).  Taken together, the only impaired transporter function in both of these 
ASD-associated variants was an impairment in AMPH-induced DA efflux.  As outlined in 
Chapter 1 (Table 1), there have been several instances of neuropsychiatric disease-associated 
hDAT variants with impaired ability to respond to AMPH.  However, more focus was given to the 
ADE phenotype present in these variants, which as seen in the hDAT T356M Drosophila and 
hDAT A559V mouse models, readily translates to the behavior of hyperlocomotion.  Until hDAT 
R51W and STX1 R26Q, there was no evidence that the AMPH-induced DA efflux mechanism 
carried any non-AMPH related behavioral importance.  Indeed, the hDAT R51W Drosophila do 
not express hyperlocomotion (Fig. 44), although they do show an expected impaired AMPH-
induced locomotion response, like hDAT T356M Drosophila.  This suggests that the ability of 
the hDAT to respond to a coordinated intracellular signal (like that provided by AMPH) may 
have a discernable role in neurotransmission and neurological pathologies. 
 
The behavioral models generated during this dissertation represent an opportunity to 
begin addressing the role of the AMPH-induced DA efflux mechanism in physiology.  If the 
AMPH-induced DA efflux mechanism does represent an ability of the transporter to respond in a 
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coordinated manner to an endogenous signal (elevated Ca2+ and CaMKII activation in the 
presence of high intracellular DA levels, for example), then it is possible that examining more 
sophisticated behaviors in these efflux-impaired organisms may reveal previously unknown 
deficits.  Again, it has been shown that the amount of DA released by an AMPH-triggered efflux 
event is enough to approach a DA quantum, similar to the amount of DA released by vesicular 
secretion (Kahlig et al., 2005).   
 
One of the greatest challenges facing this research question has been how to selectively 
manipulate the AMPH-induced efflux function of the hDAT without disrupting the essential DA 
uptake function of the hDAT.  Previously available tools, such as genetic knockouts and 
pharmacological inhibition of the hDAT, are currently not sophisticated enough to target only the 
efflux mechanism of the hDAT.  However, since the variants generated here (K/A hDAT, hDAT 
R51W) show a selective impairment in AMPH-induced DA efflux function, we can now begin to 
address questions regarding the endogenous role of this mechanism in a more precise manner. 
 
To begin narrowing the field of behavioral tests, examining known behavioral symptoms 
in human individuals with ASD may provide more focus.  For example, the reward circuitry in 
ASD patients shows alteration, as well as the striatal regions (which controls implicit learning 
and habits) (Dichter et al., 2012).  Therefore, I propose to examine reward-related behaviors of 
efflux-impaired organisms, and whether these animals respond to natural rewards (food, 
sucrose) in a manner consistent with WT.  Furthermore, if mouse models of efflux-impaired 
variants are made, exploration of ASD-associated repetitive behaviors or anxiety behaviors may 
be examined as well.   
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